

Pfizer Inc.

2024 CDP Corporate Questionnaire 2024

This document is an export of your organization's CDP questionnaire response. It contains all data points for questions that are answered or in progress. There may be questions or data points that you have been requested to provide, which are missing from this document because they are currently unanswered. Please note that it is your responsibility to verify that your questionnaire response is complete prior to submission. CDP will not be liable for any failure to do so.

[Terms of disclosure for corporate questionnaire 2024 - CDP](#)

•

Contents

C1. Introduction.....	8
(1.1) In which language are you submitting your response?	8
(1.2) Select the currency used for all financial information disclosed throughout your response.	8
(1.3) Provide an overview and introduction to your organization.	8
(1.4) State the end date of the year for which you are reporting data. For emissions data, indicate whether you will be providing emissions data for past reporting years.	9
(1.4.1) What is your organization's annual revenue for the reporting period?	10
(1.5) Provide details on your reporting boundary.	10
(1.6) Does your organization have an ISIN code or another unique identifier (e.g., Ticker, CUSIP, etc.)?	10
(1.7) Select the countries/areas in which you operate.	12
(1.8) Are you able to provide geolocation data for your facilities?	14
(1.8.1) Please provide all available geolocation data for your facilities.	14
(1.24) Has your organization mapped its value chain?	14
(1.24.1) Have you mapped where in your direct operations or elsewhere in your value chain plastics are produced, commercialized, used, and/or disposed of?	15
C2. Identification, assessment, and management of dependencies, impacts, risks, and opportunities.....	16
(2.1) How does your organization define short-, medium-, and long-term time horizons in relation to the identification, assessment, and management of your environmental dependencies, impacts, risks, and opportunities?	16
(2.2) Does your organization have a process for identifying, assessing, and managing environmental dependencies and/or impacts?	17
(2.2.1) Does your organization have a process for identifying, assessing, and managing environmental risks and/or opportunities?.....	18
(2.2.2) Provide details of your organization's process for identifying, assessing, and managing environmental dependencies, impacts, risks, and/or opportunities.	18
(2.2.7) Are the interconnections between environmental dependencies, impacts, risks and/or opportunities assessed?	27
(2.3) Have you identified priority locations across your value chain?	27
(2.4) How does your organization define substantive effects on your organization?	29
(2.5) Does your organization identify and classify potential water pollutants associated with its activities that could have a detrimental impact on water ecosystems or human health?	31
(2.5.1) Describe how your organization minimizes the adverse impacts of potential water pollutants on water ecosystems or human health associated with your activities.	31

C3. Disclosure of risks and opportunities..... 34

(3.1) Have you identified any environmental risks which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future?.....	34
(3.1.1) Provide details of the environmental risks identified which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future.	35
(3.1.2) Provide the amount and proportion of your financial metrics from the reporting year that are vulnerable to the substantive effects of environmental risks.....	41
(3.3) In the reporting year, was your organization subject to any fines, enforcement orders, and/or other penalties for water-related regulatory violations?.....	42
(3.3.2) Provide details for all significant fines, enforcement orders and/or other penalties for water-related regulatory violations in the reporting year, and your plans for resolving them.	43
(3.5) Are any of your operations or activities regulated by a carbon pricing system (i.e. ETS, Cap & Trade or Carbon Tax)?	44
(3.5.1) Select the carbon pricing regulation(s) which impact your operations.	44
(3.5.2) Provide details of each Emissions Trading Scheme (ETS) your organization is regulated by.	44
(3.5.3) Complete the following table for each of the tax systems you are regulated by.	45
(3.5.4) What is your strategy for complying with the systems you are regulated by or anticipate being regulated by?.....	47
(3.6) Have you identified any environmental opportunities which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future?	48
(3.6.1) Provide details of the environmental opportunities identified which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future.	48
(3.6.2) Provide the amount and proportion of your financial metrics in the reporting year that are aligned with the substantive effects of environmental opportunities.	57

C4. Governance 59

(4.1) Does your organization have a board of directors or an equivalent governing body?.....	59
(4.1.1) Is there board-level oversight of environmental issues within your organization?.....	60
(4.1.2) Identify the positions (do not include any names) of the individuals or committees on the board with accountability for environmental issues and provide details of the board's oversight of environmental issues.	60
(4.2) Does your organization's board have competency on environmental issues?	63
(4.3) Is there management-level responsibility for environmental issues within your organization?.....	64
(4.3.1) Provide the highest senior management-level positions or committees with responsibility for environmental issues (do not include the names of individuals).	64
(4.5) Do you provide monetary incentives for the management of environmental issues, including the attainment of targets?	69
(4.5.1) Provide further details on the monetary incentives provided for the management of environmental issues (do not include the names of individuals).	70
(4.6) Does your organization have an environmental policy that addresses environmental issues?	73

(4.6.1) Provide details of your environmental policies.	73
(4.10) Are you a signatory or member of any environmental collaborative frameworks or initiatives?	77
(4.11) In the reporting year, did your organization engage in activities that could directly or indirectly influence policy, law, or regulation that may (positively or negatively) impact the environment?	78
(4.11.1) On what policies, laws, or regulations that may (positively or negatively) impact the environment has your organization been engaging directly with policy makers in the reporting year?	80
(4.11.2) Provide details of your indirect engagement on policy, law, or regulation that may (positively or negatively) impact the environment through trade associations or other intermediary organizations or individuals in the reporting year.	82
(4.12) Have you published information about your organization's response to environmental issues for this reporting year in places other than your CDP response?	85
(4.12.1) Provide details on the information published about your organization's response to environmental issues for this reporting year in places other than your CDP response. Please attach the publication.	86

C5. Business strategy..... 91

(5.1) Does your organization use scenario analysis to identify environmental outcomes?	91
(5.1.1) Provide details of the scenarios used in your organization's scenario analysis.	91
(5.1.2) Provide details of the outcomes of your organization's scenario analysis.	100
(5.2) Does your organization's strategy include a climate transition plan?	102
(5.3) Have environmental risks and opportunities affected your strategy and/or financial planning?.....	104
(5.3.1) Describe where and how environmental risks and opportunities have affected your strategy.....	105
(5.3.2) Describe where and how environmental risks and opportunities have affected your financial planning.	107
(5.4) In your organization's financial accounting, do you identify spending/revenue that is aligned with your organization's climate transition?	109
(5.9) What is the trend in your organization's water-related capital expenditure (CAPEX) and operating expenditure (OPEX) for the reporting year, and the anticipated trend for the next reporting year?.....	109
(5.10) Does your organization use an internal price on environmental externalities?	110
(5.10.1) Provide details of your organization's internal price on carbon.	110
(5.11) Do you engage with your value chain on environmental issues?	113
(5.11.1) Does your organization assess and classify suppliers according to their dependencies and/or impacts on the environment?.....	114
(5.11.2) Does your organization prioritize which suppliers to engage with on environmental issues?	116
(5.11.5) Do your suppliers have to meet environmental requirements as part of your organization's purchasing process?.....	118
(5.11.6) Provide details of the environmental requirements that suppliers have to meet as part of your organization's purchasing process, and the compliance measures in place.	119

(5.11.7) Provide further details of your organization's supplier engagement on environmental issues.	122
(5.11.9) Provide details of any environmental engagement activity with other stakeholders in the value chain.	125
(5.13) Has your organization already implemented any mutually beneficial environmental initiatives due to CDP Supply Chain member engagement?.....	128
C6. Environmental Performance - Consolidation Approach	129
(6.1) Provide details on your chosen consolidation approach for the calculation of environmental performance data.....	129
C7. Environmental performance - Climate Change.....	130
(7.1) Is this your first year of reporting emissions data to CDP?	130
(7.1.1) Has your organization undergone any structural changes in the reporting year, or are any previous structural changes being accounted for in this disclosure of emissions data?.....	130
(7.1.2) Has your emissions accounting methodology, boundary, and/or reporting year definition changed in the reporting year?	131
(7.1.3) Have your organization's base year emissions and past years' emissions been recalculated as a result of any changes or errors reported in 7.1.1 and/or 7.1.2?	131
(7.2) Select the name of the standard, protocol, or methodology you have used to collect activity data and calculate emissions.	132
(7.3) Describe your organization's approach to reporting Scope 2 emissions.	133
(7.4) Are there any sources (e.g. facilities, specific GHGs, activities, geographies, etc.) of Scope 1, Scope 2 or Scope 3 emissions that are within your selected reporting boundary which are not included in your disclosure?	133
(7.4.1) Provide details of the sources of Scope 1, Scope 2, or Scope 3 emissions that are within your selected reporting boundary which are not included in your disclosure.	133
(7.5) Provide your base year and base year emissions.	134
(7.6) What were your organization's gross global Scope 1 emissions in metric tons CO ₂ e?.....	143
(7.7) What were your organization's gross global Scope 2 emissions in metric tons CO ₂ e?.....	144
(7.8) Account for your organization's gross global Scope 3 emissions, disclosing and explaining any exclusions.	145
(7.8.1) Disclose or restate your Scope 3 emissions data for previous years.	156
(7.9) Indicate the verification/assurance status that applies to your reported emissions.	158
(7.9.1) Provide further details of the verification/assurance undertaken for your Scope 1 emissions, and attach the relevant statements.....	159
(7.9.2) Provide further details of the verification/assurance undertaken for your Scope 2 emissions and attach the relevant statements.	160
(7.9.3) Provide further details of the verification/assurance undertaken for your Scope 3 emissions and attach the relevant statements.	162
(7.10) How do your gross global emissions (Scope 1 and 2 combined) for the reporting year compare to those of the previous reporting year?	164
(7.10.1) Identify the reasons for any change in your gross global emissions (Scope 1 and 2 combined), and for each of them specify how your emissions compare to the previous year.	164

(7.10.2) Are your emissions performance calculations in 7.10 and 7.10.1 based on a location-based Scope 2 emissions figure or a market-based Scope 2 emissions figure?	170
(7.12) Are carbon dioxide emissions from biogenic carbon relevant to your organization?	170
(7.12.1) Provide the emissions from biogenic carbon relevant to your organization in metric tons CO2.	170
(7.15) Does your organization break down its Scope 1 emissions by greenhouse gas type?	170
(7.15.1) Break down your total gross global Scope 1 emissions by greenhouse gas type and provide the source of each used global warming potential (GWP).	171
(7.16) Break down your total gross global Scope 1 and 2 emissions by country/area.	174
(7.17) Indicate which gross global Scope 1 emissions breakdowns you are able to provide.	200
(7.17.1) Break down your total gross global Scope 1 emissions by business division.	200
(7.20) Indicate which gross global Scope 2 emissions breakdowns you are able to provide.	201
(7.20.1) Break down your total gross global Scope 2 emissions by business division.	201
(7.22) Break down your gross Scope 1 and Scope 2 emissions between your consolidated accounting group and other entities included in your response.	202
(7.23) Is your organization able to break down your emissions data for any of the subsidiaries included in your CDP response?	203
(7.26) Allocate your emissions to your customers listed below according to the goods or services you have sold them in this reporting period.	203
(7.27) What are the challenges in allocating emissions to different customers, and what would help you to overcome these challenges?	229
(7.28) Do you plan to develop your capabilities to allocate emissions to your customers in the future?	229
(7.29) What percentage of your total operational spend in the reporting year was on energy?	230
(7.30) Select which energy-related activities your organization has undertaken.	230
(7.30.1) Report your organization's energy consumption totals (excluding feedstocks) in MWh.	231
(7.30.6) Select the applications of your organization's consumption of fuel.	235
(7.30.7) State how much fuel in MWh your organization has consumed (excluding feedstocks) by fuel type.	235
(7.30.9) Provide details on the electricity, heat, steam, and cooling your organization has generated and consumed in the reporting year.	243
(7.30.16) Provide a breakdown by country/area of your electricity/heat/steam/cooling consumption in the reporting year.	245
(7.30.17) Provide details of your organization's renewable electricity purchases in the reporting year by country/area.	301
(7.30.18) Provide details of your organization's low-carbon heat, steam, and cooling purchases in the reporting year by country/area.	311
(7.30.19) Provide details of your organization's renewable electricity generation by country/area in the reporting year.	313
(7.30.20) Describe how your organization's renewable electricity sourcing strategy directly or indirectly contributes to bringing new capacity into the grid in the countries/areas in which you operate.	326
(7.30.21) In the reporting year, has your organization faced barriers or challenges to sourcing renewable electricity?	326

(7.30.22) Provide details of the country/area-specific challenges to sourcing renewable electricity faced by your organization in the reporting year.....	326
(7.45) Describe your gross global combined Scope 1 and 2 emissions for the reporting year in metric tons CO2e per unit currency total revenue and provide any additional intensity metrics that are appropriate to your business operations.	327
(7.53) Did you have an emissions target that was active in the reporting year?	328
(7.53.1) Provide details of your absolute emissions targets and progress made against those targets.	328
(7.54) Did you have any other climate-related targets that were active in the reporting year?	341
(7.54.1) Provide details of your targets to increase or maintain low-carbon energy consumption or production.	341
(7.54.2) Provide details of any other climate-related targets, including methane reduction targets.....	344
(7.54.3) Provide details of your net-zero target(s).....	346
(7.55) Did you have emissions reduction initiatives that were active within the reporting year? Note that this can include those in the planning and/or implementation phases.	349
(7.55.1) Identify the total number of initiatives at each stage of development, and for those in the implementation stages, the estimated CO2e savings.....	349
(7.55.2) Provide details on the initiatives implemented in the reporting year in the table below.	350
(7.55.3) What methods do you use to drive investment in emissions reduction activities?.....	351
(7.73) Are you providing product level data for your organization’s goods or services?.....	352
(7.74) Do you classify any of your existing goods and/or services as low-carbon products?.....	353
(7.74.1) Provide details of your products and/or services that you classify as low-carbon products.....	353
(7.79) Has your organization canceled any project-based carbon credits within the reporting year?	355

C9. Environmental performance - Water security..... 356

(9.1) Are there any exclusions from your disclosure of water-related data?	356
(9.1.1) Provide details on these exclusions.	356
(9.2) Across all your operations, what proportion of the following water aspects are regularly measured and monitored?	357
(9.2.2) What are the total volumes of water withdrawn, discharged, and consumed across all your operations, how do they compare to the previous reporting year, and how are they forecasted to change?	365
(9.2.4) Indicate whether water is withdrawn from areas with water stress, provide the volume, how it compares with the previous reporting year, and how it is forecasted to change.	368
(9.2.7) Provide total water withdrawal data by source.	370
(9.2.8) Provide total water discharge data by destination.	373
(9.2.9) Within your direct operations, indicate the highest level(s) to which you treat your discharge.	376

(9.2.10) Provide details of your organization's emissions of nitrates, phosphates, pesticides, and other priority substances to water in the reporting year.	381
(9.3) In your direct operations and upstream value chain, what is the number of facilities where you have identified substantive water-related dependencies, impacts, risks, and opportunities?	382
(9.3.1) For each facility referenced in 9.3, provide coordinates, water accounting data, and a comparison with the previous reporting year.	383
(9.3.2) For the facilities in your direct operations referenced in 9.3.1, what proportion of water accounting data has been third party verified?	409
(9.4) Could any of your facilities reported in 9.3.1 have an impact on a requesting CDP supply chain member?	412
(9.5) Provide a figure for your organization's total water withdrawal efficiency.	412
(9.13) Do any of your products contain substances classified as hazardous by a regulatory authority?	412
(9.14) Do you classify any of your current products and/or services as low water impact?	413
(9.15) Do you have any water-related targets?	413
(9.15.1) Indicate whether you have targets relating to water pollution, water withdrawals, WASH, or other water-related categories.	414
(9.15.2) Provide details of your water-related targets and the progress made.	415
C10. Environmental performance - Plastics	418
(10.1) Do you have plastics-related targets, and if so what type?	418
(10.2) Indicate whether your organization engages in the following activities.	418
(10.4) Provide the total weight of plastic durable goods and durable components produced, sold and/or used, and indicate the raw material content.	421
(10.5) Provide the total weight of plastic packaging sold and/or used and indicate the raw material content.	422
(10.5.1) Indicate the circularity potential of the plastic packaging you sold and/or used.....	422
C11. Environmental performance - Biodiversity	423
(11.4.1) Provide details of your organization's activities in the reporting year located in or near to areas important for biodiversity.	423
C13. Further information & sign off	423
(13.1) Indicate if any environmental information included in your CDP response (not already reported in 7.9.1/2/3, 8.9.1/2/3/4, and 9.3.2) is verified and/or assured by a third party?	423
(13.1.1) Which data points within your CDP response are verified and/or assured by a third party, and which standards were used?	423
(13.3) Provide the following information for the person that has signed off (approved) your CDP response.	426

C1. Introduction

(1.1) In which language are you submitting your response?

Select from:

☒ English

(1.2) Select the currency used for all financial information disclosed throughout your response.

Select from:

☒ USD

(1.3) Provide an overview and introduction to your organization.

(1.3.2) Organization type

Select from:

☒ Publicly traded organization

(1.3.3) Description of organization

Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. The company was incorporated under the laws of the State of Delaware on June 2, 1942. Guided by our values and our commitments to long-term sustainability, Pfizer's environmental, social, and governance (ESG) approach informs how we can advance our purpose in a responsible and sustainable way that takes accountability for the impact we make on society. By taking proactive, collaborative steps to advance ESG at Pfizer we can help improve health outcomes, build trust, create shared value, and make a positive impact on society for years to come. Our ESG strategy includes six priority areas: product innovation; climate change; equitable access and pricing; product quality and safety; diversity equity and inclusion; and business ethics. These priorities represent the areas of most significance to our business and stakeholders. Pfizer's environmental sustainability program is focused on mitigating climate impact, conserving natural resources, and reducing waste including:

- Reducing the greenhouse gas (GHG) emissions associated with our operations. This includes application of engineering and sustainability innovations to how we design and operate our sites (e.g., manufacturing, labs, offices, etc.) and manage our operations (e.g., product transportation, business travel, renewable energy, etc.).*

- Reducing water withdrawal associated with our operations and being effective stewards of the water we use
- Decreasing waste generated from our operations through a multifaceted approach including source reduction, waste minimization, recycling, and other opportunities to reuse materials we cannot recycle ourselves
- Applying scientific innovation and operational efficiency to reduce the environmental impact of our medicines throughout the product lifecycle
- Integrating environmental sustainability criteria into our supplier selection and management processes; and
- Engaging with key suppliers of goods and services to drive the adoption of science-based GHG reduction goals

With senior leader support and collaboration at all levels, we aim to improve health outcomes, build trust, create shared value, and make a positive impact on society for years to come. Further information can be found at www.Pfizer.com or through Pfizer's social media including X (formerly known as Twitter) @Pfizer and @Pfizer News, LinkedIn, YouTube and Facebook.com/Pfizer. Disclosure Notice: The information contained in this 2024 CDP submittal is as of September 1, 2024. Pfizer assumes no obligation to update forward looking statements contained in this response as the result of new information or future events or developments. This response contains forward looking information about, among other things, potential environmental impacts to Pfizer, including regulatory, physical, and business risks and opportunities, information related to environmental sustainability strategies and goals, all of which involve substantial risks, uncertainties and assumptions. Such risks, uncertainties and assumptions include, among other things, the uncertainties inherent in determining potential impacts from climate change; changes to existing, or implementation of new regulations; projected financial impact and management cost; projected performance on climate change related goals; and the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer's business and prospects, adverse developments in Pfizer's markets, or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment or economies generally. Pfizer's past performance in attaining reductions in GHG emissions is not an indication of future performance. A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results" and in its subsequent reports on Forms 10-Q and 8-K, all of which are filed with the SEC and are available at www.sec.gov and www.pfizer.com.

(1.4) State the end date of the year for which you are reporting data. For emissions data, indicate whether you will be providing emissions data for past reporting years.

(1.4.1) End date of reporting year

12/31/2023

(1.4.2) Alignment of this reporting period with your financial reporting period

☒ Yes

(1.4.3) Indicate if you are providing emissions data for past reporting years

☒ Yes

(1.4.4) Number of past reporting years you will be providing Scope 1 emissions data for

☒ 1 year

(1.4.5) Number of past reporting years you will be providing Scope 2 emissions data for

☒ 1 year

(1.4.6) Number of past reporting years you will be providing Scope 3 emissions data for

☒ 1 year

(1.4.1) What is your organization's annual revenue for the reporting period?

58,496,000,000

(1.5) Provide details on your reporting boundary.

	Is your reporting boundary for your CDP disclosure the same as that used in your financial statements?
	<input checked="" type="checkbox"/> Yes

(1.6) Does your organization have an ISIN code or another unique identifier (e.g., Ticker, CUSIP, etc.)?

ISIN code - bond

(1.6.1) Does your organization use this unique identifier?

☒ No

ISIN code - equity

(1.6.1) Does your organization use this unique identifier?

☒ Yes

(1.6.2) Provide your unique identifier

US7170811035

CUSIP number

(1.6.1) Does your organization use this unique identifier?

☒ Yes

(1.6.2) Provide your unique identifier

717081103

Ticker symbol

(1.6.1) Does your organization use this unique identifier?

☒ Yes

(1.6.2) Provide your unique identifier

PFE

SEDOL code

(1.6.1) Does your organization use this unique identifier?

☒ No

LEI number

(1.6.1) Does your organization use this unique identifier?

☒ Yes

(1.6.2) Provide your unique identifier

765LHXWGK1KXCLTFYQ30

D-U-N-S number

(1.6.1) Does your organization use this unique identifier?

☒ No

Other unique identifier

(1.6.1) Does your organization use this unique identifier?

☒ No

(1.7) Select the countries/areas in which you operate.

Select all that apply

☒ Peru

☒ Chile

☒ China

☒ Egypt

☒ India

☒ Canada

☒ Italy

☒ Japan

☒ Kenya

☒ Spain

☒ Brazil

☒ Mexico

- ✓ France
- ✓ Greece
- ✓ Israel
- ✓ Latvia
- ✓ Turkey
- ✓ Algeria
- ✓ Austria
- ✓ Belarus
- ✓ Belgium
- ✓ Finland
- ✓ Germany
- ✓ Hungary
- ✓ Ireland
- ✓ Morocco
- ✓ Colombia
- ✓ Malaysia
- ✓ Pakistan
- ✓ Portugal
- ✓ Slovakia
- ✓ Indonesia
- ✓ Lithuania
- ✓ Singapore
- ✓ Costa Rica
- ✓ Kazakhstan
- ✓ Saudi Arabia
- ✓ South Africa
- ✓ Taiwan, China
- ✓ Republic of Korea
- ✓ Russian Federation

- ✓ Norway
- ✓ Poland
- ✓ Serbia
- ✓ Sweden
- ✓ Croatia
- ✓ Czechia
- ✓ Denmark
- ✓ Ecuador
- ✓ Estonia
- ✓ Nigeria
- ✓ Romania
- ✓ Tunisia
- ✓ Ukraine
- ✓ Bulgaria
- ✓ Slovenia
- ✓ Thailand
- ✓ Viet Nam
- ✓ Argentina
- ✓ Australia
- ✓ Luxembourg
- ✓ Netherlands
- ✓ New Zealand
- ✓ Philippines
- ✓ Switzerland
- ✓ United States of America
- ✓ United Kingdom of Great Britain and Northern Ireland

(1.8) Are you able to provide geolocation data for your facilities?

(1.8.1) Are you able to provide geolocation data for your facilities?

☒ Yes, for some facilities

(1.8.2) Comment

While we have geolocation data available, due to the large number of facilities included within the scope of this disclosure we are only providing data for the facility relevant to the Supply Chain member requesting our water response.

(1.8.1) Please provide all available geolocation data for your facilities.

Row 1

(1.8.1.1) Identifier

Newbridge

(1.8.1.2) Latitude

53.1858

(1.8.1.3) Longitude

-6.7794

(1.8.1.4) Comment

Geolocation data provided for the facility relevant to the CDP Supply chain member requesting Water Security information.

(1.24) Has your organization mapped its value chain?

(1.24.1) Value chain mapped

☒ Yes, we have mapped or are currently in the process of mapping our value chain

(1.24.2) Value chain stages covered in mapping

☒ Upstream value chain

(1.24.3) Highest supplier tier mapped

☒ Tier 1 suppliers

(1.24.4) Highest supplier tier known but not mapped

☒ Tier 2 suppliers

(1.24.7) Description of mapping process and coverage

Pfizer sets high standards for responsible supply chain management, guided by robust governance processes. This helps ensure the safety and quality of the medicines and vaccines we produce and aligns with our core value of Equity. Compliance with laws is our baseline expectation, and we also establish other risk-based assessment criteria to help assure our suppliers are responsibly managing environmental, health, and safety (EHS) risks and maintaining a robust supply chain, including establishing a comprehensive supply chain management system. We collect information regarding all our suppliers' business entities and business locations. This information is maintained in our enterprise systems.

(1.24.1) Have you mapped where in your direct operations or elsewhere in your value chain plastics are produced, commercialized, used, and/or disposed of?

	Plastics mapping	Value chain stages covered in mapping
	<input checked="" type="checkbox"/> Yes, we have mapped or are currently in the process of mapping plastics in our value chain	Select all that apply <input checked="" type="checkbox"/> Upstream value chain

C2. Identification, assessment, and management of dependencies, impacts, risks, and opportunities

(2.1) How does your organization define short-, medium-, and long-term time horizons in relation to the identification, assessment, and management of your environmental dependencies, impacts, risks, and opportunities?

Short-term

(2.1.1) From (years)

0

(2.1.3) To (years)

5

(2.1.4) How this time horizon is linked to strategic and/or financial planning

Pfizer uses a 0-5 year timeframe to assess short-term transition risks. This timeframe is useful to inform business planning and identify capital needs.

Medium-term

(2.1.1) From (years)

5

(2.1.3) To (years)

10

(2.1.4) How this time horizon is linked to strategic and/or financial planning

Pfizer uses a 5-10 year timeframe in assessing both transition and physical risks. This time horizon aligns with Pfizer's current near-term climate targets and informs strategy and investment needed as we strive to achieve our emission reduction targets.

Long-term

(2.1.1) From (years)

10

(2.1.2) Is your long-term time horizon open ended?

Select from:

☒ No

(2.1.3) To (years)

30

(2.1.4) How this time horizon is linked to strategic and/or financial planning

Pfizer defines long-term as 10-30 years for both transition and physical risks This timeframe aligns with the Corporate Net Zero Standard as well as decarbonization timelines established by many government healthcare agencies globally.

(2.2) Does your organization have a process for identifying, assessing, and managing environmental dependencies and/or impacts?

	Process in place	Dependencies and/or impacts evaluated in this process
	Select from: <input checked="" type="checkbox"/> Yes	Select from: <input checked="" type="checkbox"/> Both dependencies and impacts

(2.2.1) Does your organization have a process for identifying, assessing, and managing environmental risks and/or opportunities?

	Process in place	Risks and/or opportunities evaluated in this process	Is this process informed by the dependencies and/or impacts process?
	<i>Select from:</i> <input checked="" type="checkbox"/> Yes	<i>Select from:</i> <input checked="" type="checkbox"/> Both risks and opportunities	<i>Select from:</i> <input checked="" type="checkbox"/> Yes

(2.2.2) Provide details of your organization's process for identifying, assessing, and managing environmental dependencies, impacts, risks, and/or opportunities.

Row 1

(2.2.2.1) Environmental issue

Select all that apply

☒ Climate change

(2.2.2.2) Indicate which of dependencies, impacts, risks, and opportunities are covered by the process for this environmental issue

Select all that apply

☒ Dependencies

☒ Impacts

☒ Risks

☒ Opportunities

(2.2.2.3) Value chain stages covered

Select all that apply

- ☒ Direct operations
- ☒ Upstream value chain
- ☒ Downstream value chain

(2.2.2.4) Coverage

- ☒ Full

(2.2.2.5) Supplier tiers covered

Select all that apply

- ☒ Tier 1 suppliers

(2.2.2.7) Type of assessment

- ☒ Qualitative and quantitative

(2.2.2.8) Frequency of assessment

- ☒ More than once a year

(2.2.2.9) Time horizons covered

- ☒ Short-term
- ☒ Medium-term
- ☒ Long-term

(2.2.2.10) Integration of risk management process

- ☒ Integrated into multi-disciplinary organization-wide risk management process

(2.2.2.11) Location-specificity used

- ☒ Site-specific
- ☒ Local
- ☒ National

(2.2.2.12) Tools and methods used

Enterprise Risk Management

- ☒ Enterprise Risk Management
- ☒ Internal company methods

International methodologies and standards

- ☒ ISO 14001 Environmental Management Standard
- ☒ Other international methodologies and standards, please specify :The International Best Track Archive for Climate Stewardship (IBTrACS)

Databases

- ☒ Nation-specific databases, tools, or standards
- ☒ Other databases, please specify :World Resources Institute, NASA, European Space Agency

Other

- ☒ Desk-based research
- ☒ External consultants
- ☒ Scenario analysis
- ☒ Other, please specify :World Climate Research Programme (WCRP) Coupled Model Intercomparison Project (CMIP6)

(2.2.2.13) Risk types and criteria considered

Acute physical

- | | |
|--|--|
| <input checked="" type="checkbox"/> Drought | <input checked="" type="checkbox"/> Subsidence |
| <input checked="" type="checkbox"/> Avalanche | <input checked="" type="checkbox"/> Cold wave/frost |
| <input checked="" type="checkbox"/> Landslide | <input checked="" type="checkbox"/> Glacial lake outburst |
| <input checked="" type="checkbox"/> Wildfires | <input checked="" type="checkbox"/> Cyclones, hurricanes, typhoons |
| <input checked="" type="checkbox"/> Heat waves | <input checked="" type="checkbox"/> Heavy precipitation (rain, hail, snow/ice) |

- ☑ Flood (coastal, fluvial, pluvial, ground water)
- ☑ Storm (including blizzards, dust, and sandstorms)

Chronic physical

- ☑ Heat stress
- ☑ Soil erosion
- ☑ Solifluction
- ☑ Water stress
- ☑ Sea level rise
- ☑ Temperature variability
- ☑ Water quality at a basin/catchment level
- ☑ Precipitation or hydrological variability
- ☑ Increased severity of extreme weather events
- ☑ Water availability at a basin/catchment level
- ☑ Coastal erosion
- ☑ Soil degradation
- ☑ Permafrost thawing
- ☑ Ocean acidification
- ☑ Changing wind patterns
- ☑ Changing temperature (air, freshwater, marine water)
- ☑ Changing precipitation patterns and types (rain, hail, snow/ice)

Policy

- ☑ Carbon pricing mechanisms
- ☑ Changes to international law and bilateral agreements
- ☑ Changes to national legislation

Market

- ☑ Availability and/or increased cost of raw materials
- ☑ Changing customer behavior

Reputation

- ☑ Impact on human health
- ☑ Increased partner and stakeholder concern and partner and stakeholder negative feedback

Technology

- ☑ Transition to lower emissions technology and products

Liability

- ☒ Exposure to litigation
- ☒ Non-compliance with regulations

(2.2.2.14) Partners and stakeholders considered

Select all that apply

- | | |
|---|---|
| <input checked="" type="checkbox"/> NGOs | <input checked="" type="checkbox"/> Regulators |
| <input checked="" type="checkbox"/> Customers | <input checked="" type="checkbox"/> Local communities |
| <input checked="" type="checkbox"/> Employees | |
| <input checked="" type="checkbox"/> Investors | |
| <input checked="" type="checkbox"/> Suppliers | |

(2.2.2.15) Has this process changed since the previous reporting year?

Select from:

- ☒ No

(2.2.2.16) Further details of process

Pfizer assesses climate change risk as part of our enterprise-level EHS and business continuity risk management processes. We conduct structured evaluations of risks with the potential to have a substantive impact on Pfizer and the effectiveness of controls through our Operational Risk Review (ORR) process. Under our ORR process, cross-functional program leaders and subject matter experts assess potential climate-related risks to Pfizer's direct operations and full value chain across four risk areas (external and reputational, physical, regulatory and legal, and market and technology). Acute and chronic physical risks related to climate change are managed through Pfizer's Loss Prevention and Business Resilience teams at the enterprise and local levels. Pfizer uses natural hazard analysis and mapping tools to monitor short-, medium- and long-term physical threats to internal operations and for more than 5,000 contract manufacturers and material suppliers. To gain insight into Pfizer's current and projected resilience to acute and chronic physical risks and opportunities, we conducted a TCFD-aligned risk assessment using a panel of criteria and hazards developed in partnership with a global sustainability consultancy. The qualitative scenario analyses for physical risk were guided using IPCC-aligned predictive modeling and usage of a blend of national and global datasets, setting a foundation for further engagement with internal stakeholders spanning across Pfizer's operational geographical footprint. After a validation process with internal stakeholders, we assigned impact ratings using Pfizer methodology applied in our Enterprise Risk Management (ERM) framework. Twenty risks and opportunities with the highest potential for impact were prioritized for further comprehensive assessment. Risks identified through these assessments are prioritized based on potential severity and the effectiveness of existing controls and, if necessary, risk mitigation actions are identified. This information is reviewed as part of the ORR, and mitigation of risk is monitored through Pfizer's Loss Prevention and Business Resilience programs and escalated to company leadership as needed to inform business strategy. Key risks identified through these processes are escalated to the Pfizer Global Supply (PGS) Quality & Risk Committee (PGS Q&RC). PGS Q&RC reports key risks to the Executive Compliance Committee, chaired by the CEO, and

to the Regulatory Compliance Committee (RCC) of the Board of Directors. The PGS Q&RC risk management process also informs Pfizer's ERM program, overseen by the Audit Committee of the Board of Directors. Pfizer's ERM program provides a framework for the identification and management of significant risks. Pfizer also monitors progress on climate commitments throughout the year. Issues or events that may impact our ability to achieve established commitments are identified and escalated.

Row 2

(2.2.2.1) Environmental issue

Select all that apply

☒ Water

(2.2.2.2) Indicate which of dependencies, impacts, risks, and opportunities are covered by the process for this environmental issue

Select all that apply

☒ Dependencies

☒ Impacts

☒ Risks

☒ Opportunities

(2.2.2.3) Value chain stages covered

Select all that apply

☒ Direct operations

☒ Upstream value chain

(2.2.2.4) Coverage

☒ Full

(2.2.2.5) Supplier tiers covered

☒ Tier 1 suppliers

(2.2.2.7) Type of assessment

- ☒ Qualitative and quantitative

(2.2.2.8) Frequency of assessment

- ☒ More than once a year

(2.2.2.9) Time horizons covered

Select all that apply

- ☒ Short-term
- ☒ Medium-term
- ☒ Long-term

(2.2.2.10) Integration of risk management process

- ☒ Integrated into multi-disciplinary organization-wide risk management process

(2.2.2.11) Location-specificity used

Select all that apply

- ☒ Site-specific
- ☒ Local

(2.2.2.12) Tools and methods used

Commercially/publicly available tools

- ☒ WRI Aqueduct
- ☒ Other commercially/publicly available tools, please specify: WBCSD Global Water Tool

Enterprise Risk Management

- ☒ Enterprise Risk Management

- ☒ Internal company methods

International methodologies and standards

- ☒ IPCC Climate Change Projections

Other

- ☒ External consultants
- ☒ Internal company methods
- ☒ Scenario analysis
- ☒ Other, please specify: Swiss RE CatNet; FEMA Flood Zone Maps

(2.2.2.13) Risk types and criteria considered

Acute physical

- ☒ Cyclones, hurricanes, typhoons
- ☒ Drought
- ☒ Flood (coastal, fluvial, pluvial, ground water)
- ☒ Pollution incident
- ☒ Storm (including blizzards, dust, and sandstorms)

Chronic physical

- | | |
|--|---|
| <input checked="" type="checkbox"/> Water stress | <input checked="" type="checkbox"/> Increased severity of extreme weather events |
| <input checked="" type="checkbox"/> Sea level rise | <input checked="" type="checkbox"/> Water availability at a basin/catchment level |
| <input checked="" type="checkbox"/> Groundwater depletion | <input checked="" type="checkbox"/> Changing precipitation patterns and types (rain, hail, snow/ice) |
| <input checked="" type="checkbox"/> Declining water quality | <input checked="" type="checkbox"/> Increased levels of environmental pollutants in freshwater bodies |
| <input checked="" type="checkbox"/> Water quality at a basin/catchment level | |

Policy

- ☒ Changes to national legislation
- ☒ Introduction of regulatory standards for previously unregulated contaminants
- ☒ Poor enforcement of environmental regulation

- ☒ Regulation of discharge quality/volumes
- ☒ Statutory water withdrawal limits/changes to water allocation

Market

- ☒ Changing customer behavior
- ☒ Inadequate access to water, sanitation, and hygiene services (WASH)

Reputation

- ☒ Impact on human health
- ☒ Stakeholder conflicts concerning water resources at a basin/catchment level

(2.2.2.14) Partners and stakeholders considered

Select all that apply

- | | |
|---|--|
| <input checked="" type="checkbox"/> NGOs | <input checked="" type="checkbox"/> Regulators |
| <input checked="" type="checkbox"/> Customers | <input checked="" type="checkbox"/> Local communities |
| <input checked="" type="checkbox"/> Employees | <input checked="" type="checkbox"/> Water utilities at a local level |
| <input checked="" type="checkbox"/> Investors | <input checked="" type="checkbox"/> Other water users at the basin/catchment level |
| <input checked="" type="checkbox"/> Suppliers | |

(2.2.2.15) Has this process changed since the previous reporting year?

- ☒ Yes

(2.2.2.16) Further details of process

Pfizer uses multiple tools to assess water-related risks. We use the WRI Aqueduct, WBCSD, and IPCC Global Water tools to identify water-related risks with the potential to have substantive financial or strategic impact to the business. For WRI Aqueduct, we consider all the tool indicators in our assessment, including those related to water scarcity, water quality, environmental flows, and the accessibility of water. We perform a site-level assessment of water-related system operations and program management using an assessment methodology and risk weighting factors specific to the pharma industry developed with input from WRI, WSP and Antea (among others). Our process assesses short, medium and long-term acute and chronic water risks. As part of the site level assessment, Pfizer's Business Continuity Program undertakes a multi-step review of water supply for both production and fire protection for all Pfizer operations. Sites are also mapped against published flood maps and recommendations are made regarding flood prevention. Business continuity methodology is used to identify critical processes and products and then complete a dependency analysis/risk assessment. After applying this process, sites found to be vulnerable to water stress are required to develop water

stewardship and business continuity plans. These assessments are conducted annually, or more frequently if there are significant changes to a facility. Subject matter experts conduct focused reviews for sites determined to be at higher risk.

To gain insight into Pfizer's current and projected resilience to acute and chronic water-related risks and opportunities, we conducted a TCFD-aligned risk assessment using a panel of criteria and hazards developed in partnership with a multi-national sustainability advisory firm. We further refined our assessment process in 2023, expanding the scope of hazards considered and improving data quality by evaluating impacts at the asset level. The qualitative scenario analyses for physical risk were guided using IPCC-aligned predictive modeling and usage of a blend of national and global datasets, setting a foundation for further engagement with internal stakeholders spanning across Pfizer's operational geographical footprint. After a validation process with internal stakeholders, we assigned impact ratings using Pfizer methodology applied in our Enterprise Risk Management (ERM) framework.

The conclusions of these risk assessment activities are used to inform an annual review of water-related risk through the Global EHS Operational Risk Review process (ORR). Key risks are escalated to the Pfizer Global Supply (PGS) Quality & Risk Committee (PGS Q&RC). PGS Q&RC reports key risks to the Executive Compliance Committee, chaired by the CEO, and to the Regulatory Compliance Committee (RCC) of the Board of Directors. The PGS Q&RC risk management process also informs Pfizer's ERM program, overseen by the Audit Committee of the Board of Directors. Pfizer's ERM program provides a framework for the identification and management of significant risks. Pfizer's Water Stewardship Position Statement, published in 2022, states our commitment to assessing water stress of our internal sites and key suppliers. Our position statement can be found on our website at: [Pfizer_Water_Stewardship_Public_Position_Statement_2022.pdf](#).

(2.2.7) Are the interconnections between environmental dependencies, impacts, risks and/or opportunities assessed?

(2.2.7.1) Interconnections between environmental dependencies, impacts, risks and/or opportunities assessed

☒ Yes

(2.2.7.2) Description of how interconnections are assessed

The assessment of potential interconnections between environmental dependencies, impacts, risks and opportunities is integrated into our enterprise-level EHS and business continuity risk management processes. For example, a reliable supply of good quality water is critical to Pfizer's manufacturing operations, so water quality and availability in the short-, medium- and long-term timeframes are taken into consideration when assigning a weighting to water-related risk for these sites. Business continuity methodology is used to identify critical processes and products and then complete a dependency analysis/risk assessment. After applying this process, sites found to be vulnerable to water stress are required to develop water stewardship and business continuity plans.

(2.3) Have you identified priority locations across your value chain?

(2.3.1) Identification of priority locations

- ☒ Yes, we have identified priority locations

(2.3.2) Value chain stages where priority locations have been identified

- ☒ Direct operations

(2.3.3) Types of priority locations identified

Locations with substantive dependencies, impacts, risks, and/or opportunities

- ☒ Locations with substantive dependencies, impacts, risks, and/or opportunities relating to water

(2.3.4) Description of process to identify priority locations

Pfizer uses multiple tools to assess water-related risks. We use the WRI Aqueduct, WBCSD, and IPCC Global Water tools to identify water-related risks with the potential to have substantive financial or strategic impact to the business. For WRI Aqueduct, we consider all the tool indicators in our assessment, including those related to water scarcity, water quality, environmental flows, and the accessibility of water. We perform a site-level assessment of water-related system operations and program management using an assessment methodology and risk weighting factors specific to the pharma industry developed with input from WRI, WSP and Antea (among others). Our process assesses short, medium and long-term acute and chronic water risks. As part of the site level assessment, Pfizer's Business Continuity Program undertakes a multi-step review of water supply for both production and fire protection for all Pfizer operations. Sites are also mapped against published flood maps and recommendations are made regarding flood prevention. Business continuity methodology is used to identify critical processes and products and then complete a dependency analysis/risk assessment. After applying this process, sites found to be vulnerable to water stress are required to develop water stewardship and business continuity plans. These assessments are conducted annually, or more frequently if there are significant changes to a facility. Subject matter experts conduct focused reviews for sites determined to be at higher risk.

To improve our understanding of Pfizer's resilience to the impacts of climate change, we conducted an in-depth assessment of our potential exposure to physical risks and opportunities that could have a potential impact on our business using scenario analysis informed by data modelling insights from a global sustainability consultancy. Through this process we assessed risks, opportunities and impacts, with consideration of key sensitivities, site aspects, exposures, drivers and uncertainties.

(2.3.5) Will you be disclosing a list/spatial map of priority locations?

- ☒ Yes, we will be disclosing the list/geospatial map of priority locations

(2.3.6) Provide a list and/or spatial map of priority locations

(2.4) How does your organization define substantive effects on your organization?

Risks

(2.4.1) Type of definition

Select all that apply

☒ Qualitative

☒ Quantitative

(2.4.2) Indicator used to define substantive effect

☒ Other, please specify: Any costs (operating and/or capital)

(2.4.3) Change to indicator

☒ Absolute increase

(2.4.5) Absolute increase/ decrease figure

100,000,000

(2.4.6) Metrics considered in definition

Select all that apply

☒ Frequency of effect occurring

☒ Time horizon over which the effect occurs

☒ Likelihood of effect occurring

(2.4.7) Application of definition

For the purposes of this response, Pfizer defines “substantive” environmental risk as any climate-related or water security-related impact that could adversely impact the company’s business or financial condition or disrupt, delay or inhibit the supply of products designated as financially critical, medically necessary, and/or medically significant. For environmental risks that can be evaluated financially, Pfizer generally applies a threshold of \$100MM for considering a risk substantive in this context. We also consider certain market, reputational, regulatory and technology risks to Pfizer as part of the assessment. Pfizer applies these criteria when assessing both direct and indirect environmental risks and opportunities. For the avoidance of doubt, CDP’s phrasing of “substantive” and our response to questions presenting “substantive” climate-related risks should not be considered to relate to matters or facts that could be deemed “material” to a reasonable investor as referred to under US securities laws, similar requirements of other jurisdictions, or other voluntary frameworks. Investors should refer to disclosures in our Annual Report on Form 10-K (10-K) and in our other filings with the US Securities and Exchange Commission, including our quarterly reports on Form 10-Q and our current reports on Form 8-K, for a discussion of “material” matters.

Opportunities

(2.4.1) Type of definition

Select all that apply

- ☒ Qualitative
- ☒ Quantitative

(2.4.2) Indicator used to define substantive effect

- ☒ Revenue

(2.4.3) Change to indicator

Select from:

- ☒ Absolute increase

(2.4.5) Absolute increase/ decrease figure

100,000,000

(2.4.6) Metrics considered in definition

Select all that apply

- ☒ Frequency of effect occurring

- ☑ Time horizon over which the effect occurs
- ☑ Likelihood of effect occurring

(2.4.7) Application of definition

For the purposes of this response, Pfizer defines a “substantive” environmental opportunity as one that could potentially result in a reduction in operating expenses or an increase in revenue. Pfizer generally applies a threshold of \$100MM for considering an opportunity substantive in this context. We also consider certain market, reputational, product, operational efficiency, and business resilience opportunities in our assessment. Pfizer applies these criteria when assessing both direct and indirect environmental opportunities. For the avoidance of doubt, CDP's phrasing of "substantive" and our response to questions presenting "substantive" climate-related risks and opportunities should not be considered to relate to matters or facts that could be deemed “material” to a reasonable investor as referred to under US securities laws, similar requirements of other jurisdictions, or other voluntary frameworks. Investors should refer to disclosures in our Annual Report on Form 10-K (10-K) and in our other filings with the US Securities and Exchange Commission, including our quarterly reports on Form 10-Q and our current reports on Form 8-K, for a discussion of "material" matters.

(2.5) Does your organization identify and classify potential water pollutants associated with its activities that could have a detrimental impact on water ecosystems or human health?

(2.5.1) Identification and classification of potential water pollutants

- ☑ Yes, we identify and classify our potential water pollutants

(2.5.2) How potential water pollutants are identified and classified

Mitigating our impact on water resources includes working to ensure that our operations do not adversely affect human health or the environment. We are committed to compliance with all applicable laws and regulations. We work to meet all applicable local water quality requirements and are committed to engaging our suppliers to embed responsible environmental standards into their operations. We are also committed to limiting the discharge of active pharmaceutical ingredients (API) to wastewater from our manufacturing processes. As a member of the Antimicrobial Resistance Industry Alliance (AMRIA), we developed a unified approach to establishing wastewater discharge targets for antibiotic manufacturing, based on Predicted No Effect Concentrations (PNECs) for use in environmental risk assessments of antibiotics. Our sites are expected to meet the PNEC for the API contained in their wastewater discharge. For new projects, a risk assessment is performed during the capital project approval process to evaluate changes to environmental impacts, e.g., wastewater discharges. Additionally, every major change is reviewed through Pfizer's management of change process.

(2.5.1) Describe how your organization minimizes the adverse impacts of potential water pollutants on water ecosystems or human health associated with your activities.

Row 1

(2.5.1.1) Water pollutant category

- ☒ Other synthetic organic compounds

(2.5.1.2) Description of water pollutant and potential impacts

Pfizer is committed to limiting discharges to wastewater from our manufacturing processes, including organic compounds and active pharmaceutical ingredients, using environmental risk assessment methodologies and emission control practices and technologies.

(2.5.1.3) Value chain stage

Select all that apply

- ☒ Direct operations
- ☒ Upstream value chain
- ☒ Downstream value chain
- ☒ Other, please specify: Product use phase

(2.5.1.4) Actions and procedures to minimize adverse impacts

Select all that apply

- ☒ Upgrading of process equipment/methods
- ☒ Beyond compliance with regulatory requirements
- ☒ Reduction or phase out of hazardous substances
- ☒ Provision of best practice instructions on product use
- ☒ Implementation of integrated solid waste management systems
- ☒ Requirement for suppliers to comply with regulatory requirements
- ☒ Industrial and chemical accidents prevention, preparedness, and response
- ☒ Discharge treatment using sector-specific processes to ensure compliance with regulatory requirements
- ☒ Assessment of critical infrastructure and storage condition (leakages, spillages, pipe erosion etc.) and their resilience
- ☒ Other, please specify: Requirement for suppliers to comply with standards beyond regulatory requirements

(2.5.1.5) Please explain

Mitigating our impact on water resources includes working to ensure that our operations do not adversely affect human health or the environment. We are committed to compliance with all applicable laws and regulations. We work to meet all applicable local water quality requirements at our locations in accordance with wastewater permit requirements. Pfizer's global Ground and Surface Water Protection Standard requires our sites to assess and establish controls to prevent and mitigate risks to ground or surface water associated with the management of hazardous substances at the site. Limiting the presence of pharmaceuticals in the environment is an environmental priority for Pfizer. Pfizer is committed to responsibly managing wastewater discharges from our internal sites and working with our suppliers to help assure they are also responsibly managing their wastewater discharges. We are actively involved with the AMR Industry Alliance (AMRIA) which has a roadmap to understand and mitigate potential impacts of AMR (antimicrobial resistance), including demonstrating responsible manufacturing of our products. In 2022 Pfizer participated in an effort led by AMRIA and BSI Standards Limited to develop an antibiotic certification scheme that is designed to demonstrate implementation of AMRIA's Antibiotic Manufacturing Standard through an independent third-party certification body. Pfizer was one of the first companies to participate in the 2023 certification assessment pilot.

C3. Disclosure of risks and opportunities

(3.1) Have you identified any environmental risks which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future?

Climate change

(3.1.1) Environmental risks identified

☒ Yes, only within our direct operations

(3.1.2) Primary reason why your organization does not consider itself to have environmental risks in your direct operations and/or upstream/downstream value chain

☒ Environmental risks exist, but none with the potential to have a substantive effect on our organization

(3.1.3) Please explain

Pfizer assessed approximately 3,800 suppliers, based on their geographical location without considering adaptation or mitigation measures, against 9 key climate hazards (extreme heat, extreme cold, flooding (river, extreme rainfall, and coastal), tropical cyclones, rainfall-induced landslides, water stress and drought, and wildfires). While a number of these supplier locations were identified as being at elevated risk for one or more of these hazards by 2030 under a high carbon scenario, none were identified as having an overall elevated score when averaged across all nine climate hazards assessed. Pfizer's Loss Prevention and Business Continuity programs will continue to monitor risks to identify potential supply chain vulnerabilities and establish contingency plans to maintain supply, e.g., alternative sourcing options and holding multiple weeks of buffer inventory (depending on product). Pfizer maintains resources for assessing and establishing business continuity arrangements such as the activation of alternative supply chains. Supply chain and business continuity professionals are retained as staff and consultants to ensure these plans are updated at least annually, exercised at least annually, and key colleagues on site are trained on their content and implementation.

Water

(3.1.1) Environmental risks identified

☒ No

(3.1.2) Primary reason why your organization does not consider itself to have environmental risks in your direct operations and/or upstream/downstream value chain

☒ Environmental risks exist, but none with the potential to have a substantive effect on our organization

(3.1.3) Please explain

Pfizer uses a comprehensive risk assessment methodology to identify and evaluate water-related risks with the potential to have substantive financial or strategic impact to the business. These assessments are refreshed annually, or more frequently if there are significant changes to a facility. We have also completed detailed asset-level scenario analyses to assess potential medium- and long-term water-related risks. Based on the findings of these assessments, we consider our current business model and strategy to be resilient and have not identified any water-related risks that pose a substantive risk to our overall operations.

Plastics

(3.1.1) Environmental risks identified

☒ No

(3.1.2) Primary reason why your organization does not consider itself to have environmental risks in your direct operations and/or upstream/downstream value chain

☒ No standardized procedure

(3.1.3) Please explain

Pfizer manufactures pharmaceuticals. Plastics are used as part of R&D and manufacturing equipment, and Pfizer evaluates alternatives where appropriate. Plastic packaging is a necessary and non-discretionary component of our final products required by law but are not directly incorporated into our medicines and vaccines.

(3.1.1) Provide details of the environmental risks identified which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future.

Climate change

(3.1.1.1) Risk identifier

☒ Risk1

(3.1.1.3) Risk types and primary environmental risk driver

Policy

☒ Carbon pricing mechanisms

(3.1.1.4) Value chain stage where the risk occurs

☒ Direct operations

(3.1.1.6) Country/area where the risk occurs

Select all that apply

☒ China

☒ Italy

☒ Japan

☒ Spain

☒ Brazil

☒ Croatia

☒ Germany

☒ Ireland

☒ Morocco

☒ Pakistan

☒ United States of America

☒ Canada

☒ Mexico

☒ Sweden

☒ Austria

☒ Belgium

☒ Argentina

☒ Australia

☒ Indonesia

☒ Singapore

☒ Taiwan, China

(3.1.1.9) Organization-specific description of risk

According to the 2024 World Bank "State and Trends of Carbon Pricing" report, carbon pricing is increasingly recognized as an essential policy instrument to deliver the transition to a low-carbon economy. Approximately 24% of global emissions are currently covered by carbon pricing instruments and governments continue to

evaluate carbon pricing policies to reduce emissions. Although not financially substantive at this time, the implementation of carbon pricing schemes could result in increases in Pfizer's cost of operations. The World Bank suggests that a carbon price of \$50-100 /mtCO₂e by 2030 will be required to limit global warming below 2C. Prices are anticipated to increase (\$200/mtCO₂e) to achieve a 1.5°C scenario. Pfizer has operational control of facilities in multiple regions where carbon pricing schemes currently exist or are being considered, including 10 in the Americas, 12 in Asia-Pacific, 1 in Africa, and 16 in the European Union. We currently have 4 sites that are active under the EU ETS. Of the countries that have currently not implemented carbon taxes, the United States, which accounts for around 2/3 of Pfizer's global Scope 1&2 emissions, represents the area of greatest potential impact. To mitigate the impact from carbon fees, including increases in the cost of goods within our supply chain, Pfizer continues to focus on energy demand reduction through our internal network and supply chain GHG emission reduction goals.

(3.1.1.11) Primary financial effect of the risk

☒ Increased indirect [operating] costs

(3.1.1.12) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☒ Medium-term

(3.1.1.13) Likelihood of the risk having an effect within the anticipated time horizon

☒ Very likely

(3.1.1.14) Magnitude

☒ Medium-low

(3.1.1.16) Anticipated effect of the risk on the financial position, financial performance and cash flows of the organization in the selected future time horizons

These risks could increase operating costs, including the cost of our electricity and energy use, or otherwise increase compliance costs. Our supply chain is subject to these same transitional and physical risks and would likely pass along any increased operating costs to their customers (including Pfizer).

(3.1.1.17) Are you able to quantify the financial effect of the risk?

☒ Yes

(3.1.1.21) Anticipated financial effect figure in the medium-term – minimum (currency)

35,000,000

(3.1.1.22) Anticipated financial effect figure in the medium-term – maximum (currency)

71,000,000

(3.1.1.25) Explanation of financial effect figure

The United States accounts for approximately two-thirds of Pfizer's global Scope 1&2 GHG emissions. Pfizer performed scenario analysis to determine the potential impact to Pfizer if the United States implements a federal carbon pricing scheme consistent with IEA recommendations. The cost to Pfizer for Scope 1 emissions, calculated using 2023 Scope 1 emissions data for facilities located in the United States multiplied by \$50/mt CO2e as the minimum potential carbon tax and 100/mt CO2e as the maximum potential carbon tax, could range from approximately \$18M to \$37M per year assuming no changes to onsite sources of GHG emissions by 2030. The cost associated with Scope 2 emissions, calculated using 2023 Scope 2 emissions data for facilities located in the United States multiplied by \$50/mt CO2e as the minimum potential carbon tax and \$100/mt CO2e as the maximum potential carbon tax, could range from approximately \$17M to \$34M per year by 2030 based on GHG emissions forecasts and varying rates of adoption of green technologies across the US electrical grid. Our calculation assumes that purchased environmental attribute credits will not be allowed to be used to offset GHG emissions for the purposes of any federal carbon assessments, which is consistent with the European Union ETS. Pfizer's combined total cost for US Scope 1&2 emissions therefore could range from approximately \$35M to \$71M per year by 2030, an increase of 11% to 23% over current global energy spend.

(3.1.1.26) Primary response to risk

Compliance, monitoring and targets

☒ Establish organization-wide targets

(3.1.1.27) Cost of response to risk

31,000,000

(3.1.1.28) Explanation of cost calculation

The annual cost of response provided (\$31MM) includes an estimated \$3M in staffing and consulting costs and approximately \$28M incremental OPEX/CAPEX investment to identify, evaluate and advance energy efficiency and decarbonization projects. The estimated OPEX and CAPEX spend is derived from 2023 project data entered by sites in Pfizer's enterprise environmental reporting system. The incremental portion of that spend associated with emissions reduction was estimated based on project type, and the resulting values were aggregated to provide total projected OPEX and CAPEX spend. The estimated \$3M in staffing and consulting

costs was added to the project spend to arrive at the \$31M estimate. Going forward our annual investment may change as we seek opportunities to decarbonize our company operations subject to market and technological developments which is integrated within our annual operating planning cycle.

(3.1.1.29) Description of response

Pfizer evaluates climate change risk as part of its operating risk review process. We monitor regulatory risks arising from current and/or expected local, state, regional, national, or international regulations or legislation related to climate change and evaluate the impact on an ongoing basis. Pfizer manages risk associated with emerging regulation and/or carbon pricing initiatives through effective GHG emission reduction goals and internal energy efficiency targets to reduce potential costs associated with purchase or generation of energy. In 2023 we invested \$28M, not including staffing costs for internal energy conservation program management, to implement or begin implementing 239 projects across the company that resulted in an annual GHG emissions reduction of over 30,000 mt CO2e and an estimated annual savings of \$10M.

Climate change

(3.1.1.1) Risk identifier

☒ Risk2

(3.1.1.3) Risk types and primary environmental risk driver

Acute physical

☒ Tornado

(3.1.1.4) Value chain stage where the risk occurs

☒ Direct operations

(3.1.1.6) Country/area where the risk occurs

Select all that apply

☒ United States of America

(3.1.1.9) Organization-specific description of risk

Climate change presents risks to our operations, including the potential for more frequent and severe weather events that may impact our facilities and those of our suppliers. Pfizer uses a detailed risk review process to assess acute and chronic physical risk for our facilities and those of our material suppliers. Our assessment process utilizes models such as Swiss Re CatNet and ERM's Climate Impact Platform to assess short, medium and long-term risk associated with key climate-related physical hazards. Pfizer has multiple sites in the United States that are in locations prone to severe storms, including those potentially capable of producing tornadoes, including two manufacturing facilities and a logistics center in the Midwest (Kansas, Ohio, and Tennessee), and five manufacturing sites and three research and development (R&D) facilities located in states along the east coast (Connecticut, Massachusetts, New York, and North Carolina). In July 2023 our manufacturing facility in Rocky Mount, NC was damaged by a tornado. While manufacturing has resumed, the supply of medicines impacted by the tornado is expected to be affected through 2024. We cannot provide assurance that physical risks to our facilities and supply chain due to climate change will not occur in the future and therefore have implemented risk mitigation measures through our Loss Prevention and Business Resilience programs designed to reduce potential financial impacts.

(3.1.1.11) Primary financial effect of the risk

Select from:

☒ Other, please specify: Inventory losses, disruption in production capacity, and increased indirect costs

(3.1.1.12) Time horizon over which the risk is anticipated to have a substantive effect on the organization

☒ The risk has already had a substantive effect on our organization in the reporting year

(3.1.1.14) Magnitude

☒ Medium-low

(3.1.1.15) Effect of the risk on the financial position, financial performance and cash flows of the organization in the reporting year

Our manufacturing facility in Rocky Mount, NC was damaged by a tornado in July 2023. As a result, Pfizer recorded \$286 million to cost of sales for inventory losses, overhead costs related to the period in which the facility could not operate, and incremental costs resulting from the tornado damage. Losses incurred in 2023 were partially offset by insurance recoveries.

(3.1.1.17) Are you able to quantify the financial effect of the risk?

☒ Yes

(3.1.1.18) Financial effect figure in the reporting year (currency)

238,000,000

(3.1.1.25) Explanation of financial effect figure

For 2023, the total of \$238 million mainly includes \$286 million in inventory losses, overhead costs related to the period in which the facility could not operate, and incremental costs resulting from tornado damage to our manufacturing facility in Rocky Mount, NC, partially offset by insurance recoveries.

(3.1.1.26) Primary response to risk

Policies and plans

☒ Other policies or plans, please specify: Maintain business resilience and loss prevention plans

(3.1.1.27) Cost of response to risk

2,000,000

(3.1.1.28) Explanation of cost calculation

The estimated cost of response includes staffing costs to manage business continuity programs at the site and corporate level, subscriptions and services to perform loss prevention assessments at sites and maintain access to predictive tools to facilitate risk assessment, and maintenance of controls such as flood walls.

(3.1.1.29) Description of response

Pfizer's primary controls for the management of acute and chronic physical risks are our infrastructure and systems. Our facilities are primarily located in areas with limited exposure to physical risks and we have robust processes in place to identify and mitigate potential vulnerabilities. Through our Loss Prevention and Business Resilience programs we maintain plans to minimize business disruption, including alternative sourcing options and buffer inventory (depending on product). Pfizer maintains resources for assessing and establishing business continuity arrangements. Business continuity professionals are retained as staff and consultants to help ensure these plans are updated and exercised at least annually, and key colleagues on site are trained on the plans' content and implementation.

(3.1.2) Provide the amount and proportion of your financial metrics from the reporting year that are vulnerable to the substantive effects of environmental risks.

Climate change

(3.1.2.1) Financial metric

Select from:

☒ Other, please specify: Cost of sales, partially offset by insurance recoveries.

(3.1.2.2) Amount of financial metric vulnerable to transition risks for this environmental issue (unit currency as selected in 1.2)

0

(3.1.2.3) % of total financial metric vulnerable to transition risks for this environmental issue

Select from:

☒ Less than 1%

(3.1.2.4) Amount of financial metric vulnerable to physical risks for this environmental issue (unit currency as selected in 1.2)

238,000,000

(3.1.2.5) % of total financial metric vulnerable to physical risks for this environmental issue

Select from:

☒ Less than 1%

(3.1.2.7) Explanation of financial figures

The amount vulnerable to physical risks in the reporting year (\$238M) mainly includes \$286M inventory losses, overhead costs related to the period in which the impacted facility could not operate, and incremental costs resulting from the tornado damage to our facility in Rocky Mount, NC, partially offset by insurance recoveries.

(3.3) In the reporting year, was your organization subject to any fines, enforcement orders, and/or other penalties for water-related regulatory violations?

	Water-related regulatory violations	Fines, enforcement orders, and/or other penalties	Comment
	<i>Select from:</i> <input checked="" type="checkbox"/> Yes	<i>Select all that apply</i> <input checked="" type="checkbox"/> Enforcement orders or other penalties	<i>Details provided in 3.3.2</i>

(3.3.2) Provide details for all significant fines, enforcement orders and/or other penalties for water-related regulatory violations in the reporting year, and your plans for resolving them.

Row 1

(3.3.2.1) Type of penalty

☒ Enforcement order

(3.3.2.2) Financial impact

111,596

(3.3.2.3) Country/Area & River basin

United States of America

☒ Other, please specify: Kalamazoo

(3.3.2.4) Type of incident

☒ Other non-compliance with permits, standards, or regulations

(3.3.2.5) Description of penalty, incident, regulatory violation, significance, and resolution

An administrative consent order (ACO) resolved alleged violations of our Kalamazoo, Michigan facility's NPDES stormwater permit. None of the alleged violations included harm to public health or the environment. We are currently implementing a multi-year corrective action plan pursuant to the ACO.

(3.5) Are any of your operations or activities regulated by a carbon pricing system (i.e. ETS, Cap & Trade or Carbon Tax)?

Select from:

☒ Yes

(3.5.1) Select the carbon pricing regulation(s) which impact your operations.

Select all that apply

☒ EU ETS

☒ Ireland carbon tax

☒ Spain carbon tax

☒ Other carbon tax, please specify: Canada Carbon Tax, Croatia Carbon Tax, Germany Carbon Tax

(3.5.2) Provide details of each Emissions Trading Scheme (ETS) your organization is regulated by.

EU ETS

(3.5.2.1) % of Scope 1 emissions covered by the ETS

12

(3.5.2.2) % of Scope 2 emissions covered by the ETS

0

(3.5.2.3) Period start date

01/01/2023

(3.5.2.4) Period end date

12/31/2023

(3.5.2.5) Allowances allocated

19,499

(3.5.2.6) Allowances purchased

22,527

(3.5.2.7) Verified Scope 1 emissions in metric tons CO2e

76,819

(3.5.2.8) Verified Scope 2 emissions in metric tons CO2e

0

(3.5.2.9) Details of ownership

Select from:

☒ Facilities we own and operate

(3.5.2.10) Comment

N/A

(3.5.3) Complete the following table for each of the tax systems you are regulated by.

Ireland carbon tax

(3.5.3.1) Period start date

01/01/2023

(3.5.3.2) Period end date

12/31/2023

(3.5.3.3) % of total Scope 1 emissions covered by tax

11

(3.5.3.4) Total cost of tax paid

218,369

(3.5.3.5) Comment

Carbon taxes paid by Pfizer's three manufacturing facilities in Ireland.

Spain carbon tax

(3.5.3.1) Period start date

01/01/2023

(3.5.3.2) Period end date

12/31/2023

(3.5.3.3) % of total Scope 1 emissions covered by tax

0.3

(3.5.3.4) Total cost of tax paid

5577

(3.5.3.5) Comment

Carbon taxes paid by Pfizer's manufacturing facility in Algete, Spain.

Other carbon tax, please specify

(3.5.3.1) Period start date

01/01/2023

(3.5.3.2) Period end date

12/31/2023

(3.5.3.3) % of total Scope 1 emissions covered by tax

2

(3.5.3.4) Total cost of tax paid

411,656

(3.5.3.5) Comment

Includes carbon taxes paid in Canada, Germany and Croatia

(3.5.4) What is your strategy for complying with the systems you are regulated by or anticipate being regulated by?

Pfizer's strategy is to set corporate GHG reduction goals which in turn drive the sites to implement energy reduction projects and equipment upgrades to reduce their carbon footprint. By reducing our carbon footprint, we help minimize the impact of the carbon pricing requirements that apply to our operations. For example, our sites in Ireland collectively completed 34 projects in 2023 to reduce GHG emissions by approximately 4,500 mtCO₂e annually. As part of our efforts to reduce our overall environmental footprint globally, our manufacturing and R&D sites align their environmental sustainability masterplans with our 2040 Net Zero ambition. We seek opportunities to design new facilities and renovation projects with reduced environmental impact (such as energy consumption, water usage, and waste management) so we can reduce resource demand. For example, our new manufacturing facility in Tuas, Singapore was issued a Green Mark Gold certificate in late 2022, a new utilities building at our Kalamazoo, Michigan, location received LEED certification in 2023; and our New York headquarters received LEED Platinum certification in 2023. Also, in 2023, Pfizer adopted the My Green Labs (MGL) Certification program at our Cambridge, Massachusetts, site to facilitate engagement of laboratory-based colleagues in environmental stewardship with the aim of accelerating GHG emissions reductions in our R&D operations. The MGL Certification program has been recognized by the UN Race to Zero campaign as a key measure of progress toward a zero carbon future. A total of 19 laboratories across five of Pfizer's

research sites in Cambridge, Massachusetts; Boulder, Colorado; Groton, Connecticut; Pearl River, New York; and Andover, Massachusetts, received MGL Certifications in 2023. Pfizer invests in no- / low-carbon technologies at our sites and through power purchase agreements (PPAs) that enable sourcing of renewable energy. In 2023, we signed virtual PPAs (VPPAs) for four new solar projects in Spain that will collectively cover all of Pfizer’s purchased electricity in the European Union. These EU VPPAs, along with the North America VPPA we signed in 2021, are key steps in our plan to achieve our RE100 goal of 100% renewable energy by 2030 and the voluntary Net Zero Standard by 2040. When the North America and EU VPPA solar projects come online, they are expected to cover approximately 68% of Pfizer’s global electricity needs as measured against 2023 electricity consumption. Pfizer’s fleet of vehicles, the majority of which are used by our commercial teams to facilitate education and engagement with healthcare providers, accounted for approximately 0.5% of our total Scope 1 and 2 GHG emissions in 2023. Pfizer is working to advance fleet sustainability through transitioning to battery electric vehicles (BEV) and, where feasible, other low-emission vehicle options, and by supporting fuel management and efficient driving choices for internal combustion vehicles until they can be retired. Our transition to BEV has started in nine markets, with 484 BEVs currently in use and an additional 103 ordered as of August 2024. Through three successive emissions reduction goals, Pfizer reduced GHG emissions 60% from 2000 through 2020. We have established a near-term goal to further reduce GHG emissions 46% by 2030 from a 2019 baseline and aim to achieve the voluntary Net-Zero Standard by 2040. Pfizer’s Scope 1 and 2 GHG emissions in 2023 were approximately 2% lower than 2022 and 13% lower than the 2019 baseline.

(3.6) Have you identified any environmental opportunities which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future?

	Environmental opportunities identified
Climate change	Select from: <input checked="" type="checkbox"/> Yes, we have identified opportunities, and some/all are being realized
Water	Select from: <input checked="" type="checkbox"/> Yes, we have identified opportunities, and some/all are being realized

[Fixed row]

(3.6.1) Provide details of the environmental opportunities identified which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future.

Climate change

(3.6.1.1) Opportunity identifier

Select from:

☒ Opp1

(3.6.1.3) Opportunity type and primary environmental opportunity driver

Resource efficiency

☒ Increased efficiency of production and/or distribution processes

(3.6.1.4) Value chain stage where the opportunity occurs

Select from:

☒ Direct operations

(3.6.1.5) Country/area where the opportunity occurs

Select all that apply

☒ China

☒ India

☒ Italy

☒ Japan

☒ Spain

☒ Germany

☒ Ireland

☒ Morocco

☒ Pakistan

☒ Argentina

☒ Brazil

☒ Canada

☒ Mexico

☒ Austria

☒ Belgium

☒ Australia

☒ Indonesia

☒ Singapore

☒ United States of America

(3.6.1.8) Organization specific description

Pfizer continually seeks to drive efficiency improvements within our operations. By replacing and/or optimizing efficiency of production and HVAC equipment we strive to reduce energy consumption and GHG emissions and lower our operating costs. Pfizer aims to achieve the voluntary Net-Zero Standard by 2040 and has near-term commitments to reduce Scope 1 and 2 emissions 46% from a 2019 baseline and source 100% renewable electricity by 2030. We expect to achieve these targets in part by investing in equipment optimization and replacement at our sites. We have established internal targets to drive project implementation at our manufacturing facilities, and manufacturing leadership monitors progress toward these targets. We completed over 200 emission reduction projects at 32 sites around the world in 2023, investing approximately \$28M to reduce emissions by nearly 30,000 mt CO2e annually. These projects are projected to reduce operating costs by approximately \$10M annually, with approximately 15% of savings resulting from replacement and optimization of chillers, approximately 12% from the replacement and optimization of HVAC systems, and the rest from a combination of boiler, compressed air, steam, lighting, and other improvement projects.

(3.6.1.9) Primary financial effect of the opportunity

Select from:

☒ Reduced indirect (operating) costs

(3.6.1.10) Time horizon over which the opportunity is anticipated to have a substantive effect on the organization

Select all that apply

☒ Short-term

(3.6.1.11) Likelihood of the opportunity having an effect within the anticipated time horizon

Select from:

☒ Virtually certain (99–100%)

(3.6.1.12) Magnitude

Select from:

☒ Medium-low

(3.6.1.14) Anticipated effect of the opportunity on the financial position, financial performance and cash flows of the organization in the selected future time horizons

While not considered substantive as defined for the purposes of this submittal, we have included this opportunity as it may be of interest to our stakeholders. Savings from the implementation of emissions reduction projects are projected to have minimal impact on Pfizer's financial position, financial performance and cash flows.

(3.6.1.15) Are you able to quantify the financial effects of the opportunity?

Select from:

☒ Yes

(3.6.1.17) Anticipated financial effect figure in the short-term - minimum (currency)

0

(3.6.1.18) Anticipated financial effect figure in the short-term – maximum (currency)

10,000,000

(3.6.1.23) Explanation of financial effect figures

The estimated financial impact of \$10M per year represents the average reduction in operating costs achieved each year through the implementation of emission reduction projects. This estimate is based on projects implemented in 2023. These projects typically have a payback period of 4-10 years or less and have a lifetime greater than 6 years. We invested \$28M in energy efficiency projects in 2023 to achieve an estimated annual savings of \$10M. Approximately 15% of savings resulting from replacement and optimization of chillers, approximately 12% from the replacement and optimization of HVAC systems, and the rest from a combination of boiler, compressed air, steam, lighting, and other improvement projects.

(3.6.1.24) Cost to realize opportunity

28,000,000

(3.6.1.25) Explanation of cost calculation

The cost to realize the opportunity for 2023 provided above includes approximately \$28M OPEX and CAPEX incremental investment to identify, evaluate and advance energy efficiency and decarbonization projects.

(3.6.1.26) Strategy to realize opportunity

Pfizer's Environmental Sustainability and Impact Reduction Standard requires all sites to develop a systematic approach to conserve energy and improve efficiency. Sites identified as medium and large energy users are required to establish environmental sustainability teams and to develop and maintain sustainability master plans that include prioritized emission reduction opportunities. Project implementation is monitored at the corporate level with performance reports provided to company leadership quarterly. Pfizer has historically invested each year to reduce energy demand through end-of-life asset replacement, efficiency improvements, and installation of renewable technologies. In 2023, we invested \$28M (incremental) in energy efficiency projects to achieve an estimated annual savings of approximately \$10M. Projects with the most significant annual savings include HVAC upgrades at our Vizag, India; Nagoya, Japan, and Newbridge, Ireland sites and

chiller and colling projects at our sites in Freiburg, Germany; Grange Castle, Ireland; and Tuas, Singapore. Projects completed in 2023 are expected to reduce Pfizer's Scope 1 and 2 emissions by approximately 30,000 mt CO2e annually from 2024 forward.

Water

(3.6.1.1) Opportunity identifier

Select from:

☒ Opp2

(3.6.1.3) Opportunity type and primary environmental opportunity driver

Resource efficiency

☒ Reduced water usage and consumption

(3.6.1.4) Value chain stage where the opportunity occurs

Select from:

☒ Direct operations

(3.6.1.5) Country/area where the opportunity occurs

Select all that apply

☒ China

☒ Italy

☒ Japan

☒ Spain

☒ Brazil

☒ United States of America

☒ Mexico

☒ Belgium

☒ Ireland

☒ Argentina

☒ Australia

(3.6.1.6) River basin where the opportunity occurs

Select all that apply

☒ Other, please specify :Multiple river basins

(3.6.1.8) Organization specific description

Pfizer requires our manufacturing and research and development sites to maintain site master plans that identify opportunities to reduce their environmental footprint. Sites are expected to set annual performance targets and to identify, prioritize, and implement water conservation projects to offset increases due to increased production. Project information is entered into a global database where it is monitored by sustainability champions at the site, business, and corporate levels. Progress is reported to business leadership quarterly.

(3.6.1.9) Primary financial effect of the opportunity

Select from:

☒ Reduced indirect (operating) costs

(3.6.1.10) Time horizon over which the opportunity is anticipated to have a substantive effect on the organization

Select all that apply

☒ Short-term

(3.6.1.11) Likelihood of the opportunity having an effect within the anticipated time horizon

Select from:

☒ Virtually certain (99–100%)

(3.6.1.12) Magnitude

Select from:

☒ Low

(3.6.1.14) Anticipated effect of the opportunity on the financial position, financial performance and cash flows of the organization in the selected future time horizons

While not considered substantive as defined for the purposes of this submittal, we have included this opportunity as it may be of interest to our stakeholders. Savings from the implementation of water conservation projects are projected to have minimal impact on Pfizer's financial position, financial performance and cash flows.

(3.6.1.15) Are you able to quantify the financial effects of the opportunity?

Select from:

☒ Yes

(3.6.1.17) Anticipated financial effect figure in the short-term - minimum (currency)

0

(3.6.1.18) Anticipated financial effect figure in the short-term – maximum (currency)

246,000

(3.6.1.23) Explanation of financial effect figures

From 2024 to 2030 Pfizer expects to achieve annual savings of approximately \$246,000 as a result of projects with a water conservation component. The potential financial effect figure represents approximate estimated annual savings from the implementation of new conservation projects.

(3.6.1.24) Cost to realize opportunity

6,000,000

(3.6.1.25) Explanation of cost calculation

The cost calculation for realizing this opportunity takes into account both the estimated capital expenditures and the estimated operational expenses associated with implementing the planned water conservation projects from 2024 to 2030.

(3.6.1.26) Strategy to realize opportunity

The availability of and access to clean water is a basic human need globally that must be addressed locally. Pfizer's Water Stewardship position statement describes our commitment to being good stewards of the water we use to make medicines and vaccines, particularly in water-stressed areas. To this end, we completed water stress assessments at all Pfizer sites to identify water quality, scarcity, and availability risks across our network and are developing action plans for sites with elevated risk scores. These plans include elements such as quantifying water use, implementing mitigation plans and establishing water conservation targets, protecting water quality, improving wastewater treatment where necessary, evaluating recycling practices, and engaging with surrounding communities. We will measure progress at our internal sites while engaging with our key suppliers in water stressed areas to encourage them to develop and implement similar action plans.

Climate change

(3.6.1.1) Opportunity identifier

Select from:

☒ Opp3

(3.6.1.3) Opportunity type and primary environmental opportunity driver

Markets

☒ Use of public sector incentives

(3.6.1.4) Value chain stage where the opportunity occurs

Select from:

☒ Downstream value chain

(3.6.1.5) Country/area where the opportunity occurs

Select all that apply

☒ United Kingdom of Great Britain and Northern Ireland

(3.6.1.8) Organization specific description

An increasing number of national healthcare systems and countries have announced targets to become Net-Zero, including in their supply chain, i.e., the suppliers and pharmaceutical products used by healthcare providers. Healthcare systems may, therefore, prefer or require suppliers to provide low-carbon products. Pfizer's current and potential customers increasingly request information and data to assess our environmental commitments and performance. Pfizer has been requested to provide 2023 GHG emissions and environmental sustainability program information to over 20 customers in Europe and the United States and for several hospital tenders in Europe. We anticipate that Pfizer's commitment to ambitious climate action may help to position us favorably in supplier selection processes.

(3.6.1.9) Primary financial effect of the opportunity

Select from:

☒ Increased revenues resulting from increased demand for products and services

(3.6.1.10) Time horizon over which the opportunity is anticipated to have a substantive effect on the organization

Select all that apply

☒ Long-term

(3.6.1.11) Likelihood of the opportunity having an effect within the anticipated time horizon

Select from:

☒ Very likely (90–100%)

(3.6.1.12) Magnitude

Select from:

☒ Medium-low

(3.6.1.14) Anticipated effect of the opportunity on the financial position, financial performance and cash flows of the organization in the selected future time horizons

This opportunity has the potential to have a substantive impact on Pfizer's revenue but is not yet quantifiable.

(3.6.1.15) Are you able to quantify the financial effects of the opportunity?

Select from:

☒ Yes

(3.6.1.21) Anticipated financial effect figure in the long-term - minimum (currency)

0

(3.6.1.22) Anticipated financial effect figure in the long-term – maximum (currency)

100,000,000

(3.6.1.23) Explanation of financial effect figures

Pfizer continues to see increased requests for environmental information for more products and by more customers. We performed scenario analysis to determine the potential impact to Pfizer if customers' decarbonization demands influenced purchasing decisions. For example, England's National Health Service (NHS) publicly declared its intention to be net-zero for Scopes 1, 2 and 3 by 2045 and set a long-term target to stop purchasing from suppliers that do not meet or exceed the NHS commitment to net zero by 2030. (Reference: Delivering a 'Net Zero' National Health Service; October 2020). Pfizer's commitment to ambitious climate action may help us meet or exceed NHS's expectation. If so, we would expect to potentially maintain or increase our share of NHS purchasing decisions. The potential financial impact is a placeholder that represents our acknowledgement that the impact could be substantive but is not yet quantifiable until NHS develops its sustainable purchasing criteria and uncertainty in projecting future NHS product needs.

(3.6.1.24) Cost to realize opportunity

45,000,000

(3.6.1.25) Explanation of cost calculation

The approximate cost to maintain Pfizer's Net Zero program was calculated based on the estimated annual incremental capital spend associated with emission reduction activities (28M) and the estimated staff and consulting costs to implement corporate goals, manage programs, report performance and support sustainable science initiatives (17M).

(3.6.1.26) Strategy to realize opportunity

We recognize global climate change as one of the defining issues of our time, requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. Pfizer is continuing its near-term commitment to reduce company greenhouse gas (GHG) emissions by 46% compared with a 2019 baseline, aligned with a 1.5°C trajectory, and to drive action by encouraging suppliers to also set science-based GHG emissions reduction goals. We have further committed to reduce GHG emissions by working to achieve the voluntary Net Zero Standard by 2040, ten years earlier than the timeline described in the standard. By 2040 Pfizer aims to decrease its company GHG emissions by 95% and its value chain emissions by 90% from 2019 levels by reducing the energy demand of our operations, transitioning away from fossil fuels, sourcing renewable electricity, and engaging suppliers to catalyze equivalent action.

[Add row]

(3.6.2) Provide the amount and proportion of your financial metrics in the reporting year that are aligned with the substantive effects of environmental opportunities.

Climate change

(3.6.2.1) Financial metric

Select from:

☒ Revenue

(3.6.2.2) Amount of financial metric aligned with opportunities for this environmental issue (unit currency as selected in 1.2)

10,000,000

(3.6.2.3) % of total financial metric aligned with opportunities for this environmental issue

Select from:

☒ Less than 1%

(3.6.2.4) Explanation of financial figures

The OPEX savings associated with the implementation of energy conservation projects in 2023 was well below 1% of total OPEX spend.

Water

(3.6.2.1) Financial metric

Select from:

☒ OPEX

(3.6.2.2) Amount of financial metric aligned with opportunities for this environmental issue (unit currency as selected in 1.2)

239,000

(3.6.2.3) % of total financial metric aligned with opportunities for this environmental issue

Select from:

☒ Less than 1%

(3.6.2.4) Explanation of financial figures

The OPEX savings associated with the implementation of water conservation projects in 2023 was well below 1% of total OPEX spend.

C4. Governance

(4.1) Does your organization have a board of directors or an equivalent governing body?

(4.1.1) Board of directors or equivalent governing body

Select from:

☒ Yes

(4.1.2) Frequency with which the board or equivalent meets

Select from:

☒ More frequently than quarterly

(4.1.3) Types of directors your board or equivalent is comprised of

Select all that apply

☒ Executive directors or equivalent

☒ Independent non-executive directors or equivalent

(4.1.4) Board diversity and inclusion policy

Select from:

☒ Yes, and it is publicly available

(4.1.5) Briefly describe what the policy covers

For the purposes of this response, we are defining policy broadly to include Pfizer Inc. Corporate Governance Principles. Pursuant to its charter, the Governance & Sustainability Committee of the Board is responsible for considering a diverse pool of candidates to fill positions on the Board; however, the company does not have a formal policy on Board diversity.

(4.1.6) Attach the policy (optional)

(4.1.1) Is there board-level oversight of environmental issues within your organization?

	Board-level oversight of this environmental issue
Climate change	Select from: <input checked="" type="checkbox"/> Yes
Water	Select from: <input checked="" type="checkbox"/> Yes

(4.1.2) Identify the positions (do not include any names) of the individuals or committees on the board with accountability for environmental issues and provide details of the board’s oversight of environmental issues.

Climate change

(4.1.2.1) Positions of individuals or committees with accountability for this environmental issue

- Select all that apply
- ☒ Board chair
 - ☒ Chief Executive Officer (CEO)
 - ☒ Board-level committee

(4.1.2.2) Positions’ accountability for this environmental issue is outlined in policies applicable to the board

- Select from:
- ☒ Yes

(4.1.2.3) Policies which outline the positions' accountability for this environmental issue

Select all that apply

☒ Other policy applicable to the board, please specify: **Committee** charters, available at <https://investors.pfizer.com/Investors/Corporate-Governance/Board-Committees--Charters/default.aspx>

(4.1.2.4) Frequency with which this environmental issue is a scheduled agenda item

Select from:

☒ Scheduled agenda item in some board meetings – at least annually

(4.1.2.5) Governance mechanisms into which this environmental issue is integrated

Select all that apply

- ☒ Overseeing the setting of corporate targets
- ☒ Monitoring progress towards corporate targets
- ☒ Approving and/or overseeing employee incentives
- ☒ Overseeing reporting, audit, and verification processes
- ☒ Monitoring the implementation of a climate transition plan
- ☒ Overseeing and guiding the development of a business strategy

(4.1.2.7) Please explain

Pfizer's CEO and Chairman of the Board is responsible, in his capacity as CEO and member of the Executive Leadership Team, for guiding Pfizer's climate strategy and approving environmental sustainability-related public goals. In June 2022 he committed to accelerate the decarbonization of Pfizer's value chain, aiming to achieve the voluntary Net-Zero standard by 2040. Pfizer's management reports progress on our Net-Zero goal quarterly to the CEO and Chairman of the Board, who in turn informs the Board of Directors. The Board of Directors is fully engaged and supportive of Pfizer's ESG program. The Governance and Sustainability Committee of the Board (G&SC) is primarily responsible for oversight of our ESG strategy and reporting. Throughout the year, the G&SC receives updates from the CSO and other company leaders regarding our ESG priorities and progress and changes in the ESG external environment. Pfizer's Compensation Committee of the Board of Directors is responsible for establishing annual and long-term performance goals and reviewing and certifying performance-based compensation plans. The Committee approved the addition of an ESG modifier that includes a GHG emissions reduction metric to Pfizer's annual performance-based variable bonus program to support Pfizer's commitment to reducing GHG emissions.

Water

(4.1.2.1) Positions of individuals or committees with accountability for this environmental issue

Select all that apply

- ☒ Board chair
- ☒ Chief Executive Officer (CEO)
- ☒ Board-level committee

(4.1.2.2) Positions' accountability for this environmental issue is outlined in policies applicable to the board

Select from:

- ☒ Yes

(4.1.2.3) Policies which outline the positions' accountability for this environmental issue

Select all that apply

- ☒ Other policy applicable to the board, please specify: **Committee** charters, available at <https://investors.pfizer.com/Investors/Corporate-Governance/Board-Committees--Charters/default.aspx>

(4.1.2.4) Frequency with which this environmental issue is a scheduled agenda item

Select from:

- ☒ Scheduled agenda item in some board meetings – at least annually

(4.1.2.5) Governance mechanisms into which this environmental issue is integrated

Select all that apply

- ☒ Overseeing and guiding public policy engagement
- ☒ Overseeing and guiding the development of a business strategy
- ☒ Monitoring the implementation of the business strategy

(4.1.2.7) Please explain

Pfizer's enterprise EHS risk program is managed by the Global EHS team in partnership with Legal and with active engagement from a cross disciplinary team of leaders representing Engineering, Facilities, Sourcing, and scientific and manufacturing lines. Through the Global EHS Operational Risk Review process, key risks are escalated to the Pfizer Global Supply (PGS) Quality & Risk Committee (PGS Q&RC). PGS Q&RC reports on priority risks and mitigation, including those related to environmental issues, to the Executive Compliance Committee, chaired by the CEO, and to the Regulatory Compliance Committee (RCC) of the Board of Directors. The PGS Q&RC risk management process also informs Pfizer's Enterprise Risk Management (ERM) program, overseen by the Audit Committee of the Board of Directors. Pfizer's ERM process assesses on an annual basis our operations and risk management priorities, including risks related to environmental issues and the long-term sustainability of the business. Each risk is prioritized and assigned to a member or members, as appropriate, of Pfizer's Executive Leadership Team. The Audit Committee of the Board of Directors has primary responsibility for overseeing Pfizer's ERM program. Periodically, the Regulatory and Compliance Committee and the Audit Committee hold joint sessions to discuss risks relevant to both Committees' areas of risk oversight, including an annual discussion of the ERM program. The Board is kept informed of its committees' risk oversight and other activities through reports by the committee chairs to the full Board. Our cross-functional Sustainability Steering Committee, chaired by our Chief Sustainability Officer, advises on key issues and guides the integration and implementation of Pfizer's non-financial reporting related to ESG. This Committee is overseen by a dedicated Executive Sustainability Committee, chaired by the Executive Leadership Team member leading Corporate Affairs, who reports directly to the Chairman and CEO. Our ESG governance has as its foundation oversight by the Board of Directors, commitment and accountability by leadership, and engagement by colleagues across the company. Diverse perspectives from internal and external stakeholders inform our ESG strategy and priorities. The Board of Directors is fully engaged and supportive of Pfizer's ESG program. The G&SC of the Board is primarily responsible for oversight of our ESG strategy and reporting. Throughout the year, the G&SC receives updates from company leaders regarding our ESG priorities and progress and changes in the ESG external environment.

(4.2) Does your organization's board have competency on environmental issues?

Climate change

(4.2.1) Board-level competency on this environmental issue

Select from:

☒ Yes

(4.2.2) Mechanisms to maintain an environmentally competent board

Select all that apply

☒ Other, please specify: Pfizer's BoD is composed of a diverse group of esteemed medical professionals, scientists, academics, and business leaders with skills, experience and academic training that provides them with competence to advise on environmental matters.

Water

(4.2.1) Board-level competency on this environmental issue

Select from:

☒ Yes

(4.2.2) Mechanisms to maintain an environmentally competent board

Select all that apply

☒ Other, please specify: Pfizer's BoD is composed of a diverse group of esteemed medical professionals, scientists, academics, and business leaders with skills, experience and academic training that provides them with competence to advise on environmental matters.

[Fixed row]

(4.3) Is there management-level responsibility for environmental issues within your organization?

	Management-level responsibility for this environmental issue
Climate change	Select from: <input checked="" type="checkbox"/> Yes
Water	Select from: <input checked="" type="checkbox"/> Yes

[Fixed row]

(4.3.1) Provide the highest senior management-level positions or committees with responsibility for environmental issues (do not include the names of individuals).

Climate change

(4.3.1.1) Position of individual or committee with responsibility

Executive level

- ☒ Chief Executive Officer (CEO)

(4.3.1.2) Environmental responsibilities of this position

Dependencies, impacts, risks and opportunities

- ☒ Managing environmental dependencies, impacts, risks, and opportunities

Policies, commitments, and targets

- ☒ Monitoring compliance with corporate environmental policies and/or commitments
- ☒ Setting corporate environmental policies and/or commitments
- ☒ Setting corporate environmental targets

Strategy and financial planning

- ☒ Developing a business strategy which considers environmental issues

(4.3.1.4) Reporting line

Select from:

- ☒ Reports to the board directly

(4.3.1.5) Frequency of reporting to the board on environmental issues

Select from:

- ☒ Quarterly

(4.3.1.6) Please explain

The CEO and Chairman of the Board is responsible, in his capacity as CEO and member of the Executive Leadership Team, for guiding Pfizer's climate strategy and approving environmental sustainability-related public goals. In June 2022 he committed to accelerate the decarbonization of Pfizer's value chain, aiming to achieve the voluntary Net-Zero standard by 2040. Pfizer's Strategy & Consulting team collects and reports progress on Pfizer's GHG reduction targets to the CEO and Chairman of the Board, who in turn reports them to the Board of Directors.

Water

(4.3.1.1) Position of individual or committee with responsibility

Executive level

- ☒ Chief Executive Officer (CEO)

(4.3.1.2) Environmental responsibilities of this position

Dependencies, impacts, risks and opportunities

- ☒ Managing environmental dependencies, impacts, risks, and opportunities

Strategy and financial planning

- ☒ Developing a business strategy which considers environmental issues

(4.3.1.4) Reporting line

Select from:

- ☒ Reports to the board directly

(4.3.1.5) Frequency of reporting to the board on environmental issues

Select from:

- ☒ Half-yearly

(4.3.1.6) Please explain

The PGS Q&RC provides updates on priority risks and mitigation, including those related to climate change and pharmaceuticals in the environment, to the Executive Compliance Committee, chaired by the CEO, and to the Regulatory Compliance Committee (RCC) of the Board of Directors twice each year. The PGS Q&RC risk management process also informs Pfizer's Enterprise Risk Management (ERM) program, overseen by the Audit Committee of the Board of Directors.

Climate change

(4.3.1.1) Position of individual or committee with responsibility

Executive level

- ☒ President

(4.3.1.2) Environmental responsibilities of this position

Policies, commitments, and targets

- ☒ Monitoring compliance with corporate environmental policies and/or commitments

Strategy and financial planning

- ☒ Implementing a climate transition plan
- ☒ Implementing the business strategy related to environmental issues
- ☒ Managing annual budgets related to environmental issues
- ☒ Managing major capital and/or operational expenditures relating to environmental issues

(4.3.1.4) Reporting line

Select from:

- ☒ Reports to the Chief Executive Officer (CEO)

(4.3.1.5) Frequency of reporting to the board on environmental issues

Select from:

- ☒ Not reported to the board

(4.3.1.6) Please explain

Pfizer's EVP, Chief Global Supply Officer, leads Pfizer's Global Supply division (PGS), and is responsible for implementation of Pfizer's Net Zero strategy. Product manufacturing at our internal network of sites, managed by PGS, accounts for approximately 70% of the company's energy consumption and Scope 1 & 2 GHG emissions. The EVP, Chief Global Supply Officer, has operational control over PGS operations and strategy, including OPEX/CAPEX investment in emission reduction projects and oversight of Pfizer's manufacturing supply chain which accounts for the majority of our Scope 3 emissions. Environmental sustainability has

been integrated into the overarching PGS strategy and GHG emissions reduction is monitored as a key performance indicator (KPI). Performance against this goal is included in a monthly dashboard reviewed by the PGS Executive Leadership Team.

Climate change

(4.3.1.1) Position of individual or committee with responsibility

Committee

- ☒ Sustainability committee

(4.3.1.2) Environmental responsibilities of this position

Policies, commitments, and targets

- ☒ Monitoring compliance with corporate environmental policies and/or commitments

Strategy and financial planning

- ☒ Developing a business strategy which considers environmental issues

(4.3.1.4) Reporting line

Select from:

- ☒ Reports to the Chief Executive Officer (CEO)

(4.3.1.5) Frequency of reporting to the board on environmental issues

Select from:

- ☒ As important matters arise

(4.3.1.6) Please explain

Our cross-functional Sustainability Steering Committee, chaired by our Chief Sustainability Officer, advises on key issues and guides the integration and implementation of Pfizer's non-financial reporting related to ESG. This Committee is overseen by a dedicated Executive Sustainability Committee, chaired by the Executive Leadership Team member leading Corporate Affairs, who reports directly to the Chairman and CEO. Our ESG governance has as its foundation oversight by the Board of Directors, commitment and accountability by leadership, and engagement by colleagues across the company. Diverse perspectives from internal and

external stakeholders inform our ESG strategy and priorities. The Board of Directors is fully engaged and supportive of Pfizer's ESG program. The G&SC of the Board is primarily responsible for oversight of our ESG strategy and reporting. Throughout the year, the G&SC receives updates from company leaders regarding our ESG priorities and progress and changes in the ESG external environment.

[Add row]

(4.5) Do you provide monetary incentives for the management of environmental issues, including the attainment of targets?

Climate change

(4.5.1) Provision of monetary incentives related to this environmental issue

Select from:

☒ Yes

(4.5.2) % of total C-suite and board-level monetary incentives linked to the management of this environmental issue

0.01

(4.5.3) Please explain

Pfizer's performance-based variable short-term incentive program, applicable to the CEO and Named Executive Officers, includes a +/-5% ESG modifier. This modifier is based on three KPIs, including a GHG emissions reduction target. Short-term incentives represent approximately 15-18% of total executive compensation. The total percentage of incentives linked to the climate change is 0.003% but has been entered as 0.01% as the system does not accommodate a third decimal place.

Water

(4.5.1) Provision of monetary incentives related to this environmental issue

Select from:

☒ No, and we do not plan to introduce them in the next two years

(4.5.3) Please explain

Pfizer currently does not have monetary incentives related to water program management.

(4.5.1) Provide further details on the monetary incentives provided for the management of environmental issues (do not include the names of individuals).

Climate change

(4.5.1.1) Position entitled to monetary incentive

Facility/Unit/Site management

☒ Site manager

(4.5.1.2) Incentives

Select all that apply

☒ Bonus - % of salary

(4.5.1.3) Performance metrics

Targets

☒ Progress towards environmental targets

☒ Achievement of environmental targets

Emission reduction

☒ Reduction in absolute emissions

(4.5.1.4) Incentive plan the incentives are linked to

Select from:

☒ Short-Term Incentive Plan, or equivalent, only (e.g. contractual annual bonus)

(4.5.1.5) Further details of incentives

Site-specific targets for energy consumption and GHG emission reduction projects are included in goals against which monetary awards are determined.

(4.5.1.6) How the position's incentives contribute to the achievement of your environmental commitments and/or climate transition plan

Pfizer's manufacturing sites account for approximately 70% of the company's energy consumption and Scope 1 & 2 GHG emissions. Pfizer is aiming to achieve the voluntary Net-Zero Standard by 2040 and has near-term commitments to reduce Scope 1 and 2 emissions 46% from a 2019 baseline and source 100% renewable electricity by 2030. We expect to achieve these targets in part by investing in equipment optimization and replacement at our sites. We have established site-specific targets to drive project implementation at our manufacturing facilities, and progress toward these targets is factored into annual performance assessments.

Climate change

(4.5.1.1) Position entitled to monetary incentive

Senior-mid management

☒ Other senior-mid manager, please specify: All participants in Pfizer's Global Performance Plan (short-term incentive plan for non-sales colleagues)

(4.5.1.2) Incentives

Select all that apply

☒ Bonus - % of salary

(4.5.1.3) Performance metrics

Targets

☒ Progress towards environmental targets

☒ Achievement of environmental targets

Emission reduction

☒ Reduction in absolute emissions

(4.5.1.4) Incentive plan the incentives are linked to

Select from:

- ☒ Short-Term Incentive Plan, or equivalent, only (e.g. contractual annual bonus)

(4.5.1.5) Further details of incentives

Pfizer's performance-based variable bonus program, applicable to the CEO and Executive Leadership Team as well as approximately 50% of Pfizer colleagues, includes a +/-5% ESG modifier. This modifier is based on three KPIs, including a GHG emissions reduction target.

(4.5.1.6) How the position's incentives contribute to the achievement of your environmental commitments and/or climate transition plan

The inclusion of ESG modifiers in Pfizer's Global Performance Plan serves to further embed robust ESG management into our strategic decisions, business operations, and governance and supports continued focus on implementation of our climate strategy.

Climate change

(4.5.1.1) Position entitled to monetary incentive

Senior-mid management

- ☒ Other senior-mid manager, please specify: All participants in Pfizer's Global Performance Plan (short-term incentive plan for non-sales colleagues)

(4.5.1.2) Incentives

Select all that apply

- ☒ Bonus - % of salary

(4.5.1.3) Performance metrics

Targets

- ☒ Progress towards environmental targets
☒ Achievement of environmental targets

(4.5.1.4) Incentive plan the incentives are linked to

Select from:

☒ Short-Term Incentive Plan, or equivalent, only (e.g. contractual annual bonus)

(4.5.1.5) Further details of incentives

Pfizer’s Global Performance Plan, a performance-based variable bonus program, applicable to the CEO and Executive Leadership Team as well as approximately 50% of Pfizer colleagues, includes a 5% ESG modifier. This modifier is based on three KPIs, including a GHG emissions reduction target.

(4.5.1.6) How the position’s incentives contribute to the achievement of your environmental commitments and/or climate transition plan

The inclusion of ESG modifiers in Pfizer’s Global Performance Plan serves to further embed robust ESG management into our strategic decisions business operations and governance and supports continued focus on implementation of our climate strategy.

(4.6) Does your organization have an environmental policy that addresses environmental issues?

	Does your organization have any environmental policies?
	Select from: <input checked="" type="checkbox"/> Yes

[Fixed row]

(4.6.1) Provide details of your environmental policies.

Row 1

(4.6.1.1) Environmental issues covered

Select all that apply

- ☒ Climate change

(4.6.1.2) Level of coverage

Select from:

- ☒ Organization-wide

(4.6.1.3) Value chain stages covered

Select all that apply

- ☒ Direct operations
- ☒ Upstream value chain

(4.6.1.4) Explain the coverage

At Pfizer, we recognize global climate change as one of the defining issues of our time requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. In our Climate Change position statement we affirm our commitment to collaborating to reduce GHG emissions across our value chain, including our near-term commitment to reduce company GHG emissions by 46% compared with a 2019 baseline, aligned with a 1.5°C trajectory, and to drive action by encouraging suppliers to also set science-based GHG emissions reduction goals.

(4.6.1.5) Environmental policy content

Environmental commitments

- ☒ Commitment to comply with regulations and mandatory standards
- ☒ Commitment to take environmental action beyond regulatory compliance
- ☒ Commitment to implementation of nature-based solutions that support landscape restoration and long-term protection of natural ecosystems
- ☒ Commitment to stakeholder engagement and capacity building on environmental issues

Climate-specific commitments

- ☒ Commitment to 100% renewable energy
- ☒ Commitment to net-zero emissions

Social commitments

- ☒ Commitment to promote gender equality and women's empowerment
- ☒ Commitment to respect internationally recognized human rights

Additional references/Descriptions

- ☒ Recognition of environmental linkages and trade-offs
- ☒ Description of environmental requirements for procurement
- ☒ Description of impacts on natural resources and ecosystems
- ☒ Reference to timebound environmental milestones and targets
- ☒ Description of membership and financial support provided to organizations that seek to influence public policy
- ☒ Description of grievance/whistleblower mechanism to monitor non-compliance with the environmental policy and raise/address/escalate any other greenwashing concerns

(4.6.1.6) Indicate whether your environmental policy is in line with global environmental treaties or policy goals

Select all that apply

- ☒ Yes, in line with the Paris Agreement

(4.6.1.7) Public availability

Select from:

- ☒ Publicly available

(4.6.1.8) Attach the policy

Pfizer EHS Policy & Climate Position Statement.pdf

Row 2

(4.6.1.1) Environmental issues covered

Select all that apply

- ☒ Water

(4.6.1.2) Level of coverage

Select from:

- ☒ Organization-wide

(4.6.1.3) Value chain stages covered

Select all that apply

- ☒ Direct operations
- ☒ Upstream value chain

(4.6.1.4) Explain the coverage

Our Water Stewardship Position Statement acknowledges the global significance of access to clean water and reiterates Pfizer's commitment to conserving water. Specifically, in water-stressed areas, conservation includes minimizing water withdrawal, mitigating potential impact on water quality from our own operations and those of our supply chain, and responsibly managing discharges to water.

(4.6.1.5) Environmental policy content

Environmental commitments

- ☒ Commitment to comply with regulations and mandatory standards
- ☒ Commitment to take environmental action beyond regulatory compliance

Water-specific commitments

- ☒ Commitment to reduce water consumption volumes
- ☒ Commitment to reduce water withdrawal volumes
- ☒ Commitment to reduce or phase out hazardous substances
- ☒ Commitment to control/reduce/eliminate water pollution
- ☒ Commitment to the conservation of freshwater ecosystems
- ☒ Commitment to water stewardship and/or collective action

Social commitments

- ☒ Commitment to promote gender equality and women's empowerment
- ☒ Commitment to respect internationally recognized human rights

Additional references/Descriptions

- ☒ Acknowledgement of the human right to water and sanitation
- ☒ Description of grievance/whistleblower mechanism to monitor non-compliance with the environmental policy and raise/address/escalate any other greenwashing concerns
- ☒ Description of membership and financial support provided to organizations that seek to influence public policy
- ☒ Recognition of environmental linkages and trade-offs
- ☒ Reference to timebound environmental milestones and targets

(4.6.1.6) Indicate whether your environmental policy is in line with global environmental treaties or policy goals

Select all that apply

- ☒ Yes, in line with Sustainable Development Goal 6 on Clean Water and Sanitation

(4.6.1.7) Public availability

Select from:

- ☒ Publicly available

[Add row]

(4.10) Are you a signatory or member of any environmental collaborative frameworks or initiatives?

(4.10.1) Are you a signatory or member of any environmental collaborative frameworks or initiatives?

Select from:

- ☒ Yes

(4.10.2) Collaborative framework or initiative

Select all that apply

- ☒ Race to Zero Campaign
- ☒ RE100
- ☒ Science-Based Targets Initiative (SBTi)

(4.10.3) Describe your organization's role within each framework or initiative

RE100: Pfizer is a member of Renewable Energy 100 (RE100) and has a goal to achieve 100% renewable electricity by 2030. SBTi: In 2015, we were one of the first companies to have our then GHG emissions reduction goal approved by the Science Based Targets Initiative (SBTi), and we remain committed to developing and implementing a science-based climate action strategy. Our current near-term climate targets have been validated by the SBTi. TCFD: As described in our Climate Change Position Statement, we conduct robust risk assessments to safeguard resiliency of our research, manufacturing, and commercial activities and to transparently report on our progress, risks, and opportunities aligned with Task Force on Climate-related Financial Disclosure (TCFD) recommendations. UN Global Compact: Pfizer is proud to have been one of the early signatories to the United Nations (UN) Global Compact, an initiative that calls on companies to align strategies and operations with universal principles on human rights, labor, environment, and anti-corruption, and to take actions that advance societal goals.

(4.11) In the reporting year, did your organization engage in activities that could directly or indirectly influence policy, law, or regulation that may (positively or negatively) impact the environment?

(4.11.1) External engagement activities that could directly or indirectly influence policy, law, or regulation that may impact the environment

Select all that apply

- ☒ Yes, we engaged directly with policy makers
- ☒ Yes, we engaged indirectly through, and/or provided financial or in-kind support to a trade association or other intermediary organization or individual whose activities could influence policy, law, or regulation

(4.11.2) Indicate whether your organization has a public commitment or position statement to conduct your engagement activities in line with global environmental treaties or policy goals

Select from:

- ☒ Yes, we have a public commitment or position statement in line with global environmental treaties or policy goals

(4.11.3) Global environmental treaties or policy goals in line with public commitment or position statement

Select all that apply

- ☒ Paris Agreement
- ☒ Sustainable Development Goal 6 on Clean Water and Sanitation

(4.11.4) Attach commitment or position statement

Pfizer EHS Policy & Climate Position Statement & Water Position Statement.pdf

(4.11.5) Indicate whether your organization is registered on a transparency register

Select from:

☒ Yes

(4.11.6) Types of transparency register your organization is registered on

Select all that apply

☒ Mandatory government register

(4.11.7) Disclose the transparency registers on which your organization is registered & the relevant ID numbers for your organization

For the US, Pfizer's Federal Lobbying ID numbers are: House: 313540000; Senate: 31326-12. For the EU Transparency Register, Pfizer's ID is: 4263301811-33

(4.11.8) Describe the process your organization has in place to ensure that your external engagement activities are consistent with your environmental commitments and/or transition plan

Our climate and water-related engagement activities with policy makers, trade associations, and other organizations are guided by our Climate Change Position Statement and our Water Stewardship Position Statement, which outline Pfizer's approach to these environmental issues and the policies that will help support Pfizer's climate change and water stewardship strategy. Our support of these organizations and any tax-exempt organizations that write and endorse model legislation is evaluated annually by the company's U.S. Government Relations leaders based on these organizations' expertise in healthcare policy and advocacy and support of key issues of importance to Pfizer. In addition to their positions on health care policy issues, we realize these organizations may engage in a broad range of other issues that extend beyond the scope of what is of primary importance to Pfizer. If concerns arise about a particular issue, we convey our concerns, as appropriate, through our colleagues who serve on the boards and committees of these groups. We believe there is value in making sure our positions on issues important to Pfizer and our industry are communicated and understood within those organizations. Pfizer's participation as a member of these various industry and trade groups comes with the understanding that we may not always agree with the positions of the larger organization and/or other members.

(4.11.1) On what policies, laws, or regulations that may (positively or negatively) impact the environment has your organization been engaging directly with policy makers in the reporting year?

Row 1

(4.11.1.1) Specify the policy, law, or regulation on which your organization is engaging with policy makers

Singapore adoption of ISSB disclosure framework

(4.11.1.2) Environmental issues the policy, law, or regulation relates to

Select all that apply

☒ Climate change

(4.11.1.3) Focus area of policy, law, or regulation that may impact the environment

Transparency and due diligence

☒ Mandatory environmental reporting

(4.11.1.4) Geographic coverage of policy, law, or regulation

Select from:

☒ National

(4.11.1.5) Country/area/region the policy, law, or regulation applies to

Select all that apply

☒ Singapore

(4.11.1.6) Your organization's position on the policy, law, or regulation

Select from:

☒ Support with no exceptions

(4.11.1.8) Type of direct engagement with policy makers on this policy, law, or regulation

Select all that apply

☒ Ad-hoc meetings

(4.11.1.9) Funding figure your organization provided to policy makers in the reporting year relevant to this policy, law, or regulation (currency)

0

(4.11.1.10) Explain the relevance of this policy, law, or regulation to the achievement of your environmental commitments and/or transition plan, how this has informed your engagement, and how you measure the success of your engagement

Singapore government representatives reached out to Pfizer in early 2023 to request feedback on their proposed approach to the adoption of climate-related disclosure requirements. We shared that, as stated in our Climate Change Position Statement, Pfizer supports governmental policy frameworks that include clear mechanisms to increase global engagement, cooperation, and accountability around climate change. Therefore, where countries are considering the implementation of climate-related disclosures, Pfizer supports the adoption of standardized disclosure requirements, interoperable with other global frameworks, that allow companies to report at the corporate/enterprise level following internationally recognized frameworks. On February 28, 2024, Singapore announced it will implement mandatory climate-related disclosure requirements in line with the ISSB standards starting as early as 2025.

(4.11.1.11) Indicate if you have evaluated whether your organization's engagement on this policy, law, or regulation is aligned with global environmental treaties or policy goals

Select from:

☒ Yes, we have evaluated, and it is aligned

(4.11.1.12) Global environmental treaties or policy goals aligned with your organization's engagement on this policy, law or regulation

Select all that apply

☒ Paris Agreement

[Add row]

(4.11.2) Provide details of your indirect engagement on policy, law, or regulation that may (positively or negatively) impact the environment through trade associations or other intermediary organizations or individuals in the reporting year.

Row 1

(4.11.2.1) Type of indirect engagement

Select from:

☒ Indirect engagement via a trade association

(4.11.2.4) Trade association

North America

☒ US Chamber of Commerce

(4.11.2.5) Environmental issues relevant to the policies, laws, or regulations on which the organization or individual has taken a position

Select all that apply

☒ Climate change

(4.11.2.6) Indicate whether your organization's position is consistent with the organization or individual you engage with

Select from:

☒ Mixed

(4.11.2.7) Indicate whether your organization attempted to influence the organization or individual's position in the reporting year

Select from:

☒ Yes, we attempted to influence them but they did not change their position

(4.11.2.8) Describe how your organization's position is consistent with or differs from the organization or individual's position, and any actions taken to influence their position

Pfizer recognizes climate change as one of the defining issues of our time requiring collective action to mitigate the potential risks it poses. As such, Pfizer committed to further reducing GHG emissions aligned with science by aiming to achieve the voluntary Net-Zero Standard by 2040, ten years earlier than the timeline described in the standard and reporting transparently on its progress. Pfizer appreciates that voluntary measures often offer the greatest opportunity for companies to design innovative solutions that work best for their situation, product range, and investment timelines. Tackling climate change, however, will require action from all parties across all sectors, and Pfizer supports policy efforts that are science- and market-based to encourage and advance such action. The company also seeks to engage its value chain partners to support them in achieving science aligned reductions in GHG emissions. The Chamber acknowledges the severity of the climate threat, that humans are contributing, and that steps need to be taken to address the crisis. The organization recognizes the role that business and market-driven solutions can play in slowing the effects of climate change. In addition, governments and technological solutions should be leveraged but solutions must be realistic, durable, and reinforce U.S. economic competitiveness. On climate change, both Pfizer and the Chamber favor market-based and technology-based solutions. Pfizer is committed to taking responsible climate action and reducing environmental impact; the Chamber also advocates for corporations to take such actions. The Chamber has been criticized for its history of opposition to legislation targeting climate change and reliance on an "all of the above" approach which may prolong dependence on fossil fuels. For these reasons, there is misalignment between Pfizer and the Chamber on this topic. Pfizer participates in the Energy, Environment, Climate & Sustainability Committee and the ESG Working Group through which we provide comments on relevant topics consistent with our Climate Change Position Statement and commitment to transparency.

(4.11.2.9) Funding figure your organization provided to this organization or individual in the reporting year (currency)

608300

(4.11.2.10) Describe the aim of this funding and how it could influence policy, law or regulation that may impact the environment

Pfizer is a member of several industry and trade groups that represent both the pharmaceutical industry and the business community at large to bring about consensus on broad policy issues that can impact Pfizer's business objectives and ability to serve patients. The funding figure reported represents the portion of Pfizer's dues used for US federal lobbying activity in 2023 as reported by the trade association.

(4.11.2.11) Indicate if you have evaluated whether your organization's engagement is aligned with global environmental treaties or policy goals

Select from:

☒ Yes, we have evaluated, and it is aligned

(4.11.2.12) Global environmental treaties or policy goals aligned with your organization's engagement on policy, law or regulation

Select all that apply

☒ Paris Agreement

Row 2

(4.11.2.1) Type of indirect engagement

Select from:

☒ Indirect engagement via a trade association

(4.11.2.4) Trade association

Europe

☒ Other trade association in Europe, please specify: European Federation of Pharmaceutical Industries and Associations (EFPIA)

(4.11.2.5) Environmental issues relevant to the policies, laws, or regulations on which the organization or individual has taken a position

Select all that apply

☒ Water

(4.11.2.6) Indicate whether your organization's position is consistent with the organization or individual you engage with

Select from:

☒ Consistent

(4.11.2.7) Indicate whether your organization attempted to influence the organization or individual's position in the reporting year

Select from:

☒ Yes, and they have changed their position

(4.11.2.8) Describe how your organization's position is consistent with or differs from the organization or individual's position, and any actions taken to influence their position

The joint AESGP – EFPIA – EGA Position Paper on Pharmaceuticals in the Environment (PiE) (<https://www.efpia.eu/media/25274/eps-position-paper-october-2015.pdf>) states: “The European pharmaceutical industry, represented by the Association of the European Self-Medication Industry (AESGP), the European Federation of Pharmaceutical Industries (EFPIA), and the European Generic and Biosimilar Medicines Association (EGA), recognizes and understands the concerns raised by stakeholders as regards the presence of pharmaceuticals in the environment (PiE). For this reason, we have come together to develop the Eco-Pharmaco-Stewardship (EPS) concept, a proposal that strives to protect patients' access to medicines while appropriately considering environmental aspects.” On PiE, both Pfizer and EFPIA propose actions in three areas: 1. Encouraging further research to assess the impact of PiE; 2. Manage pharmaceutical sites' effluents effectively; 3. Monitor environmental impact through extended Environmental Risk Assessment (eERA). Pfizer has collaborated with EFPIA in shaping their position on water issues by providing multidisciplinary input including technical, legal and government affair expertise.

(4.11.2.11) Indicate if you have evaluated whether your organization's engagement is aligned with global environmental treaties or policy goals

Select from:

☒ Yes, we have evaluated, and it is aligned

(4.11.2.12) Global environmental treaties or policy goals aligned with your organization's engagement on policy, law or regulation

Select all that apply

☒ Sustainable Development Goal 6 on Clean Water and Sanitation

[Add row]

(4.12) Have you published information about your organization's response to environmental issues for this reporting year in places other than your CDP response?

Select from:

☒ Yes

(4.12.1) Provide details on the information published about your organization's response to environmental issues for this reporting year in places other than your CDP response. Please attach the publication.

Row 1

(4.12.1.1) Publication

Select from:

- ☒ In voluntary sustainability reports

(4.12.1.3) Environmental issues covered in publication

Select all that apply

- ☒ Climate change
☒ Water
☒ Biodiversity

(4.12.1.4) Status of the publication

Select from:

- ☒ Complete

(4.12.1.5) Content elements

Select all that apply

- | | |
|---|--|
| <input checked="" type="checkbox"/> Strategy | <input checked="" type="checkbox"/> Value chain engagement |
| <input checked="" type="checkbox"/> Governance | <input checked="" type="checkbox"/> Dependencies & Impacts |
| <input checked="" type="checkbox"/> Emission targets | <input checked="" type="checkbox"/> Water accounting figures |
| <input checked="" type="checkbox"/> Emissions figures | <input checked="" type="checkbox"/> Other, please specify : Waste metrics |
| <input checked="" type="checkbox"/> Risks & Opportunities | |

(4.12.1.6) Page/section reference

(4.12.1.7) Attach the relevant publication

Pfizer_2023_Impact_Report_11MAR2024.pdf

(4.12.1.8) Comment

Pfizer's 2023 Impact Report is available online at: https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf

Row 2

(4.12.1.1) Publication

Select from:

☒ In mainstream reports

(4.12.1.3) Environmental issues covered in publication

Select all that apply

☒ Climate change

(4.12.1.4) Status of the publication

Select from:

☒ Complete

(4.12.1.5) Content elements

Select all that apply

☒ Risks & Opportunities

(4.12.1.6) Page/section reference

Climate Change and Sustainability, p. 25

(4.12.1.7) Attach the relevant publication

2023-10k.pdf

(4.12.1.8) Comment

Pfizer's 2023 10-K Report is available online at: https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/2023-10k.pdf

Row 3

(4.12.1.1) Publication

Select from:

☒ In voluntary communications

(4.12.1.3) Environmental issues covered in publication

Select all that apply

☒ Climate change

(4.12.1.4) Status of the publication

Select from:

☒ Complete

(4.12.1.5) Content elements

Select all that apply

☒ Public policy engagement

☒ Strategy

(4.12.1.6) Page/section reference

Full document

(4.12.1.7) Attach the relevant publication

Climate_Change_Position_Statement_December_2022.pdf

(4.12.1.8) Comment

Pfizer's Climate Change Position Statement is available online at: https://cdn.pfizer.com/pfizercom/about/Climate_Change_Position_Statement_December_2022.pdf

Row 4

(4.12.1.1) Publication

Select from:

☒ In voluntary communications

(4.12.1.3) Environmental issues covered in publication

Select all that apply

☒ Water

(4.12.1.4) Status of the publication

Select from:

☒ Complete

(4.12.1.5) Content elements

Select all that apply

☒ Strategy

☒ Value chain engagement

(4.12.1.6) Page/section reference

Full document

(4.12.1.7) Attach the relevant publication

Pfizer_Water_Stewardship_Public_Position_Statement_2022.pdf

(4.12.1.8) Comment

Pfizer's Water Stewardship Position Statement is available at: https://cdn.pfizer.com/pfizercom/Pfizer_Water_Stewardship_Public_Position_Statement_2022.pdf
[Add row]

C5. Business strategy

(5.1) Does your organization use scenario analysis to identify environmental outcomes?

Climate change

(5.1.1) Use of scenario analysis

Select from:

☒ Yes

(5.1.2) Frequency of analysis

Select from:

☒ More than once a year

Water

(5.1.1) Use of scenario analysis

Select from:

☒ Yes

(5.1.2) Frequency of analysis

Select from:

☒ More than once a year

[Fixed row]

(5.1.1) Provide details of the scenarios used in your organization's scenario analysis.

Climate change

(5.1.1.1) Scenario used

Physical climate scenarios

☒ RCP 2.6

(5.1.1.2) Scenario used SSPs used in conjunction with scenario

Select from:

☒ SSP1

(5.1.1.3) Approach to scenario

Select from:

☒ Qualitative and quantitative

(5.1.1.4) Scenario coverage

Select from:

☒ Organization-wide

(5.1.1.5) Risk types considered in scenario

Select all that apply

☒ Acute physical

☒ Chronic physical

(5.1.1.6) Temperature alignment of scenario

Select from:

☒ 1.6°C - 1.9°C

(5.1.1.7) Reference year

2020

(5.1.1.8) Timeframes covered

Select all that apply

☒ 2030

☒ 2050

(5.1.1.9) Driving forces in scenario

Direct interaction with climate

☒ On asset values, on the corporate

(5.1.1.10) Assumptions, uncertainties and constraints in scenario

This physical risk scenario is aligned to the current commitments under the Paris Agreement. The world shifts towards a more sustainable path, emphasizing more inclusive development, driven by an increasing commitment to achieving development goals. Key parameters and assumptions: global Net-Zero is reached in 2050; renewables account for more than half of the energy supply by 2050; and there are few challenges to climate mitigation and adaptation.

(5.1.1.11) Rationale for choice of scenario

Scenario selection was based upon a review of guidance from TCFD, CDP, Climate Action 100 Benchmark, and IIGCC and considered temperature outcomes, sectoral and geographical coverage, data availability, time horizons, and market recognition. Timeframes selected align with Pfizer's strategic planning, including our 2040 Net Zero target, international and national climate policy milestones, and the expected lifetime of our assets.

Water

(5.1.1.1) Scenario used

Water scenarios

☒ WRI Aqueduct

(5.1.1.3) Approach to scenario

Select from:

- ☒ Qualitative and quantitative

(5.1.1.4) Scenario coverage

Select from:

- ☒ Organization-wide

(5.1.1.5) Risk types considered in scenario

Select all that apply

- ☒ Acute physical
- ☒ Chronic physical
- ☒ Policy
- ☒ Reputation
- ☒ Liability

(5.1.1.7) Reference year

2023

(5.1.1.8) Timeframes covered

Select all that apply

- ☒ 2025

(5.1.1.9) Driving forces in scenario

Local ecosystem asset interactions, dependencies and impacts

- ☒ Climate change (one of five drivers of nature change)

Stakeholder and customer demands

- ☒ Impact of nature footprint on reputation
- ☒ Impact of nature service delivery on consumer
- ☒ Sensitivity to inequity of nature impacts

Direct interaction with climate

☒ On asset values, on the corporate

(5.1.1.10) Assumptions, uncertainties and constraints in scenario

No additional assumptions, uncertainties or constraints beyond those inherent in WRI's Aqueduct Tool (version 4.0).

(5.1.1.11) Rationale for choice of scenario

WRI's Aqueduct Tool is used to identify potential baseline/short-term risks and assess the adequacy of site Water Stewardship plans. Medium- and long-term water-related risks are assessed as part of the climate change physical risk analysis using the RCP 2.6 and RCP 8.5 scenarios.

Climate change

(5.1.1.1) Scenario used

Physical climate scenarios

☒ RCP 8.5

(5.1.1.2) Scenario used SSPs used in conjunction with scenario

Select from:

☒ SSP5

(5.1.1.3) Approach to scenario

Select from:

☒ Qualitative and quantitative

(5.1.1.4) Scenario coverage

Select from:

- ☒ Organization-wide

(5.1.1.5) Risk types considered in scenario

Select all that apply

- ☒ Acute physical
- ☒ Chronic physical

(5.1.1.6) Temperature alignment of scenario

Select from:

- ☒ 4.0°C and above

(5.1.1.7) Reference year

2020

(5.1.1.8) Timeframes covered

Select all that apply

- ☒ 2030
- ☒ 2050

(5.1.1.9) Driving forces in scenario

Direct interaction with climate

- ☒ On asset values, on the corporate

(5.1.1.10) Assumptions, uncertainties and constraints in scenario

This is a physical risk high emissions scenario with no additional climate policy (business-as-usual). The push for economic and social development is coupled with the exploitation of abundant fossil fuel resources and the adoption of resource and energy intensive lifestyles around the world. Key parameters and assumptions: energy demand triples by 2100, dominated by fossil fuels; current atmospheric CO2 levels double by 2050; there are many challenges to climate mitigation, with few challenges to adaptation.

(5.1.1.11) Rationale for choice of scenario

Scenario selection was based upon a review of guidance from TCFD, CDP, Climate Action 100 Benchmark, and IIGCC and considered temperature outcomes, sectoral and geographical coverage, data availability, time horizons, and market recognition. Timeframes selected align with Pfizer's strategic planning, including our 2040 Net Zero target, international and national climate policy milestones, and the expected lifetime of our assets.

Climate change

(5.1.1.1) Scenario used

Climate transition scenarios

☒ NGFS scenarios framework, please specify :Net Zero 2050

(5.1.1.3) Approach to scenario

Select from:

☒ Qualitative and quantitative

(5.1.1.4) Scenario coverage

Select from:

☒ Organization-wide

(5.1.1.5) Risk types considered in scenario

Select all that apply

☒ Policy

☒ Market

☒ Reputation

☒ Technology

☒ Liability

(5.1.1.6) Temperature alignment of scenario

Select from:

☒ 1.5°C or lower

(5.1.1.7) Reference year

2020

(5.1.1.8) Timeframes covered

Select all that apply

☒ 2030

☒ 2040

☒ 2050

(5.1.1.9) Driving forces in scenario

Stakeholder and customer demands

☒ Consumer sentiment

Regulators, legal and policy regimes

☒ Global regulation

☒ Global targets

Relevant technology and science

☒ Other relevant technology and science driving forces, please specify :New technologies to enable decarbonization

(5.1.1.10) Assumptions, uncertainties and constraints in scenario

This is an ambitious transition risk scenario that limits global warming to 1.5°C through stringent climate policies and innovation, reaching Net-Zero greenhouse gas emissions around 2050. Key parameters and assumptions include the immediate introduction of ambitious climate policy and that global Net-Zero is reached in 2050. IPCC's SSP2 'Middle of the Road' socioeconomic assumptions were adjusted for COVID-19 impact.

(5.1.1.11) Rationale for choice of scenario

Scenario selection was based upon a review of guidance from TCFD, CDP, Climate Action 100 Benchmark, and IIGCC and considered temperature outcomes, sectoral and geographical coverage, data availability, time horizons, and market recognition. Timeframes selected align with Pfizer's strategic planning, including our 2040 Net Zero target, international and national climate policy milestones, and the expected lifetime of our assets.

Climate change

(5.1.1.1) Scenario used

Climate transition scenarios

☒ NGFS scenarios framework, please specify :Current Policies

(5.1.1.3) Approach to scenario

Select from:

☒ Qualitative and quantitative

(5.1.1.4) Scenario coverage

Select from:

☒ Organization-wide

(5.1.1.5) Risk types considered in scenario

Select all that apply

☒ Policy

☒ Market

☒ Reputation

☒ Technology

☒ Liability

(5.1.1.6) Temperature alignment of scenario

Select from:

☒ 3.0°C - 3.4°C

(5.1.1.7) Reference year

2020

(5.1.1.8) Timeframes covered

Select all that apply

☒ 2030

☒ 2040

☒ 2050

(5.1.1.9) Driving forces in scenario

Regulators, legal and policy regimes

☒ Global regulation

☒ Global targets

(5.1.1.10) Assumptions, uncertainties and constraints in scenario

This transition risk scenario assumes that only currently implemented policies are preserved, with an expected temperature outcome of 3°C. This scenario assumes that emissions peak in 2080. IPCC's SSP2 'Middle of the Road' socioeconomic assumptions were adjusted for COVID-19 impact.

(5.1.1.11) Rationale for choice of scenario

Scenario selection was based upon a review of guidance from TCFD, CDP, Climate Action 100 Benchmark, and IIGCC and considered temperature outcomes, sectoral and geographical coverage, data availability, time horizons, and market recognition. Timeframes selected align with Pfizer's strategic planning, including our 2040 Net Zero target, international and national climate policy milestones, and the expected lifetime of our assets.

(5.1.2) Provide details of the outcomes of your organization's scenario analysis.

Climate change

(5.1.2.1) Business processes influenced by your analysis of the reported scenarios

Select all that apply

- ☒ Risk and opportunities identification, assessment and management
- ☒ Resilience of business model and strategy

(5.1.2.2) Coverage of analysis

Select from:

- ☒ Organization-wide

(5.1.2.3) Summarize the outcomes of the scenario analysis and any implications for other environmental issues

Physical Risk: Scenario analysis indicated that by 2030, under a high emissions scenario, almost half of the 40 manufacturing and R&D sites assessed are at a high risk of water scarcity and drought, and 7 of Pfizer's 36 manufacturing sites are at high risk of flooding. Risk remains high through 2050. Potential financial impacts include increased capital expenditures, increased direct (operating) costs, decreased asset value or asset useful life leading to write-offs, and decreased revenues due to reduced production capacity. Also, while scenario analysis does not show extreme heat as presenting a high risk to Pfizer in 2030, by 2050, under a high emissions scenario, 8 of the 40 manufacturing and R&D sites assessed were at a high risk of extreme heat. Extreme heat may increase potential financial risk for Pfizer by increasing operating costs associated with running air conditioning and backup generators, and/or reducing revenue due to production shutdowns. The output of this analysis is currently being used to drive detailed assessments, develop mitigation plans, and allocate capital for sites with potential increased risk. This work will continue through the end of 2024. Transition (Policy): Pfizer is increasingly exposed to the cost of carbon in our operations and could be exposed to pass-through costs in the supply chain. The potential risk of increased direct and indirect (operating) costs was rated high for 2030, 2040, and 2050 under a Net-Zero scenario where carbon pricing mechanisms are expected to increase. Additionally, a transition away from fossil fuels may result in volatile energy and fuel prices, potentially increasing direct costs for Pfizer, especially in 2040 and beyond. Transition (Technology): A growing need to decarbonize to meet both our Net-Zero goal and external stakeholder pressure will require investment to decarbonize capital assets. Technology risk was rated medium for 2030 and high for 2040 and 2050, with potential financial impacts of increased capital expenditures, decreased asset value or asset useful life leading to write-offs, and asset impairment or early retirement of existing assets. Transition (Market): A number of national healthcare systems and countries have announced Net-Zero targets which may result in increasing pressure for suppliers to decarbonize products across their life cycle including Scope 3 emissions. As 80% of Pfizer's emissions are Scope 3, there is additional complexity in producing low-carbon products as it relies on suppliers decarbonizing their operations. Risk was rated medium for 2030 and high for 2040 and 2050, with a potential impact of decreased revenues due to reduced demand for products and services. While a number of risks and opportunities with the potential to impact financial performance and position were identified through our analysis, we concluded that Pfizer's current business model and strategy is resilient under the assessed scenarios.

Water

(5.1.2.1) Business processes influenced by your analysis of the reported scenarios

Select all that apply

- ☒ Risk and opportunities identification, assessment and management
- ☒ Resilience of business model and strategy

(5.1.2.2) Coverage of analysis

Select from:

- ☒ Organization-wide

(5.1.2.3) Summarize the outcomes of the scenario analysis and any implications for other environmental issues

Through scenario analysis we have currently identified six manufacturing and two R&D facilities that are currently exposed to water risks, and one additional PGS facility that is projected to be exposed to water risk in the 2030 and 2050 time horizons. These risks were determined not to be substantive and will continue to be monitored and managed through our Water Stewardship and Business Resilience programs. We are currently working to validate scenario analysis results for additional facilities within our direct operations and supply chain.

[Fixed row]

(5.2) Does your organization's strategy include a climate transition plan?

(5.2.1) Transition plan

Select from:

- ☒ Yes, we have a climate transition plan which aligns with a 1.5°C world

(5.2.3) Publicly available climate transition plan

Select from:

- ☒ No

(5.2.4) Plan explicitly commits to cease all spending on, and revenue generation from, activities that contribute to fossil fuel expansion

Select from:

☒ No, and we do not plan to add an explicit commitment within the next two years

(5.2.6) Explain why your organization does not explicitly commit to cease all spending on and revenue generation from activities that contribute to fossil fuel expansion

Pfizer manufactures pharmaceuticals. While we use fossil fuels and fossil fuel-based materials in our operations, we do not anticipate our use to contribute to fossil fuel expansion. Pfizer is a member of RE100 and has committed to achieve 100% renewable electricity by 2030. Transitioning away from fossil fuels is part of our strategy to achieve Net-Zero.

(5.2.7) Mechanism by which feedback is collected from shareholders on your climate transition plan

Select from:

☒ We have a different feedback mechanism in place

(5.2.8) Description of feedback mechanism

Pfizer has established a strategic plan to advance our Net-Zero goal and therefore our responses in this questionnaire align to CDP's expectations of a transition plan per CDP guidance. Our annual Impact Report alongside our Annual Report and proxy statement, provides stakeholders with prior-year GHG emissions data and information on progress toward our Net-Zero goal. Pfizer hosts an annual shareholder meeting in April, providing interested parties an opportunity to ask questions or provide feedback on, among other matters, our annual disclosures. We also work to engage investors on ESG issues through ongoing one-on-one conversations, surveys and questionnaires, and targeted communications, for example ESG-related content on our Investor Insights website. We also host investor-aimed fireside chats to review priority ESG initiatives and topics, including on priority areas such as equitable access and climate action.

(5.2.9) Frequency of feedback collection

Select from:

☒ More frequently than annually

(5.2.10) Description of key assumptions and dependencies on which the transition plan relies

To achieve Net-Zero, Pfizer plans to transition to renewable and no-carbon technologies across our operations and strive to deliver similar action throughout our vast global supply chain, all while continuing to deliver on our commitments to patients. This transition will challenge our global network, requiring invention and tenacity, and will include large strategic infrastructure projects, as well as actions from our colleagues. Our key areas of focus include advancing conservation programs at our sites to reduce energy demand, increasing manufacturing process efficiency to limit energy demand, identifying low- or no-carbon solutions at the scale and intensity needed to meet the utility demands of R&D and manufacturing operations; and transitioning our sales fleet vehicles to electric and hybrid alternatives. Pfizer's

ambition to achieve Net-Zero assumes new technologies will become available to enable the transition in the time and scale needed. We particularly need solutions to generate heat and produce steam to meet the demand of product manufacturing operations and to accelerate the transition from natural gas-powered systems to low/no carbon energy sources. Accelerating change requires dedication and action from Pfizer's extensive globally distributed value chain, who also face similar challenges in the pace of transition. The scale of change needed cannot be underestimated. It requires collective contribution and the creation of progressive standards that incentivize change. Voluntary measures, such as those being taken by Pfizer and companies around the world, often offer the greatest opportunity for companies to design innovative solutions that work best for their particular situation, product range, and investment timelines. Tackling climate change, however, will require action from parties across all sectors, and Pfizer urges governments globally to establish ambitious climate policies to stabilize global temperature rise at 1.5 degrees.

(5.2.11) Description of progress against transition plan disclosed in current or previous reporting period

Pfizer's 2023 scope 1 and 2 GHG emissions were 2.3% lower than 2022 and 13% lower than the 2019 baseline. We sourced 10% renewable electricity in 2023. We have entered into virtual power purchase agreements covering North America and the European Union. These projects, expected to come online in 2025, will cover approximately 68% of Pfizer's electricity needs (as measured against 2023 electricity consumption). We have also made progress in reducing scope 3 emissions. Our 2023 scope 3 emissions associated with upstream transportation and distribution, which increased significantly in 2021 and 2022 as a result of the global distribution of the Covid-19 vaccine and treatment, decreased by 31% compared to 2022. We continue working to accelerate change across our supply chain and, as of the end of 2023, 51% of our suppliers of goods and services by spend have committed to science-based GHG emission reduction targets.

(5.2.13) Other environmental issues that your climate transition plan considers

Select all that apply

☒ No other environmental issue considered

[Fixed row]

(5.3) Have environmental risks and opportunities affected your strategy and/or financial planning?

(5.3.1) Environmental risks and/or opportunities have affected your strategy and/or financial planning

Select from:

☒ Yes, both strategy and financial planning

(5.3.2) Business areas where environmental risks and/or opportunities have affected your strategy

Select all that apply

☒ Products and services

- ☒ Upstream/downstream value chain
 - ☒ Investment in R&D
 - ☒ Operations
- [Fixed row]

(5.3.1) Describe where and how environmental risks and opportunities have affected your strategy.

Products and services

(5.3.1.1) Effect type

Select all that apply

- ☒ Opportunities

(5.3.1.2) Environmental issues relevant to the risks and/or opportunities that have affected your strategy in this area

Select all that apply

- ☒ Climate change
- ☒ Water

(5.3.1.3) Describe how environmental risks and/or opportunities have affected your strategy in this area

Pfizer has leveraged our achievements in green chemistry, success with our public GHG emission reduction goals and water stewardship program, and commitment to science-based targets to develop substantiated environmental information which has been shared with potential customers/retailers and governmental tenders in response to their requests for such information. We anticipate that our goal to achieve Net-Zero GHG emissions, as well as an ability to provide environmental footprint details for our products, will become increasingly important to our customers in the next 3-5 years.

Upstream/downstream value chain

(5.3.1.1) Effect type

Select all that apply

- ☒ Risks

(5.3.1.2) Environmental issues relevant to the risks and/or opportunities that have affected your strategy in this area

Select all that apply

☒ Climate change

(5.3.1.3) Describe how environmental risks and/or opportunities have affected your strategy in this area

As one of the first companies to receive validation of our GHG emission reduction goal by the Science Based Target Initiative (SBTi) in 2015, Pfizer remains committed to ambitious long-term actions aligned with science. As part of our near-term targets, approved by SBTi, we aim to use our influence to catalyze similar reductions across our value chain. We are implementing a multipronged approach, including embedding environmental sustainability criteria in our vendor selection processes, strengthening expectations within contracts and engaging with key suppliers of goods and services to drive at least 64% by spend to adopt science-based GHG emission reduction goals by 2025. By 2040 Pfizer aims to decrease its company GHG emissions by 95% and its value chain emissions by 90% from 2019 levels by reducing the energy demand of our operations, transitioning away from fossil fuels, sourcing renewable electricity, and engaging suppliers to catalyze equivalent action.

Investment in R&D

(5.3.1.1) Effect type

Select all that apply

☒ Opportunities

(5.3.1.2) Environmental issues relevant to the risks and/or opportunities that have affected your strategy in this area

Select all that apply

☒ Climate change

☒ Water

(5.3.1.3) Describe how environmental risks and/or opportunities have affected your strategy in this area

Pfizer has a long history of using the concepts of green chemistry and promoting them across the industry. Through scientific innovation we aim to design more efficient processes that can reduce the environmental impact of our medicines throughout the product life cycle. To support environmental footprint reduction efforts, Pfizer is conducting life cycle assessments (LCAs) across our small molecule, large molecule, vaccine, and device portfolios. Guided by these assessments, we are working to define environmental sustainability criteria across the product lifecycle. For example, through LCAs conducted to date we have determined that up to 90% of the carbon footprint of our small molecule products is associated with the manufacture of the active pharmaceutical ingredients (API), while the remainder is attributed to packaging, excipients, and other elements. Many factors contribute to the carbon footprint of API: manufacturing equipment, number of process steps,

route efficiency and use of higher intensity materials such as precious metal catalysts used in the manufacturing process. Organic solvents commonly employed to allow the necessary conditions for chemical reactions to progress represent one of the most significant contributors to the API carbon footprint. We continue to evaluate ways to reduce the environmental impact of our products through the use of new technology, application of green chemistry and water conservation principles and solvent recycling and reuse.

Operations

(5.3.1.1) Effect type

Select all that apply

☒ Opportunities

(5.3.1.2) Environmental issues relevant to the risks and/or opportunities that have affected your strategy in this area

Select all that apply

☒ Climate change

☒ Water

(5.3.1.3) Describe how environmental risks and/or opportunities have affected your strategy in this area

To help achieve our sustainability goals, Pfizer has implemented numerous efficiency improvements to our operations. We look for opportunities to design environmental sustainability attributes into new facility or renovation projects, replace equipment at end of life with energy and water-efficient alternates, and invests in no- / low-carbon technologies at our sites and through power purchase agreements (PPAs) that enable sourcing of renewable energy. In 2023, we signed virtual PPAs (VPPAs) for four new solar projects in Spain that will collectively cover all of Pfizer's purchased electricity in the European Union. These EU VPPAs, along with the North America VPPA we signed in 2021, are key steps in our plan to achieve our RE100 goal of 100% renewable energy by 2030 and the voluntary Net Zero Standard by 2040. When the North America and EU VPPA solar projects come online, they are expected to cover approximately 68% of Pfizer's global electricity needs as measured against 2023 electricity consumption. We are a member of Renewable Energy 100 (RE100) and we have a goal to achieve 80% renewable electricity by 2025 and 100% by 2030. We are currently working to develop site-specific emissions reduction plans to achieve our near-term (2030) and Net Zero (2040) targets. In addition, through our water stewardship program we completed water stress assessments at all Pfizer sites to identify water quality, scarcity, and availability risks across our network and are developing action plans for sites with elevated risk scores. These plans include elements such as quantifying water use, implementing mitigation plans and establishing water conservation targets, protecting water quality, improving wastewater treatment where necessary, evaluating recycling practices, and engaging with surrounding communities.

[Add row]

(5.3.2) Describe where and how environmental risks and opportunities have affected your financial planning.

Row 1

(5.3.2.1) Financial planning elements that have been affected

Select all that apply

- ☒ Assets
- ☒ Revenues
- ☒ Indirect costs
- ☒ Access to capital
- ☒ Capital expenditures
- ☒ Acquisitions and divestments

(5.3.2.2) Effect type

Select all that apply

- ☒ Risks
- ☒ Opportunities

(5.3.2.3) Environmental issues relevant to the risks and/or opportunities that have affected these financial planning elements

Select all that apply

- ☒ Climate change
- ☒ Water

(5.3.2.4) Describe how environmental risks and/or opportunities have affected these financial planning elements

Climate-related risks and opportunities have influenced Pfizer's business strategy and are incorporated into financial planning. In 2020, Pfizer completed a 1.25 billion ten-year sustainability bond, a first for a biopharmaceutical company. Proceeds from the bond are being used to help manage our environmental impact and support increased patient access to Pfizer's medicines and vaccines, especially among underserved populations, and strengthen healthcare systems. In total, \$946 million in net proceeds from the sustainability bond issuance were allocated to environmental projects, supporting green design and construction of new office and manufacturing facilities. One of these projects, our New York headquarters building, was awarded LEED Platinum certification, and another, a manufacturing facility in Singapore, was issued a Green Mark Gold certificate in recognition of sustainability and environmental responsibility measures incorporated into their design. Over the past few years Pfizer has received an increasing number of requests for environmental performance information from current and prospective customers. While the level of influence that our environmental performance has on customer purchasing decisions has not been fully quantified, the revenue associated with customers

requesting this information is estimated to be more than \$100 million and is factored into revenue forecasts. Annual internal targets are established for energy conservation project savings. Our sites are required to maintain master plans that identify opportunities for emission reductions. These projects are reviewed through our capital project appropriation process. The costs to implement these projects, as well as the expected cost savings, are included in the sites' operating budgets and/or capital plans. Our Loss Prevention and Business Resilience programs assess and manage potential impacts of acute and chronic physical risks on our operations. Assessments are refreshed annually. Costs to maintain Pfizer's risk engineering provider are estimated at \$1.35 million annually. Costs relating to property protection and supply chain management are annualized, expected to be incurred annually, and are incorporated into existing budgets. Site protection systems improvements and maintenance costs are estimated at \$3 million annually. Direct staff costs related to managing this risk are estimated at \$2.0 million annually.

(5.4) In your organization's financial accounting, do you identify spending/revenue that is aligned with your organization's climate transition?

	Identification of spending/revenue that is aligned with your organization's climate transition
	Select from: <input checked="" type="checkbox"/> No, but we plan to in the next two years

[Fixed row]

(5.9) What is the trend in your organization's water-related capital expenditure (CAPEX) and operating expenditure (OPEX) for the reporting year, and the anticipated trend for the next reporting year?

(5.9.1) Water-related CAPEX (+/- % change)

0

(5.9.2) Anticipated forward trend for CAPEX (+/- % change)

0

(5.9.3) Water-related OPEX (+/- % change)

0

(5.9.4) Anticipated forward trend for OPEX (+/- % change)

0

(5.9.5) Please explain

Capital and operating expenditures have remained relatively flat across the organization. Water costs represent less than 1% of Pfizer's CAPEX and OPEX spend. These costs include payments for utilities as well as investments in water conservation projects. OPEX spend includes spend related to purchased water, chilled water and water filtration and treatment supplies. CAPEX spend includes water-related capital projects, including project management.

[Fixed row]

(5.10) Does your organization use an internal price on environmental externalities?

	Use of internal pricing of environmental externalities	Environmental externality priced
	Select from: <input checked="" type="checkbox"/> Yes	Select all that apply <input checked="" type="checkbox"/> Carbon

[Fixed row]

(5.10.1) Provide details of your organization's internal price on carbon.

Row 1

(5.10.1.1) Type of pricing scheme

Select from:

- ☒ Shadow price

(5.10.1.2) Objectives for implementing internal price

Select all that apply

- ☒ Conduct cost-benefit analysis
- ☒ Drive energy efficiency
- ☒ Drive low-carbon investment

(5.10.1.3) Factors considered when determining the price

Select all that apply

- ☒ Alignment to scientific guidance
- ☒ Alignment with the price of a carbon tax
- ☒ Scenario analysis

(5.10.1.4) Calculation methodology and assumptions made in determining the price

Pfizer uses a \$200/mtCO₂e internal carbon price to assess certain capital projects and opportunities. This price aligns with current and projected international tax schemes that may apply to Pfizer based on its operational locations.

(5.10.1.5) Scopes covered

Select all that apply

- ☒ Scope 1
- ☒ Scope 2

(5.10.1.6) Pricing approach used – spatial variance

Select from:

- ☒ Uniform

(5.10.1.8) Pricing approach used – temporal variance

Select from:

☒ Evolutionary

(5.10.1.9) Indicate how you expect the price to change over time

We anticipate a yearly increase of 3% in our internal carbon price, which is currently set at 200/mtCO₂e.

(5.10.1.10) Minimum actual price used (currency per metric ton CO₂e)

200

(5.10.1.11) Maximum actual price used (currency per metric ton CO₂e)

200

(5.10.1.12) Business decision-making processes the internal price is applied to

Select all that apply

☒ Capital expenditure

☒ Risk management

☒ Opportunity management

(5.10.1.13) Internal price is mandatory within business decision-making processes

Select from:

☒ No

(5.10.1.14) % total emissions in the reporting year in selected scopes this internal price covers

3

(5.10.1.15) Pricing approach is monitored and evaluated to achieve objectives

Select from:

☒ Yes

(5.10.1.16) Details of how the pricing approach is monitored and evaluated to achieve your objectives

Pfizer uses the internal carbon price to influence equipment selection and design for new operations. For example, at our sites in Ringaskiddy and Grange Castle, Ireland, our focus on Net Zero planning along with consideration of the future price of carbon led us to select designs for new buildings that include space heating which is provided by recovered waste heat and heat pumps. In the case of the facility in Grange Castle currently under construction, this change resulted in a modelled steam demand that was 50% lower than a conventional design.

(5.11) Do you engage with your value chain on environmental issues?

	Engaging with this stakeholder on environmental issues	Environmental issues covered
Suppliers	<i>Select from:</i> <input checked="" type="checkbox"/> Yes	<i>Select all that apply</i> <input checked="" type="checkbox"/> Climate change <input checked="" type="checkbox"/> Water <input checked="" type="checkbox"/> Plastics
Customers	<i>Select from:</i> <input checked="" type="checkbox"/> Yes	<i>Select all that apply</i> <input checked="" type="checkbox"/> Climate change <input checked="" type="checkbox"/> Water
Investors and shareholders	<i>Select from:</i> <input checked="" type="checkbox"/> Yes	<i>Select all that apply</i> <input checked="" type="checkbox"/> Climate change
Other value chain stakeholders	<i>Select from:</i> <input checked="" type="checkbox"/> Yes	<i>Select all that apply</i> <input checked="" type="checkbox"/> Climate change <input checked="" type="checkbox"/> Water <input checked="" type="checkbox"/> Plastics

[Fixed row]

(5.11.1) Does your organization assess and classify suppliers according to their dependencies and/or impacts on the environment?

Climate change

(5.11.1.1) Assessment of supplier dependencies and/or impacts on the environment

Select from:

☒ Yes, we assess the dependencies and/or impacts of our suppliers

(5.11.1.2) Criteria for assessing supplier dependencies and/or impacts on the environment

Select all that apply

☒ Contribution to supplier-related Scope 3 emissions

(5.11.1.3) % Tier 1 suppliers assessed

Select from:

☒ 100%

(5.11.1.4) Define a threshold for classifying suppliers as having substantive dependencies and/or impacts on the environment

Pfizer uses risk assessment and spend-based GHG emissions estimates to identify suppliers with substantive dependencies or impacts on the environment. For climate change, this includes roughly 500 suppliers that represent approximately 80% of our scope 3 emissions of purchased goods and services.

(5.11.1.5) % Tier 1 suppliers meeting the thresholds for substantive dependencies and/or impacts on the environment

Select from:

☒ 1-25%

(5.11.1.6) Number of Tier 1 suppliers meeting the thresholds for substantive dependencies and/or impacts on the environment

Water

(5.11.1.1) Assessment of supplier dependencies and/or impacts on the environment

Select from:

- ☒ Yes, we assess the dependencies and/or impacts of our suppliers

(5.11.1.2) Criteria for assessing supplier dependencies and/or impacts on the environment

Select all that apply

- ☒ Basin/landscape condition
- ☒ Dependence on water
- ☒ Impact on water availability
- ☒ Impact on pollution levels

(5.11.1.3) % Tier 1 suppliers assessed

Select from:

- ☒ 1-25%

(5.11.1.4) Define a threshold for classifying suppliers as having substantive dependencies and/or impacts on the environment

Pfizer uses supplier self-assessments and audits analysis to identify suppliers with substantive dependencies or impacts on the environment. We do not currently have any suppliers considered to have a substantive dependency or impact to water.

(5.11.1.5) % Tier 1 suppliers meeting the thresholds for substantive dependencies and/or impacts on the environment

Select from:

- ☒ None

[Fixed row]

(5.11.2) Does your organization prioritize which suppliers to engage with on environmental issues?

Climate change

(5.11.2.1) Supplier engagement prioritization on this environmental issue

Select from:

- ☒ Yes, we prioritize which suppliers to engage with on this environmental issue

(5.11.2.2) Criteria informing which suppliers are prioritized for engagement on this environmental issue

Select all that apply

- ☒ In line with the criteria used to classify suppliers as having substantive dependencies and/or impacts relating to climate change
- ☒ Business risk mitigation
- ☒ Procurement spend
- ☒ Regulatory compliance

(5.11.2.4) Please explain

Pfizer's Scope 3 GHG footprint is approximately four times that associated with the company's direct operations. We recognize action is needed throughout our value chain to address the complex threat of climate change. The procurement of goods and services, essential to producing medicines and vaccines, is the most significant contributor to our Scope 3 emissions. We are therefore urging all our suppliers to commit to ambitious, science based GHG reduction targets and have integrated environmental criteria in our supplier sourcing, contracting, and performance management processes. We are focusing our engagement efforts on the approximately 10% of our suppliers by number that drive the majority of emissions and asked these suppliers to set reduction targets aligned with SBTi guidance for their Scope 1 and 2 GHG emissions by the end of 2025. Our Sourcing, External Supply, and Global EHS colleagues are engaging with many of these suppliers to review their climate commitments and review alignment with Pfizer's expectations. We believe that through our layered approach of influence through competitive bidding, contracting, and supply relationship management we will increase the total number of suppliers engaged which will help to result in an annual reduction in total emissions.

Water

(5.11.2.1) Supplier engagement prioritization on this environmental issue

Select from:

- ☒ Yes, we prioritize which suppliers to engage with on this environmental issue

(5.11.2.2) Criteria informing which suppliers are prioritized for engagement on this environmental issue

Select all that apply

- ☒ In line with the criteria used to classify suppliers as having substantive dependencies and/or impacts relating to water
- ☒ Business risk mitigation
- ☒ Regulatory compliance
- ☒ Supplier performance improvement

(5.11.2.4) Please explain

As stated in our Water Stewardship Position Statement, published in January 2022, limiting the presence of pharmaceuticals in the environment is an environmental priority for Pfizer. Therefore, we remain committed to the AMR Industry Alliance (AMRIA) Roadmap, including demonstrating the responsible manufacturing of our products and providing greater transparency to our actions. We have conducted risk assessments against science-based discharge targets (known as Predicted No Effect Concentrations or PNECs) at approximately 100 antibiotic supplier locations as part of our commitment to help our suppliers achieve published wastewater PNECs by the end of 2025 and are piloting innovative wastewater management and treatment practices at several sites, including manufacturing and supplier sites, to advance our management of wastewater discharges.

Plastics

(5.11.2.1) Supplier engagement prioritization on this environmental issue

Select from:

- ☒ Yes, we prioritize which suppliers to engage with on this environmental issue

(5.11.2.2) Criteria informing which suppliers are prioritized for engagement on this environmental issue

Select all that apply

- ☒ Material sourcing

(5.11.2.4) Please explain

Pfizer is using scientific innovation to design more efficient processes that can reduce the environmental impact of our medicines throughout the product life cycle. We are integrating sustainable product design principles within our R&D processes and aim to positively impact our environmental performance by systematically conserving energy, reducing water and raw materials usage, driving out waste, and embracing circular solutions where possible. For example, our Sustainable

Packaging team has engaged with suppliers on projects to implement the use of bio-based plastic packaging at one of our facilities, pilot the use of a lower plastic stretch wrap material for shipping; and to identify opportunities to recycle plastic packaging.

(5.11.5) Do your suppliers have to meet environmental requirements as part of your organization's purchasing process?

Climate change

(5.11.5.1) Suppliers have to meet specific environmental requirements related to this environmental issue as part of the purchasing process

Select from:

☒ Yes, environmental requirements related to this environmental issue are included in our supplier contracts

(5.11.5.2) Policy in place for addressing supplier non-compliance

Select from:

☒ Yes, we have a policy in place for addressing non-compliance

(5.11.5.3) Comment

Through our contracts, we require our suppliers to establish a science based GHG emissions reduction target for their operations (i.e., covering Scope 1 and 2) or provide evidence of a comparable alternative in effect and, during the duration of the agreement, demonstrate progress in achieving the target.

Water

(5.11.5.1) Suppliers have to meet specific environmental requirements related to this environmental issue as part of the purchasing process

Select from:

☒ Yes, environmental requirements related to this environmental issue are included in our supplier contracts

(5.11.5.2) Policy in place for addressing supplier non-compliance

Select from:

☒ Yes, we have a policy in place for addressing non-compliance

(5.11.5.3) Comment

Pfizer is a founding member of the Pharmaceutical Supply Chain Initiative (PSCI), a collaboration of pharma companies with a purpose to define, implement and champion responsible supply chain practices. The PSCI Principles for Responsible Supply Chain Management articulate the members' expectations for suppliers to operate in a manner that minimizes adverse impacts on the environment, including ensuring the safe handling of wastewater discharge and preventing and mitigating releases to the environment. Pfizer has incorporated the PSCI Principles into our supply agreement templates and our Supplier Conduct Principles. Additionally, Pfizer is committed to limiting discharge of active pharmaceutical ingredients (API) to wastewater from our manufacturing processes. Pfizer has incorporated into our supply agreement templates requirements for suppliers to assess and mitigate, if needed, discharges of API.

(5.11.6) Provide details of the environmental requirements that suppliers have to meet as part of your organization's purchasing process, and the compliance measures in place.

Climate change

(5.11.6.1) Environmental requirement

Select from:

☒ Setting a science-based emissions reduction target

(5.11.6.2) Mechanisms for monitoring compliance with this environmental requirement

Select all that apply

☒ Second-party verification

(5.11.6.3) % tier 1 suppliers by procurement spend required to comply with this environmental requirement

Select from:

☒ 51-75%

(5.11.6.4) % tier 1 suppliers by procurement spend in compliance with this environmental requirement

Select from:

☒ 51-75%

(5.11.6.7) % tier 1 supplier-related scope 3 emissions attributable to the suppliers required to comply with this environmental requirement

Select from:

☒ 51-75%

(5.11.6.8) % tier 1 supplier-related scope 3 emissions attributable to the suppliers in compliance with this environmental requirement

Select from:

☒ 51-75%

(5.11.6.9) Response to supplier non-compliance with this environmental requirement

Select from:

☒ Retain and engage

(5.11.6.10) % of non-compliant suppliers engaged

Select from:

☒ 76-99%

(5.11.6.11) Procedures to engage non-compliant suppliers

Select all that apply

☒ Providing information on appropriate actions that can be taken to address non-compliance

(5.11.6.12) Comment

Responses to this question are based on suppliers of purchased goods and services (Scope 3 Category 1) only and based on spend. Emissions from this category represent 78% of Pfizer's total Scope 3 emissions.

Water

(5.11.6.1) Environmental requirement

Select from:

- ☒ Substitution of hazardous substances with less harmful substances

(5.11.6.2) Mechanisms for monitoring compliance with this environmental requirement

Select all that apply

- ☒ Second-party verification

(5.11.6.3) % tier 1 suppliers by procurement spend required to comply with this environmental requirement

Select from:

- ☒ 51-75%

(5.11.6.4) % tier 1 suppliers by procurement spend in compliance with this environmental requirement

Select from:

- ☒ 26-50%

(5.11.6.9) Response to supplier non-compliance with this environmental requirement

Select from:

- ☒ Retain and engage

(5.11.6.10) % of non-compliant suppliers engaged

Select from:

- ☒ 76-99%

(5.11.6.11) Procedures to engage non-compliant suppliers

Select all that apply

- ☒ Developing quantifiable, time-bound targets and milestones to bring suppliers back into compliance

(5.11.6.12) Comment

Our established risk-based evaluation of suppliers, including contract manufacturers, assesses EHS and sustainability performance. Evaluations include engagement with suppliers to help support their efforts to improve EHS sustainability and labor and human rights performance. We apply a risk-based approach to determine where to complete our evaluations and apply our efforts where we believe there is opportunity to make the greatest potential impact and drive improvement. We require our suppliers to develop action plans in response to our audits and implement improved controls as needed. Pfizer is pursuing opportunities with our suppliers and contract manufacturers to implement certification of our antibiotic products. Our efforts to promote adherence to voluntary discharge limits across our supply chain were recognized in a report published by the Access to Medicine Foundation that assesses steps that pharmaceutical manufacturers are taking to curb the development and spread of AMR (AMR Report on Responsible Manufacturing, August 2023).

(5.11.7) Provide further details of your organization's supplier engagement on environmental issues.

Climate change

(5.11.7.2) Action driven by supplier engagement

Select from:

- ☒ Emissions reduction

(5.11.7.3) Type and details of engagement

Capacity building

- ☒ Support suppliers to set their own environmental commitments across their operations

Information collection

- ☒ Collect GHG emissions data at least annually from suppliers

Innovation and collaboration

- ☒ Collaborate with suppliers on innovations to reduce environmental impacts in products and services
- ☒ Collaborate with suppliers on innovative business models and corporate renewable energy sourcing mechanisms

(5.11.7.4) Upstream value chain coverage

Select all that apply

☒ Tier 1 suppliers

(5.11.7.5) % of tier 1 suppliers by procurement spend covered by engagement

Select from:

☒ 76-99%

(5.11.7.6) % of tier 1 supplier-related scope 3 emissions covered by engagement

Select from:

☒ 76-99%

(5.11.7.9) Describe the engagement and explain the effect of your engagement on the selected environmental action

Recognizing that our Scope 3 (value chain) GHG footprint is approximately four times that associated with our direct operations, Pfizer has been driving action throughout our value chain to help address the complex threat of climate change. Procurement of goods and services, which is essential to producing medicines and vaccines, is the most significant contributor to our scope 3 emissions. We therefore expect all our suppliers to commit to ambitious, science-based GHG reduction targets and have integrated environmental criteria in our supplier sourcing, contracting, and performance management processes. In 2023 we conducted a virtual supplier summit to communicate our expectations and provide resources to assist suppliers in progressing climate action. To support suppliers in their decarbonization journey, we encouraged energy PPA education through the Energize program and offered sponsorships for the Activate program, a collective initiative that targets sustainability / GHG emission improvements at active pharmaceutical ingredient (API) suppliers including Contract Manufacturing Organizations. The measure of success for our supplier engagement program is the percentage of purchased goods and services spend with suppliers that have obtained or have publicly committed to obtain Science Based Targets initiative (SBTi) approval of their emission reduction targets and companies with scope 1 and 2 targets set at a level equivalent to SBTi criteria. Our Goal or threshold for success is to drive 64% of our suppliers of goods and services by spend to set science-based GHG emission reduction goals by 2025. As a result of our engagement efforts, in 2023 51% of our suppliers of goods and services by spend had committed to science-based GHG emission reduction targets, an increase of 22% compared to 2022.

(5.11.7.10) Engagement is helping your tier 1 suppliers meet an environmental requirement related to this environmental issue

Select from:

☒ Yes, please specify the environmental requirement: Setting a science-based emission reduction target

(5.11.7.11) Engagement is helping your tier 1 suppliers engage with their own suppliers on the selected action

Select from:

☒ Yes

Water

(5.11.7.2) Action driven by supplier engagement

Select from:

☒ Total water withdrawal volumes reduction

(5.11.7.3) Type and details of engagement

Innovation and collaboration

☒ Collaborate with suppliers on innovations to reduce environmental impacts in products and services

☒ Incentivize collaborative sustainable water management in river basins

(5.11.7.4) Upstream value chain coverage

Select all that apply

☒ Tier 1 suppliers

(5.11.7.5) % of tier 1 suppliers by procurement spend covered by engagement

Select from:

☒ 51-75%

(5.11.7.7) % tier 1 suppliers with substantive impacts and/or dependencies related to this environmental issue covered by engagement

Select from:

☒ None

(5.11.7.9) Describe the engagement and explain the effect of your engagement on the selected environmental action

The availability of and access to clean water is a basic human need globally that must be addressed locally. Pfizer's Water Stewardship position statement describes our commitment to being good stewards of the water we use to make medicines and vaccines, particularly in water-stressed areas. To this end, we completed water stress assessments at all Pfizer sites to identify water quality, scarcity, and availability risks across our network and are developing action plans for sites with elevated risk scores. These plans include elements such as quantifying water use, implementing mitigation plans and establishing water conservation targets, protecting water quality, improving wastewater treatment where necessary, evaluating recycling practices, and engaging with surrounding communities. We engage with our key suppliers in water stressed areas to encourage them to develop and implement similar action plans. Our established risk-based evaluation of suppliers, including contract manufacturers, assesses EHS and sustainability performance, including supplier's water stewardship programs. Evaluations include engagement with suppliers to help support their efforts to improve EHS, sustainability, and labor and human rights performance. We apply a risk-based approach to determine where to complete our evaluations and apply our efforts where we believe there is opportunity to make the greatest potential impact and drive improvement. The success of our water-related supplier engagement program is measured by the number of supplier EHS assessments performed. Through a combination of remote and on-site audits, we assessed EHS performance for 109 supplier facilities in 2023, resulting in 878 observations. We require our suppliers to develop action plans in response to our audits and implement improved controls, as needed. For the past 3 years (2021-2023) we have performed over 100 supplier EHS reviews each year.

(5.11.7.10) Engagement is helping your tier 1 suppliers meet an environmental requirement related to this environmental issue

Select from:

☒ Yes, please specify the environmental requirement: Setting and monitoring water pollution-related targets

(5.11.7.11) Engagement is helping your tier 1 suppliers engage with their own suppliers on the selected action

Select from:

☒ Yes

[Add row]

(5.11.9) Provide details of any environmental engagement activity with other stakeholders in the value chain.

Climate change

(5.11.9.1) Type of stakeholder

Select from:

☒ Customers

(5.11.9.2) Type and details of engagement

Education/Information sharing

- ☒ Share information on environmental initiatives, progress and achievements

Innovation and collaboration

- ☒ Align your organization's goals to support customers' targets and ambitions
- ☒ Engage with stakeholders to advocate for policy or regulatory change

(5.11.9.3) % of stakeholder type engaged

Select from:

- ☒ 100%

(5.11.9.4) % stakeholder-associated scope 3 emissions

Select from:

- ☒ 100%

(5.11.9.5) Rationale for engaging these stakeholders and scope of engagement

Pfizer recognizes that ESG issues are increasingly a priority to stakeholders, including our customers and shareholders. We proactively share information on our climate change performance and strategy with current and prospective customers through our annual Impact Report, postings on our Pfizer.com website, press releases, and social media posts. We frequently respond to requests from our customers for details of our environmental sustainability program and performance data and in 2023 provided information to support Scope 3 reporting for customers representing over \$3B in revenue. We are committed to continue collaborating with our customers to identify opportunities to reduce emissions. Pfizer is also working with our peers in the pharma industry, many of which are also our customers, to identify opportunities to drive emissions reductions in the pharmaceutical supply chain. Pfizer is proud to be part of Energize, a first-of-its-kind collaboration launched in November 2021 between 10 global pharmaceutical companies to engage suppliers in decarbonization of the pharmaceutical value chain through renewable energy procurement. The program, which is designed and delivered by Schneider Electric, will enable pharmaceutical suppliers to learn more about renewable energy adoption and contracting. This will offer suppliers which may not otherwise have the internal resources or expertise available the opportunity to participate in the market for PPAs. In November 2022, Pfizer also joined a collective action initiative, Activate, to support the decarbonization of a major source of GHG emissions in the pharmaceutical value chain. Through Activate, Pfizer will work in partnership with peer pharma companies, many of which are also our customers, to accelerate decarbonization in active pharmaceutical ingredient (API) supply chains. Activate targets sustainability / GHG emission improvements at API suppliers including Contract Manufacturing Organizations.

(5.11.9.6) Effect of engagement and measures of success

Pfizer is identified as a top supplier by the US government and is listed on their Federal Contractor Climate Risk Management Scorecard with a 'green' status, meeting the government's expectations for public disclosure, GHG emissions disclosure, and GHG emissions reduction targets (<https://d2d.gsa.gov/report/gsa-federal-contractor-climate-risk-management-scorecardorecard> D2D). As of the end of 2023, over 230 suppliers have registered for Energize as a result of Pfizer's invitations and we have sponsored more than 70 participants in Activate.

Water

(5.11.9.1) Type of stakeholder

Select from:

☒ Customers

(5.11.9.2) Type and details of engagement

Innovation and collaboration

☒ Collaborate with stakeholders on innovations to reduce environmental impacts in products and services

(5.11.9.3) % of stakeholder type engaged

Select from:

☒ 1-25%

(5.11.9.5) Rationale for engaging these stakeholders and scope of engagement

Pharmaceuticals in the environment and antimicrobial resistance (AMR) continue to be priority environmental issues for our industry. Pfizer is committed to limiting discharge of active pharmaceutical ingredients to wastewater from our manufacturing processes, using environmental risk assessment methodologies and emission control practices and technologies. As a founding member of the AMR (Antimicrobial Resistance) Industry Alliance Manufacturing Working Group, Pfizer has partnered with peer companies, many of whom may also be our customers, and key stakeholders to establish and implement a common framework for managing antibiotic discharge. As a result, the AMR Industry Alliance in June 2022 published its Antibiotic Manufacturing Standard: Minimizing risk of developing antibiotic resistance and aquatic ecotoxicity in the environment resulting from the manufacturing of human antibiotics.

(5.11.9.6) Effect of engagement and measures of success

In 2023, Pfizer continued to participate in the development of the certification program designed to demonstrate implementation of AMRIA's Antibiotic Manufacturing Standard through an independent third-party certification body. In collaboration with BSI Standards Limited, Pfizer participated in assessments to pilot the certification process at one of our API manufacturing sites and one of our contract manufacturer antibiotic drug product sites. These assessments indicated compliance with the AMRIA Standard and both sites were recommended for certification. Additionally, learnings from these pilots were used to shape the certification program, which officially launched in June 2023.

(5.13) Has your organization already implemented any mutually beneficial environmental initiatives due to CDP Supply Chain member engagement?

	Environmental initiatives implemented due to CDP Supply Chain member engagement	Primary reason for not implementing environmental initiatives	Explain why your organization has not implemented any environmental initiatives
	<i>Select from:</i> <input checked="" type="checkbox"/> No, and we do not plan to within the next two years	<i>Select from:</i> <input checked="" type="checkbox"/> Other, please specify :Pfizer already engages with pharma peers on beneficial environmental initiatives	<i>Pfizer already engages with pharma peers on beneficial environmental initiatives</i>

[Fixed row]

C6. Environmental Performance - Consolidation Approach

(6.1) Provide details on your chosen consolidation approach for the calculation of environmental performance data.

Climate change

(6.1.1) Consolidation approach used

Select from:

☒ Operational control

(6.1.2) Provide the rationale for the choice of consolidation approach

The operational control boundary best represents sites and activities over which Pfizer has full authority to introduce and implement operating policies and can therefore drive reductions in emissions.

Water

(6.1.1) Consolidation approach used

Select from:

☒ Operational control

(6.1.2) Provide the rationale for the choice of consolidation approach

The operational control boundary best represents sites and activities over which Pfizer has full authority to introduce and implement operating policies and can therefore best manage water use and wastewater discharge quality.

C7. Environmental performance - Climate Change

(7.1) Is this your first year of reporting emissions data to CDP?

Select from:

☒ No

(7.1.1) Has your organization undergone any structural changes in the reporting year, or are any previous structural changes being accounted for in this disclosure of emissions data?

(7.1.1.1) Has there been a structural change?

Select all that apply

☒ Yes, an acquisition

☒ Yes, a divestment

☒ Yes, other structural change, please specify

(7.1.1.2) Name of organization(s) acquired, divested from, or merged with

Divestitures: Pfizer's manufacturing site in Perth, Australia was acquired by the Bridgewest Group; ownership of our manufacturing facility in Hsinchu, Taiwan was transferred to Glaxo Smithkline (GSK); and our office campus in Collegeville, Pennsylvania was sold to David Werner Real Estate Investments. Acquisitions: Pfizer acquired Lucira Health.

(7.1.1.3) Details of structural change(s), including completion dates

Pfizer's manufacturing location in Perth, Australia was divested to the Bridgewest Group in April 2023. Pfizer finished exiting our manufacturing site in Hsinchu, Taiwan, transferring ownership to GSK at the end of 2022. Both sites were removed from Pfizer's footprint as part of our 2023 baseline adjustment process. Pfizer completed the acquisition of Lucira Health in April 2023. Emissions associated with Lucira's operations have been incorporated into Pfizer's footprint. Our commercial office in Collegeville, Pennsylvania was acquired by David Werner Real Estate Investments in August 2023. Pfizer continues to occupy a portion of this property through a lease agreement and emissions associated with our operations there are included in our footprint. Other structural changes include reductions in footprint at our office locations in Paris, France; Mexico City, Mexico; and Zurich, Switzerland. These locations are now included in our Scope 3 Upstream Leased GHG

emissions calculation. Note that Pfizer completed the acquisition of Seagen in December 2023. Seagen emissions will be integrated into Pfizer's baseline for the 2024 reporting year.

(7.1.2) Has your emissions accounting methodology, boundary, and/or reporting year definition changed in the reporting year?

(7.1.2.1) Change(s) in methodology, boundary, and/or reporting year definition?

Select all that apply

- ☒ Yes, a change in methodology
- ☒ Yes, a change in boundary

(7.1.2.2) Details of methodology, boundary, and/or reporting year definition change(s)

Pfizer's reporting boundary has been adjusted to reflect acquisitions, divestitures, and office footprint reductions. Emission factors have been updated to reflect the latest releases from issuing bodies. Emissions for Scope 3 Purchased Goods and Services and Capital Goods were calculated based on spend using US EPA Supply Chain Greenhouse Gas Emission Factors (v1.2 by NAICS-6), adjusted for inflation to 2023. We previously used UK DEFRA emission factors to calculate these categories. In 2023 we aligned our methodology for calculating Scope 3 Upstream Transportation and Distribution emissions with the Global Logistics Emissions Council (GLEC) framework and expanded our use of primary activity data to estimate shipment-level emissions. We have also updated our methodology for calculating Scope 3 Business Travel emissions to include estimates for travel booked outside of Pfizer's travel system, which account for approximately 10% of total business travel emissions.

(7.1.3) Have your organization's base year emissions and past years' emissions been recalculated as a result of any changes or errors reported in 7.1.1 and/or 7.1.2?

(7.1.3.1) Base year recalculation

Select from:

- ☒ Yes

(7.1.3.2) Scope(s) recalculated

Select all that apply

- ☒ Scope 1
- ☒ Scope 2, location-based
- ☒ Scope 2, market-based
- ☒ Scope 3

(7.1.3.3) Base year emissions recalculation policy, including significance threshold

Pfizer's base year emissions are reviewed at least annually and adjusted for any changes to footprint, including acquisitions, divestitures, and closures. Emission factors are updated annually to reflect any changes from issuing bodies and are applied retroactively from the effective date which may impact the baseline year. These adjustments are applied for all changes regardless of significance. Additionally, base year emissions may be recalculated to reflect changes in methodology if the change increases or decreases emissions by 5% or more.

(7.1.3.4) Past years' recalculation

Select from:

- ☒ Yes

[Fixed row]

(7.2) Select the name of the standard, protocol, or methodology you have used to collect activity data and calculate emissions.

Select all that apply

- ☒ IEA CO2 Emissions from Fuel Combustion
- ☒ The Greenhouse Gas Protocol: Scope 2 Guidance
- ☒ US EPA Mandatory Greenhouse Gas Reporting Rule
- ☒ The Greenhouse Gas Protocol: Public Sector Standard
- ☒ IPCC Guidelines for National Greenhouse Gas Inventories, 2006
- ☒ US EPA Emissions & Generation Resource Integrated Database (eGRID)
- ☒ The Greenhouse Gas Protocol: Corporate Value Chain (Scope 3) Standard

- ☒ Smart Freight Centre: GLEC Framework for Logistics Emissions Methodologies
- ☒ The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (Revised Edition)
- ☒ US EPA Center for Corporate Climate Leadership: Direct Emissions from Mobile Combustion Sources
- ☒ Defra Environmental Reporting Guidelines: Including streamlined energy and carbon reporting guidance, 2019

(7.3) Describe your organization's approach to reporting Scope 2 emissions.

	Scope 2, location-based	Scope 2, market-based	Comment
	<i>Select from:</i> <input checked="" type="checkbox"/> We are reporting a Scope 2, location-based figure	<i>Select from:</i> <input checked="" type="checkbox"/> We are reporting a Scope 2, market-based figure	<i>We report both location and market-based figures</i>

[Fixed row]

(7.4) Are there any sources (e.g. facilities, specific GHGs, activities, geographies, etc.) of Scope 1, Scope 2 or Scope 3 emissions that are within your selected reporting boundary which are not included in your disclosure?

Select from:

- ☒ Yes

(7.4.1) Provide details of the sources of Scope 1, Scope 2, or Scope 3 emissions that are within your selected reporting boundary which are not included in your disclosure.

Row 1

(7.4.1.1) Source of excluded emissions

Emissions associated with the transportation and distribution of products within some markets outside the United States (US)

(7.4.1.2) Scope(s) or Scope 3 category(ies)

Select all that apply

☒ Scope 3: Upstream transportation and distribution

(7.4.1.6) Relevance of Scope 3 emissions from this source

Select from:

☒ Emissions are relevant but not yet calculated

(7.4.1.9) Estimated percentage of total Scope 3 emissions this excluded source represents

1.4

(7.4.1.10) Explain why this source is excluded

We previously have not had access to data to enable the calculation of GHG emissions for third-party transportation in local markets outside of the US. We are currently implementing a solution that will enable us to calculate these emissions.

(7.4.1.11) Explain how you estimated the percentage of emissions this excluded source represents

*The US is the only market for which we are currently able to report in-market transportation emissions. Using this market as a benchmark, we estimate all other markets globally will collectively emit approximately 1.5 times the amount of the US market (39,971 mt CO₂e * 1.5 = 59,957 mt CO₂e).*

(7.5) Provide your base year and base year emissions.

Scope 1

(7.5.1) Base year end

12/31/2019

(7.5.2) Base year emissions (metric tons CO₂e)

700,185

(7.5.3) Methodological details

Pfizer's organizational boundaries for GHG reporting include all owned sites and leased facilities where Pfizer has operational control. Data are baseline adjusted to reflect acquisitions and divestitures, reported absolute, using boundaries per the World Resources Institute (WRI) Greenhouse Gas (GHG) Protocol, and include certain estimates and assumptions. Additional information on Pfizer's GHG emissions calculation methodology can be found on our website: https://cdn.pfizer.com/pfizercom/GHG_Calculation_Methodology_JUL2023.pdf.

Scope 2 (location-based)

(7.5.1) Base year end

12/31/2019

(7.5.2) Base year emissions (metric tons CO2e)

557,783

(7.5.3) Methodological details

Pfizer's organizational boundaries for GHG reporting include all owned sites and leased facilities where Pfizer has operational control. Data are baseline adjusted to reflect acquisitions and divestitures, reported absolute, using boundaries per the World Resources Institute (WRI) Greenhouse Gas (GHG) Protocol, and include certain estimates and assumptions. Additional information on Pfizer's GHG emissions calculation methodology can be found on our website: https://cdn.pfizer.com/pfizercom/GHG_Calculation_Methodology_JUL2023.pdf.

Scope 2 (market-based)

(7.5.1) Base year end

12/31/2019

(7.5.2) Base year emissions (metric tons CO2e)

570,557

(7.5.3) Methodological details

Pfizer's organizational boundaries for GHG reporting include all owned sites and leased facilities where Pfizer has operational control. Data are baseline adjusted to reflect acquisitions and divestitures, reported absolute, using boundaries per the World Resources Institute (WRI) Greenhouse Gas (GHG) Protocol, and include certain estimates and assumptions. Additional information on Pfizer's GHG emissions calculation methodology can be found on our website: https://cdn.pfizer.com/pfizercom/GHG_Calculation_Methodology_JUL2023.pdf.

Scope 3 category 1: Purchased goods and services

(7.5.1) Base year end

12/31/2019

(7.5.2) Base year emissions (metric tons CO2e)

2,412,778

(7.5.3) Methodological details

Emissions calculated based on 2019 spend data. Spend data is extracted from Pfizer's accounting system by category. Spend associated with purchased goods and services with an associated GHG footprint is segregated by product or service type and multiplied by the most appropriate emission factor to estimate emissions (CO2e). Spend not considered to have a significant Scope 3 GHG footprint (e.g., colleague wages, customer rebates, taxes, etc.) is excluded from the calculation. US EPA Supply Chain Greenhouse Gas Emission Factors v1.2 by NAICS-6 are used to calculate emissions.

Scope 3 category 2: Capital goods

(7.5.1) Base year end

12/31/2019

(7.5.2) Base year emissions (metric tons CO2e)

116,064

(7.5.3) Methodological details

Emissions calculated based on 2019 spend data. Spend data is extracted from Pfizer's accounting system by category. Spend associated with capital goods is segregated by product or service type and multiplied by the most appropriate emission factor using US EPA Supply Chain Greenhouse Gas Emission Factors v1.2 by NAICS-6.

Scope 3 category 3: Fuel-and-energy-related activities (not included in Scope 1 or 2)

(7.5.1) Base year end

12/31/2019

(7.5.2) Base year emissions (metric tons CO2e)

252,909

(7.5.3) Methodological details

Emissions calculated using electricity, heat, and steam as well as stationary and mobile fuels consumption reported by operations within Pfizer's control. For fuels, consumption by fuel type (in MWh) was multiplied by the appropriate emission factors to determine GHG emissions. Emissions from UK sources calculated using UK Government GHG Conversion Factors for Company Reporting (2020) and include CO₂, CH₄ and N₂O (CO₂eq). For electricity, heat and steam, WTT emissions globally were calculated using UK Government Conversion Factors for Company Reporting Emissions associated with transportation and distribution losses for the UK were calculated using UK factors for sites in the UK and using IEA CO₂ emissions from fuel combustion 2017 for the rest of the world. T&D losses calculated using IEA factors include CO₂ emissions only. T&D losses associated with chilled water were excluded due to unavailability of an emission factor but are anticipated to be

Scope 3 category 4: Upstream transportation and distribution

(7.5.1) Base year end

12/31/2019

(7.5.2) Base year emissions (metric tons CO2e)

248,613

(7.5.3) Methodological details

Emissions estimates related to upstream transportation include international transportation, market transportation within the US, and emissions associated with the use of dry ice in cold chain transportation globally. 1. Emissions associated with international transportation and distribution services are calculated by our Global Logistics Network Services (GL&NS) team using transportation, mode, distance, shipment weight, and average emission factors from the GLEC Framework from Smart Freight Center. Primary operational data from our Enterprise Resource Planning tools are leveraged by the GL&NS team to obtain origin, destination, and shipment weight data. Emissions are reduced through the application of low emissions fuels certificates provided by logistics suppliers. 2. Emissions data for US

market transportation is obtained directly from our three main vendors (FedEx-Parcel, UPS-Parcel, and CH Robinson). Additionally, for other US vendors, fuel surcharge data is used to estimate gallons of diesel fuel consumed by full truckload shipments, and GLEC v3 emission factors are applied to estimate GHG emissions. Emissions are estimated for less than truckload shipments using weight, average distance/shipment, and average freight emission factors from the GLEC Framework from Smart Freight Center. Activity data is provided by the US market logistics team. 3. Pfizer's sites report liquid CO₂ used and dry ice purchased in Pfizer's internal EHS reporting system. Emissions are calculated using emission factors developed by an external engineering firm. For the conversion of liquid CO₂ to dry ice, an emission factor of 0.55kgCO₂/kg liquid CO₂ is applied to calculate scope 1 emissions, and a factor of 0.45kgCO₂/kg liquid CO₂ is applied for scope 3. For purchased dry ice, a factor of 1kg CO₂/1Kg dry ice is applied to estimate scope 3 emissions. Emissions associated with the transportation of goods purchased from our Tier 1 suppliers (e.g., raw materials, packaging materials) are excluded as they are included in Category 1, Purchased Goods and Services. Additionally, emissions associated with market logistics outside the US and emissions associated with the operations of third-party logistics centers are not included in the calculation.

Scope 3 category 5: Waste generated in operations

(7.5.1) Base year end

12/31/2019

(7.5.2) Base year emissions (metric tons CO₂e)

9512

(7.5.3) Methodological details

Emissions (CO₂eq) calculated using waste disposal and wastewater discharge data reported by operations within Pfizer's control and UK Government GHG Conversion Factors for Company Reporting (2020). Emission factors include collection, transportation and landfill emissions ('gate to grave') for waste sent to landfill. For combustion and recycling, the factors consider transport to an energy recovery or material reclamation facility only. Because most of the waste reported by sites as "other disposal" by Pfizer locations was sent to wastewater treatment, the wastewater treatment emission factor was used to estimate emissions for all waste reported in this category.

Scope 3 category 6: Business travel

(7.5.1) Base year end

12/31/2019

(7.5.2) Base year emissions (metric tons CO₂e)

(7.5.3) Methodological details

Emissions associated with air travel, hotel stays, car use (rental and personal), and rail travel booked within Pfizer's travel system are calculated by the consulting arm of Pfizer's travel agency using detailed primary data such as distance, aircraft type, cabin class, etc. plus secondary data when primary data is not available. Air travel emission factors include radiative force. Personal and rental car travel emissions include WTT emissions. Emissions associated with personal car by the field force in the US are calculated using data from the company's reimbursement service provider and US EPA emission factors. Air travel booked outside Pfizer's travel system is estimated using spend data, and leakage rates for other forms of travel are estimated based on industry averages as reported in the paper "Data Dive: How 2021 Priorities Can Be Guided by Leakage Data" by Emburse. Emissions associated with this travel are estimated by Pfizer's travel agency consulting firm.

Scope 3 category 7: Employee commuting

(7.5.1) Base year end

12/31/2019

(7.5.2) Base year emissions (metric tons CO2e)

60,645

(7.5.3) Methodological details

Emissions estimated based on Pfizer's employee headcount as of June 30, 2019. Commuting distance for all colleagues estimated based on data published by NationMaster using the median distance per region to estimate for countries not covered by the source data. Commuting methods for North American colleagues estimated based on a study published by Bloomberg in 2019. Commuting method assumptions for colleagues outside North America were made based on general knowledge of the region. Emissions associated with employee commuting in North America were calculated using US EPA Climate Leaders GHG 2020 emission factors. Emissions for all other regions were calculated using DEFRA emission factors (average car, unknown fuel type; national rail; light rail and tram; and average local bus).

Scope 3 category 8: Upstream leased assets

(7.5.1) Base year end

12/31/2019

(7.5.2) Base year emissions (metric tons CO2e)

(7.5.3) Methodological details

Leased facility square footage for sites not within Pfizer's operational control derived from Pfizer's corporate real estate database. Emissions estimated using the Greenhouse Gas Protocol/Quantis Scope 3 Evaluator.

Scope 3 category 9: Downstream transportation and distribution**(7.5.1) Base year end**

12/31/2019

(7.5.2) Base year emissions (metric tons CO2e)

99,576

(7.5.3) Methodological details

Emissions estimated based on number of products sold and average distance of travel to medical offices, pharmacies and retailers in the US only using DEFRA emission factors.

Scope 3 category 10: Processing of sold products**(7.5.1) Base year end**

12/31/2019

(7.5.2) Base year emissions (metric tons CO2e)

0

(7.5.3) Methodological details

Not Applicable

Scope 3 category 11: Use of sold products

(7.5.1) Base year end

12/31/2019

(7.5.2) Base year emissions (metric tons CO2e)

0

(7.5.3) Methodological details

Not Applicable

Scope 3 category 12: End of life treatment of sold products

(7.5.1) Base year end

12/31/2019

(7.5.2) Base year emissions (metric tons CO2e)

0

(7.5.3) Methodological details

Not Applicable

Scope 3 category 13: Downstream leased assets

(7.5.1) Base year end

12/31/2019

(7.5.2) Base year emissions (metric tons CO2e)

0

(7.5.3) Methodological details

Not Applicable

Scope 3 category 14: Franchises

(7.5.1) Base year end

12/31/2019

(7.5.2) Base year emissions (metric tons CO2e)

0

(7.5.3) Methodological details

Not Applicable

Scope 3 category 15: Investments

(7.5.1) Base year end

12/31/2019

(7.5.2) Base year emissions (metric tons CO2e)

33,892

(7.5.3) Methodological details

Emissions data provided by Pfizer's joint venture operations where we have influence and/or operational control.

Scope 3: Other (upstream)

(7.5.1) Base year end

12/31/2019

(7.5.2) Base year emissions (metric tons CO2e)

0

(7.5.3) Methodological details

Not Applicable

Scope 3: Other (downstream)

(7.5.1) Base year end

12/31/2019

(7.5.2) Base year emissions (metric tons CO2e)

0

(7.5.3) Methodological details

Not Applicable

[Fixed row]

(7.6) What were your organization's gross global Scope 1 emissions in metric tons CO2e?

Reporting year

(7.6.1) Gross global Scope 1 emissions (metric tons CO2e)

620,124

(7.6.3) Methodological details

Pfizer's organizational boundaries for GHG reporting include all owned sites and leased facilities where Pfizer has operational control. Data are baseline adjusted to reflect acquisitions and divestitures, reported absolute, using boundaries per the World Resources Institute (WRI) Greenhouse Gas (GHG) Protocol, and include certain estimates and assumptions. Additional information on Pfizer's GHG emissions calculation methodology can be found on our website: https://cdn.pfizer.com/pfizercom/GHG_Calculation_Methodology_JUL2023.pdf.

Past year 1

(7.6.1) Gross global Scope 1 emissions (metric tons CO2e)

647,707

(7.6.2) End date

12/31/2022

(7.6.3) Methodological details

Pfizer's organizational boundaries for GHG reporting include all owned sites and leased facilities where Pfizer has operational control. Data are baseline adjusted to reflect acquisitions and divestitures, reported absolute, using boundaries per the World Resources Institute (WRI) Greenhouse Gas (GHG) Protocol, and include certain estimates and assumptions. Additional information on Pfizer's GHG emissions calculation methodology can be found on our website: https://cdn.pfizer.com/pfizercom/GHG_Calculation_Methodology_JUL2023.pdf.

(7.7) What were your organization's gross global Scope 2 emissions in metric tons CO2e?

Reporting year

(7.7.1) Gross global Scope 2, location-based emissions (metric tons CO2e)

500,077

(7.7.2) Gross global Scope 2, market-based emissions (metric tons CO2e) (if applicable)

486,384

(7.7.4) Methodological details

Pfizer's organizational boundaries for GHG reporting include all owned sites and leased facilities where Pfizer has operational control. Data are baseline adjusted to reflect acquisitions and divestitures, reported absolute, using boundaries per the World Resources Institute (WRI) Greenhouse Gas (GHG) Protocol, and include certain estimates and assumptions. Additional information on Pfizer's GHG emissions calculation methodology can be found on our website: https://cdn.pfizer.com/pfizercom/GHG_Calculation_Methodology_JUL2023.pdf.

Past year 1

(7.7.1) Gross global Scope 2, location-based emissions (metric tons CO2e)

500,399

(7.7.2) Gross global Scope 2, market-based emissions (metric tons CO2e) (if applicable)

484,471

(7.7.3) End date

12/31/2022

(7.7.4) Methodological details

Pfizer's organizational boundaries for GHG reporting include all owned sites and leased facilities where Pfizer has operational control. Data are baseline adjusted to reflect acquisitions and divestitures, reported absolute, using boundaries per the World Resources Institute (WRI) Greenhouse Gas (GHG) Protocol, and include certain estimates and assumptions. Additional information on Pfizer's GHG emissions calculation methodology can be found on our website: https://cdn.pfizer.com/pfizercom/GHG_Calculation_Methodology_JUL2023.pdf.

(7.8) Account for your organization's gross global Scope 3 emissions, disclosing and explaining any exclusions.

Purchased goods and services

(7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

(7.8.2) Emissions in reporting year (metric tons CO2e)

3,401,334

(7.8.3) Emissions calculation methodology

Select all that apply

☒ Spend-based method

(7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

0

(7.8.5) Please explain

Emissions calculated based on 2023 spend data. Spend data is extracted from Pfizer's accounting system by category. Spend associated with purchased goods and services with an associated GHG footprint is segregated by product or service type and multiplied by the most appropriate emission factor to estimate emissions (CO2e). Spend not considered to have a significant Scope 3 GHG footprint (e.g., colleague wages, customer rebates, taxes, etc.) is excluded from the calculation. US EPA Supply Chain Greenhouse Gas Emission Factors v12 by NAICS6, adjusted for inflation to 2023, are used to calculate emissions. Calculated emissions decreased in 2023 primarily due to the reduction in spend related to the production of COVID19-related products in addition to differences between the US EPA emission factors and the DEFRA factors previously used for calculating emissions.

Capital goods

(7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

(7.8.2) Emissions in reporting year (metric tons CO2e)

126,588

(7.8.3) Emissions calculation methodology

Select all that apply

☒ Spend-based method

(7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

0

(7.8.5) Please explain

Emissions calculated based on 2023 spend data. Spend data is extracted from Pfizer's accounting system by category. Spend associated with capital goods is segregated by product or service type and multiplied by the most appropriate emission factor using US EPA Supply Chain Greenhouse Gas Emission Factors v1.2 by NAICS-6, adjusted for inflation to 2023.

Fuel-and-energy-related activities (not included in Scope 1 or 2)

(7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

(7.8.2) Emissions in reporting year (metric tons CO2e)

263,780

(7.8.3) Emissions calculation methodology

Select all that apply

☒ Average data method

(7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

100

(7.8.5) Please explain

Emissions calculated using electricity, heat, and steam as well as stationary and mobile fuels consumption reported by operations within Pfizer's control. 1. For fuels, consumption by fuel type (in MWh) was multiplied by the appropriate emission factor to determine GHG emissions. Emissions from all sources were calculated using UK Government GHG Conversion Factors for Company Reporting (2023) and include CO₂, CH₄, and N₂O (CO₂e). 2. For UK sites, electricity well-to-tank (WTT)-generation, WTT-transmission and distribution (T&D), and distribution T&D emissions were calculated using 2023 UK Government GHG Conversion Factors and include CO₂, CH₄, and N₂O (CO₂e). 3. For non-UK sites, electricity WTT-generation and WTT-T&D emissions were calculated using 2021 UK Government GHG Conversion Factors and include CO₂, CH₄, and N₂O (CO₂e). Distribution (T&D losses) are calculated using IEA Emission Factors 2023 Edition (the 2023 edition includes 2021 emission factors data) and include CO₂ emissions only. 4. For heat and steam, WTT-generation, WTT-T&D, and T&D emissions for all countries were calculated using 2023 UK Government GHG Conversion Factors and include CO₂, CH₄, and N₂O (CO₂e). T&D losses associated with chilled water were excluded due to unavailability of an emission factor but are anticipated to be <0.1% of total.

Upstream transportation and distribution

(7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

(7.8.2) Emissions in reporting year (metric tons CO₂e)

305,229

(7.8.3) Emissions calculation methodology

Select all that apply

☒ Fuel-based method

☒ Distance-based method

(7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

12

(7.8.5) Please explain

Emissions estimates related to upstream transportation include international transportation, market (i.e., domestic) transportation in the US, and emissions associated with the use of dry ice in COVID vaccine transportation globally. 1. Emissions associated with international transportation and distribution services are calculated by our Global Logistics Network Services (GL&NS) team using transportation, mode, distance, shipment weight, and average emission factors from the GLEC

Framework from Smart Freight Center. Primary operational data from our Enterprise Resource Planning tools are leveraged by the GL&NS team to obtain origin, destination, and shipment weight data. Emissions are reduced through the application of low emissions fuels certificates provided by logistics suppliers. 2. Emissions data for US market transportation is obtained directly from our three main vendors (FedEx-Parcel, UPS-Parcel, and CH Robinson). Additionally, for other US vendors, fuel surcharge data is used to estimate gallons of diesel fuel consumed by full truckload shipments, and GLEC v3 emission factors are applied to estimate GHG emissions. Emissions are estimated for less than truckload shipments using weight, average distance/shipment, and average freight emission factors from the GLEC Framework from Smart Freight Center. Activity data is provided by the US market logistics team. 3. Pfizer's sites report liquid CO2 used and dry ice purchased in Pfizer's internal EHS reporting system. Emissions are calculated using emission factors developed by an external engineering firm. For the conversion of liquid CO2 to dry ice, an emission factor of 0.55kgCO2/kg liquid CO2 is applied to calculate scope 1 emissions, and a factor of 0.45kgCO2/kg liquid CO2 is applied for scope 3. For purchased dry ice, a factor of 1kg CO2/1Kg dry ice is applied to estimate scope 3 emissions. Emissions associated with the transportation of goods purchased from our Tier 1 suppliers (e.g., raw materials, packaging materials) are excluded as they are included in Category 1, Purchased Goods and Services. Additionally, emissions associated with market logistics outside the US and emissions associated with the operations of third-party logistics centers are not included in the calculation.

Waste generated in operations

(7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

(7.8.2) Emissions in reporting year (metric tons CO2e)

8795

(7.8.3) Emissions calculation methodology

Select all that apply

☒ Waste-type-specific method

(7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

100

(7.8.5) Please explain

Emissions (CO2e) calculated using waste disposal and wastewater discharge data reported by operations within Pfizer's control and UK Government GHG Conversion Factors for Company Reporting (2023). Emission factors include collection, transportation, and landfill emissions ('gate to grave') for waste sent to landfill.

For combustion and recycling, the factors consider transport to an energy recovery or material reclamation facility only. The majority of waste reported as “other disposal” by Pfizer locations was sent to wastewater treatment, therefore the emission factor for wastewater treatment was used to estimate emissions for all waste reported in this category.

Business travel

(7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

(7.8.2) Emissions in reporting year (metric tons CO₂e)

172,510

(7.8.3) Emissions calculation methodology

Select all that apply

☒ Hybrid method

(7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

90

(7.8.5) Please explain

Emissions associated with air travel, hotel stays, car use (rental and personal), and rail travel booked within Pfizer’s travel system are calculated by the consulting arm of Pfizer’s travel agency using detailed primary data such as distance, aircraft type, cabin class, etc. plus secondary data when primary data is not available. Air travel emission factors include radiative force. Personal and rental car travel emissions include WTT emissions. Emissions associated with personal car by the field force in the US are calculated by the company’s reimbursement service provider using 2023 US EPA vehicle emission factors. Air travel booked outside Pfizer’s travel system is estimated using spend data, and leakage rates for other forms of travel are estimated based on industry averages as reported in the paper “Data Dive: How 2021 Priorities Can Be Guided by Leakage Data” by Emburse. Emissions associated with this travel are estimated by Pfizer’s travel agency consulting firm.

Employee commuting

(7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

(7.8.2) Emissions in reporting year (metric tons CO2e)

21,745

(7.8.3) Emissions calculation methodology

Select all that apply

☒ Average data method

(7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

0

(7.8.5) Please explain

Emissions associated with employee commuting were estimated using the average method described in the GHG Protocol Scope 3 Technical Guidance publication. Emissions are estimated based on Pfizer's employee headcount as of Dec 31, 2023. A corporate headcount report was used to determine the number of colleagues working onsite full time, colleagues eligible for the company's flexible work program, and colleagues who work remotely full time. Colleagues working onsite full time were assumed to commute 200 days per year. Colleagues eligible for flexible working were assumed to commute 100 days per year. Emissions associated with remote working are not included. The commuting distance for all colleagues was estimated based on data published by Nation Master using the median distance per region to estimate for countries not covered by the source data. Average distance per region was then used in final calculation by region. Commuting methods for North American colleagues estimated based on a study published by Bloomberg in 2019. Commuting method assumptions for colleagues outside North America were made based on general knowledge of the region. Emissions associated with employee commuting in North America are calculated using US EPA 2023 GHG Emission Factors Hub emission factors (Table 10- passenger car, commuter rail, transit rail, and bus. Emissions for all other regions are calculated using DEFRA emission factors (average car, unknown fuel type; national rail light rail and tram; and average local bus). This is a conservative estimate as emissions generated by commuters using company owned vehicles are also reported in Scope 1. Pfizer is working to enhance its calculation methodology for this category.

Upstream leased assets

(7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

(7.8.2) Emissions in reporting year (metric tons CO2e)

27,306

(7.8.3) Emissions calculation methodology

Select all that apply

- ☒ Fuel-based method
- ☒ Asset-specific method

(7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

29

(7.8.5) Please explain

Emissions for 61% of our leased locations between 10,000 ft² and 100,000 ft² in size are calculated in Pfizer's internal EHS reporting system using actual energy consumption data. For the remaining locations between 10,000 ft² and 100,000 ft², as well as all leased sites below 10,000 ft², the GHG Protocol Scope 3 Category 8 Technical Guidance hybrid method is used to calculate emissions (asset-specific and average data method). For emission factors, average emissions by floor space are used. Average emission factor was developed using emissions and square footage data from leased sites under operational control. Leased facility square footage for sites not within Pfizer's operational control is obtained from Pfizer's corporate real estate database. Additionally, for sites under 10,000 ft² where square footage data is not currently available, a conservative estimate was provided by a subject matter expert.

Downstream transportation and distribution

(7.8.1) Evaluation status

Select from:

- ☒ Relevant, calculated

(7.8.2) Emissions in reporting year (metric tons CO2e)

4446

(7.8.3) Emissions calculation methodology

Select all that apply

☒ Distance-based method

(7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

0

(7.8.5) Please explain

Data for downstream US and Europe domestic transportation and distribution services is obtained from Pfizer's Network and Site Analytics team and includes origin and destination, mass of goods, and total distance travelled. Emissions are estimated using the distance, shipment weight, and GLEC emission factors for road transportation for the US, Europe & LATAM.

Processing of sold products

(7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

(7.8.5) Please explain

Pfizer products are not further processed in significant quantities.

Use of sold products

(7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

(7.8.5) Please explain

Pfizer products are not likely to create significant GHG emissions in normal use.

End of life treatment of sold products

(7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

(7.8.5) Please explain

GHG emissions associated with the normal use of Pfizer products are negligible. Products returned to Pfizer for destruction by Pfizer are accounted for in waste treatment estimate.

Downstream leased assets

(7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

(7.8.5) Please explain

Emissions from real estate assets within Pfizer sites leased out to third parties are mainly included in Scope 1 and 2 emissions and therefore were not included in Scope 3 calculations.

Franchises

(7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

(7.8.5) Please explain

Pfizer does not operate franchises.

Investments

(7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

(7.8.2) Emissions in reporting year (metric tons CO2e)

6754

(7.8.3) Emissions calculation methodology

Select all that apply

☒ Fuel-based method

(7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

100

(7.8.5) Please explain

Emissions data provided by Pfizer's joint venture operations where we have influence and/or operational control.

Other (upstream)

(7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

(7.8.5) Please explain

Not applicable - Pfizer does not have other upstream emissions.

Other (downstream)

(7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

(7.8.5) Please explain

Not applicable - Pfizer does not have other downstream emissions.

[Fixed row]

(7.8.1) Disclose or restate your Scope 3 emissions data for previous years.

Past year 1

(7.8.1.1) End date

12/30/2022

(7.8.1.2) Scope 3: Purchased goods and services (metric tons CO2e)

8,247,666

(7.8.1.3) Scope 3: Capital goods (metric tons CO2e)

282,414

(7.8.1.4) Scope 3: Fuel and energy-related activities (not included in Scopes 1 or 2) (metric tons CO2e)

262,990

(7.8.1.5) Scope 3: Upstream transportation and distribution (metric tons CO2e)

439,678

(7.8.1.6) Scope 3: Waste generated in operations (metric tons CO2e)

8650

(7.8.1.7) Scope 3: Business travel (metric tons CO2e)

93,734

(7.8.1.8) Scope 3: Employee commuting (metric tons CO2e)

38,557

(7.8.1.9) Scope 3: Upstream leased assets (metric tons CO2e)

30,449

(7.8.1.10) Scope 3: Downstream transportation and distribution (metric tons CO2e)

8351

(7.8.1.11) Scope 3: Processing of sold products (metric tons CO2e)

0

(7.8.1.12) Scope 3: Use of sold products (metric tons CO2e)

0

(7.8.1.13) Scope 3: End of life treatment of sold products (metric tons CO2e)

0

(7.8.1.14) Scope 3: Downstream leased assets (metric tons CO2e)

0

(7.8.1.15) Scope 3: Franchises (metric tons CO2e)

0

(7.8.1.16) Scope 3: Investments (metric tons CO2e)

6939

(7.8.1.17) Scope 3: Other (upstream) (metric tons CO2e)

0

(7.8.1.18) Scope 3: Other (downstream) (metric tons CO2e)

0

(7.8.1.19) Comment

Upstream transportation and distribution emissions for 2022 have been recalculated using our 2023 methodology which is aligned with the Global Logistics Emissions Council (GLEC) framework, resulting in a 38.3% decrease from the previously reported value. Emissions associated with waste generated in operations in 2022 have been updated to reflect the baseline adjustment of our internal footprint, resulting in a decrease of 0.6% compared to the previously reported value. Business Travel emissions for 2022 have been updated to include estimates for travel booked outside of Pfizer's travel system, resulting in a 16.9% increase compared to the previously reported value.

(7.9) Indicate the verification/assurance status that applies to your reported emissions.

	Verification/assurance status
Scope 1	Select from: <input checked="" type="checkbox"/> Third-party verification or assurance process in place

	Verification/assurance status
Scope 2 (location-based or market-based)	<i>Select from:</i> <input checked="" type="checkbox"/> Third-party verification or assurance process in place
Scope 3	<i>Select from:</i> <input checked="" type="checkbox"/> Third-party verification or assurance process in place

[Fixed row]

(7.9.1) Provide further details of the verification/assurance undertaken for your Scope 1 emissions, and attach the relevant statements.

Row 1

(7.9.1.1) Verification or assurance cycle in place

Select from:

☒ Annual process

(7.9.1.2) Status in the current reporting year

Select from:

☒ Complete

(7.9.1.3) Type of verification or assurance

Select from:

☒ Reasonable assurance

(7.9.1.4) Attach the statement

(7.9.1.5) Page/section reference

pp. 1-2

(7.9.1.6) Relevant standard

Select from:

☒ ISAE3000

(7.9.1.7) Proportion of reported emissions verified (%)

100

[Add row]

(7.9.2) Provide further details of the verification/assurance undertaken for your Scope 2 emissions and attach the relevant statements.

Row 1

(7.9.2.1) Scope 2 approach

Select from:

☒ Scope 2 location-based

(7.9.2.2) Verification or assurance cycle in place

Select from:

☒ Annual process

(7.9.2.3) Status in the current reporting year

Select from:

☒ Complete

(7.9.2.4) Type of verification or assurance

Select from:

☒ Reasonable assurance

(7.9.2.5) Attach the statement

ERM CVS Limited Assurance Report for Pfizer - 2024 CDP Questionnaire (FINAL).pdf

(7.9.2.6) Page/ section reference

pp. 1-2

(7.9.2.7) Relevant standard

Select from:

☒ ISAE3000

(7.9.2.8) Proportion of reported emissions verified (%)

100

Row 2

(7.9.2.1) Scope 2 approach

Select from:

☒ Scope 2 market-based

(7.9.2.2) Verification or assurance cycle in place

Select from:

☒ Annual process

(7.9.2.3) Status in the current reporting year

Select from:

☒ Complete

(7.9.2.4) Type of verification or assurance

Select from:

☒ Reasonable assurance

(7.9.2.5) Attach the statement

ERM CVS Limited Assurance Report for Pfizer - 2024 CDP Questionnaire (FINAL).pdf

(7.9.2.6) Page/ section reference

pp. 1-2

(7.9.2.7) Relevant standard

Select from:

☒ ISAE3000

(7.9.2.8) Proportion of reported emissions verified (%)

100
[Add row]

(7.9.3) Provide further details of the verification/assurance undertaken for your Scope 3 emissions and attach the relevant statements.

Row 1

(7.9.3.1) Scope 3 category

Select all that apply

- ☒ Scope 3: Investments
- ☒ Scope 3: Capital goods
- ☒ Scope 3: Business travel
- ☒ Scope 3: Employee commuting
- ☒ Scope 3: Upstream leased assets
- ☒ Scope 3: Purchased goods and services
- ☒ Scope 3: Waste generated in operations
- ☒ Scope 3: Upstream transportation and distribution
- ☒ Scope 3: Fuel and energy-related activities (not included in Scopes 1 or 2)

(7.9.3.2) Verification or assurance cycle in place

Select from:

- ☒ Annual process

(7.9.3.3) Status in the current reporting year

Select from:

- ☒ Complete

(7.9.3.4) Type of verification or assurance

Select from:

- ☒ Limited assurance

(7.9.3.5) Attach the statement

ERM CVS Limited Assurance Report for Pfizer - 2024 CDP Questionnaire (FINAL).pdf

(7.9.3.6) Page/section reference

pp. 1-2

(7.9.3.7) Relevant standard

Select from:

- ☒ ISAE3000

(7.9.3.8) Proportion of reported emissions verified (%)

100

[Add row]

(7.10) How do your gross global emissions (Scope 1 and 2 combined) for the reporting year compare to those of the previous reporting year?

Select from:

☒ Decreased

(7.10.1) Identify the reasons for any change in your gross global emissions (Scope 1 and 2 combined), and for each of them specify how your emissions compare to the previous year.

Change in renewable energy consumption

(7.10.1.1) Change in emissions (metric tons CO₂e)

6344

(7.10.1.2) Direction of change in emissions

Select from:

☒ Decreased

(7.10.1.3) Emissions value (percentage)

0.06

(7.10.1.4) Please explain calculation

Change in emissions divided by total scope 1&2 emissions in reporting year (-633 / 1,132,178)

Other emissions reduction activities

(7.10.1.1) Change in emissions (metric tons CO2e)

30483

(7.10.1.2) Direction of change in emissions

Select from:

☒ Decreased

(7.10.1.3) Emissions value (percentage)

2.69

(7.10.1.4) Please explain calculation

Change in emissions divided by total scope 12 emissions in reporting year (-30,483 / 1,132,178)

Divestment

(7.10.1.1) Change in emissions (metric tons CO2e)

8943

(7.10.1.2) Direction of change in emissions

Select from:

☒ Decreased

(7.10.1.3) Emissions value (percentage)

0.79

(7.10.1.4) Please explain calculation

Change in emissions divided by total scope 1&2 emissions in reporting year (-8,943 / 1,132,178)

Acquisitions

(7.10.1.1) Change in emissions (metric tons CO2e)

0

(7.10.1.2) Direction of change in emissions

Select from:

☒ No change

(7.10.1.3) Emissions value (percentage)

0

(7.10.1.4) Please explain calculation

N/A

Mergers

(7.10.1.1) Change in emissions (metric tons CO2e)

0

(7.10.1.2) Direction of change in emissions

Select from:

☒ No change

(7.10.1.3) Emissions value (percentage)

0

(7.10.1.4) Please explain calculation

N/A

Change in output

(7.10.1.1) Change in emissions (metric tons CO2e)

20,622

(7.10.1.2) Direction of change in emissions

Select from:

☒ Increased

(7.10.1.3) Emissions value (percentage)

1.3

(7.10.1.4) Please explain calculation

Change in emissions associated with production increases and site expansion divided by total scope 1&2 emissions in reporting year (-14,911 / 1,132,178)

Change in methodology

(7.10.1.1) Change in emissions (metric tons CO2e)

0

(7.10.1.2) Direction of change in emissions

Select from:

☒ No change

(7.10.1.3) Emissions value (percentage)

0

(7.10.1.4) Please explain calculation

N/A

Change in boundary

(7.10.1.1) Change in emissions (metric tons CO2e)

522

(7.10.1.2) Direction of change in emissions

Select from:

☒ Decreased

(7.10.1.3) Emissions value (percentage)

0.05

(7.10.1.4) Please explain calculation

Change in emissions divided by total scope 1&2 emissions in reporting year (-522 / 1,132,178)

Change in physical operating conditions

(7.10.1.1) Change in emissions (metric tons CO2e)

0

(7.10.1.2) Direction of change in emissions

Select from:

☒ No change

(7.10.1.3) Emissions value (percentage)

0

(7.10.1.4) Please explain calculation

N/A

Unidentified

(7.10.1.1) Change in emissions (metric tons CO2e)

0

(7.10.1.2) Direction of change in emissions

Select from:

☒ No change

(7.10.1.3) Emissions value (percentage)

0

(7.10.1.4) Please explain calculation

N/A

Other

(7.10.1.1) Change in emissions (metric tons CO2e)

0

(7.10.1.2) Direction of change in emissions

Select from:

☒ No change

(7.10.1.3) Emissions value (percentage)

0

(7.10.1.4) Please explain calculation

N/A

[Fixed row]

(7.10.2) Are your emissions performance calculations in 7.10 and 7.10.1 based on a location-based Scope 2 emissions figure or a market-based Scope 2 emissions figure?

Select from:

☒ Market-based

(7.12) Are carbon dioxide emissions from biogenic carbon relevant to your organization?

Select from:

☒ Yes

(7.12.1) Provide the emissions from biogenic carbon relevant to your organization in metric tons CO2.

	CO2 emissions from biogenic carbon (metric tons CO2)	Comment
	12585	Sources of biogenic emissions include wood chips and wood pellets used by Pfizer facilities and biodiesel 100 and ethanol E100 fuels used by Fleet.

[Fixed row]

(7.15) Does your organization break down its Scope 1 emissions by greenhouse gas type?

Select from:

☒ Yes

(7.15.1) Break down your total gross global Scope 1 emissions by greenhouse gas type and provide the source of each used global warming potential (GWP).

Row 1

(7.15.1.1) Greenhouse gas

Select from:

☒ CO2

(7.15.1.2) Scope 1 emissions (metric tons of CO2e)

585,615

(7.15.1.3) GWP Reference

Select from:

☒ IPCC Fifth Assessment Report (AR5 – 100 year)

Row 2

(7.15.1.1) Greenhouse gas

Select from:

☒ CH4

(7.15.1.2) Scope 1 emissions (metric tons of CO2e)

351

(7.15.1.3) GWP Reference

Select from:

☒ IPCC Fifth Assessment Report (AR5 – 100 year)

Row 3

(7.15.1.1) Greenhouse gas

Select from:

☒ N2O

(7.15.1.2) Scope 1 emissions (metric tons of CO2e)

1213

(7.15.1.3) GWP Reference

Select from:

☒ IPCC Fifth Assessment Report (AR5 – 100 year)

Row 4

(7.15.1.1) Greenhouse gas

Select from:

☒ SF6

(7.15.1.2) Scope 1 emissions (metric tons of CO2e)

621

(7.15.1.3) GWP Reference

Select from:

☒ IPCC Fifth Assessment Report (AR5 – 100 year)

Row 5

(7.15.1.1) Greenhouse gas

Select from:

☒ HFCs

(7.15.1.2) Scope 1 emissions (metric tons of CO₂e)

21,227

(7.15.1.3) GWP Reference

Select from:

☒ IPCC Fifth Assessment Report (AR5 – 100 year)

Row 6

(7.15.1.1) Greenhouse gas

Select from:

☒ Other, please specify :VOC

(7.15.1.2) Scope 1 emissions (metric tons of CO₂e)

11,065

(7.15.1.3) GWP Reference

Select from:

☒ Other, please specify :Internal Calculation

Row 7

(7.15.1.1) Greenhouse gas

Select from:

☒ Other, please specify :Acetylene

(7.15.1.2) Scope 1 emissions (metric tons of CO₂e)

1

(7.15.1.3) GWP Reference

Select from:

☒ IPCC Fifth Assessment Report (AR5 – 100 year)

[Add row]

(7.16) Break down your total gross global Scope 1 and 2 emissions by country/area.

Algeria

(7.16.1) Scope 1 emissions (metric tons CO₂e)

700

(7.16.2) Scope 2, location-based (metric tons CO₂e)

1522

(7.16.3) Scope 2, market-based (metric tons CO₂e)

1522

Argentina

(7.16.1) Scope 1 emissions (metric tons CO₂e)

1998

(7.16.2) Scope 2, location-based (metric tons CO2e)

2660

(7.16.3) Scope 2, market-based (metric tons CO2e)

2660

Australia

(7.16.1) Scope 1 emissions (metric tons CO2e)

3248

(7.16.2) Scope 2, location-based (metric tons CO2e)

7832

(7.16.3) Scope 2, market-based (metric tons CO2e)

7832

Austria

(7.16.1) Scope 1 emissions (metric tons CO2e)

387

(7.16.2) Scope 2, location-based (metric tons CO2e)

2693

(7.16.3) Scope 2, market-based (metric tons CO2e)

1718

Belarus

(7.16.1) Scope 1 emissions (metric tons CO2e)

33

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Belgium

(7.16.1) Scope 1 emissions (metric tons CO2e)

27,117

(7.16.2) Scope 2, location-based (metric tons CO2e)

9676

(7.16.3) Scope 2, market-based (metric tons CO2e)

10,648

Brazil

(7.16.1) Scope 1 emissions (metric tons CO2e)

8037

(7.16.2) Scope 2, location-based (metric tons CO2e)

2223

(7.16.3) Scope 2, market-based (metric tons CO2e)

97

Bulgaria

(7.16.1) Scope 1 emissions (metric tons CO2e)

148

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Canada

(7.16.1) Scope 1 emissions (metric tons CO2e)

5365

(7.16.2) Scope 2, location-based (metric tons CO2e)

23

(7.16.3) Scope 2, market-based (metric tons CO2e)

23

Chile

(7.16.1) Scope 1 emissions (metric tons CO2e)

349

(7.16.2) Scope 2, location-based (metric tons CO2e)

63

(7.16.3) Scope 2, market-based (metric tons CO2e)

63

China

(7.16.1) Scope 1 emissions (metric tons CO2e)

347

(7.16.2) Scope 2, location-based (metric tons CO2e)

5839

(7.16.3) Scope 2, market-based (metric tons CO2e)

5839

Colombia

(7.16.1) Scope 1 emissions (metric tons CO2e)

503

(7.16.2) Scope 2, location-based (metric tons CO2e)

30

(7.16.3) Scope 2, market-based (metric tons CO2e)

30

Costa Rica

(7.16.1) Scope 1 emissions (metric tons CO2e)

631

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Croatia

(7.16.1) Scope 1 emissions (metric tons CO2e)

1615

(7.16.2) Scope 2, location-based (metric tons CO2e)

1062

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Czechia

(7.16.1) Scope 1 emissions (metric tons CO2e)

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Denmark**(7.16.1) Scope 1 emissions (metric tons CO2e)**

221

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Ecuador**(7.16.1) Scope 1 emissions (metric tons CO2e)**

29

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Egypt

(7.16.1) Scope 1 emissions (metric tons CO2e)

543

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Estonia

(7.16.1) Scope 1 emissions (metric tons CO2e)

60

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Finland

(7.16.1) Scope 1 emissions (metric tons CO2e)

196

(7.16.2) Scope 2, location-based (metric tons CO2e)

353

(7.16.3) Scope 2, market-based (metric tons CO2e)

564

France

(7.16.1) Scope 1 emissions (metric tons CO2e)

1404

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Germany

(7.16.1) Scope 1 emissions (metric tons CO2e)

11,723

(7.16.2) Scope 2, location-based (metric tons CO2e)

10,586

(7.16.3) Scope 2, market-based (metric tons CO2e)

9231

Greece

(7.16.1) Scope 1 emissions (metric tons CO2e)

765

(7.16.2) Scope 2, location-based (metric tons CO2e)

167

(7.16.3) Scope 2, market-based (metric tons CO2e)

217

Hungary

(7.16.1) Scope 1 emissions (metric tons CO2e)

378

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

India

(7.16.1) Scope 1 emissions (metric tons CO2e)

9759

(7.16.2) Scope 2, location-based (metric tons CO2e)

36,136

(7.16.3) Scope 2, market-based (metric tons CO2e)

36,136

Indonesia

(7.16.1) Scope 1 emissions (metric tons CO2e)

459

(7.16.2) Scope 2, location-based (metric tons CO2e)

3819

(7.16.3) Scope 2, market-based (metric tons CO2e)

3819

Ireland

(7.16.1) Scope 1 emissions (metric tons CO2e)

70,295

(7.16.2) Scope 2, location-based (metric tons CO2e)

25,332

(7.16.3) Scope 2, market-based (metric tons CO2e)

124

Israel

(7.16.1) Scope 1 emissions (metric tons CO2e)

602

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Italy

(7.16.1) Scope 1 emissions (metric tons CO2e)

23,568

(7.16.2) Scope 2, location-based (metric tons CO2e)

7654

(7.16.3) Scope 2, market-based (metric tons CO2e)

12,394

Japan

(7.16.1) Scope 1 emissions (metric tons CO2e)

4786

(7.16.2) Scope 2, location-based (metric tons CO2e)

18,000

(7.16.3) Scope 2, market-based (metric tons CO2e)

17,964

Kazakhstan

(7.16.1) Scope 1 emissions (metric tons CO2e)

83

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Kenya

(7.16.1) Scope 1 emissions (metric tons CO2e)

15

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Latvia

(7.16.1) Scope 1 emissions (metric tons CO2e)

50

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Lithuania

(7.16.1) Scope 1 emissions (metric tons CO2e)

121

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Luxembourg

(7.16.1) Scope 1 emissions (metric tons CO2e)

74

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Malaysia

(7.16.1) Scope 1 emissions (metric tons CO2e)

7

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Mexico

(7.16.1) Scope 1 emissions (metric tons CO2e)

3695

(7.16.2) Scope 2, location-based (metric tons CO2e)

3153

(7.16.3) Scope 2, market-based (metric tons CO2e)

3153

Morocco

(7.16.1) Scope 1 emissions (metric tons CO2e)

799

(7.16.2) Scope 2, location-based (metric tons CO2e)

1418

(7.16.3) Scope 2, market-based (metric tons CO2e)

1418

Netherlands

(7.16.1) Scope 1 emissions (metric tons CO2e)

493

(7.16.2) Scope 2, location-based (metric tons CO2e)

111

(7.16.3) Scope 2, market-based (metric tons CO2e)

160

New Zealand

(7.16.1) Scope 1 emissions (metric tons CO2e)

10

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Nigeria

(7.16.1) Scope 1 emissions (metric tons CO2e)

123

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Norway

(7.16.1) Scope 1 emissions (metric tons CO2e)

47

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Pakistan

(7.16.1) Scope 1 emissions (metric tons CO2e)

1897

(7.16.2) Scope 2, location-based (metric tons CO2e)

6680

(7.16.3) Scope 2, market-based (metric tons CO2e)

6680

Peru

(7.16.1) Scope 1 emissions (metric tons CO2e)

59

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Philippines

(7.16.1) Scope 1 emissions (metric tons CO2e)

902

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Poland

(7.16.1) Scope 1 emissions (metric tons CO2e)

697

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Portugal

(7.16.1) Scope 1 emissions (metric tons CO2e)

733

(7.16.2) Scope 2, location-based (metric tons CO2e)

161

(7.16.3) Scope 2, market-based (metric tons CO2e)

301

Republic of Korea

(7.16.1) Scope 1 emissions (metric tons CO2e)

7

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Romania

(7.16.1) Scope 1 emissions (metric tons CO2e)

284

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Russian Federation

(7.16.1) Scope 1 emissions (metric tons CO2e)

1649

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Saudi Arabia

(7.16.1) Scope 1 emissions (metric tons CO2e)

720

(7.16.2) Scope 2, location-based (metric tons CO2e)

3940

(7.16.3) Scope 2, market-based (metric tons CO2e)

3940

Serbia

(7.16.1) Scope 1 emissions (metric tons CO2e)

62

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Singapore

(7.16.1) Scope 1 emissions (metric tons CO2e)

22,650

(7.16.2) Scope 2, location-based (metric tons CO2e)

14,462

(7.16.3) Scope 2, market-based (metric tons CO2e)

14,462

Slovakia

(7.16.1) Scope 1 emissions (metric tons CO2e)

326

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Slovenia

(7.16.1) Scope 1 emissions (metric tons CO2e)

67

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

South Africa

(7.16.1) Scope 1 emissions (metric tons CO2e)

26

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Spain

(7.16.1) Scope 1 emissions (metric tons CO2e)

4341

(7.16.2) Scope 2, location-based (metric tons CO2e)

1841

(7.16.3) Scope 2, market-based (metric tons CO2e)

328

Sweden

(7.16.1) Scope 1 emissions (metric tons CO2e)

296

(7.16.2) Scope 2, location-based (metric tons CO2e)

811

(7.16.3) Scope 2, market-based (metric tons CO2e)

693

Switzerland

(7.16.1) Scope 1 emissions (metric tons CO2e)

227

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Taiwan, China

(7.16.1) Scope 1 emissions (metric tons CO2e)

781

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Thailand

(7.16.1) Scope 1 emissions (metric tons CO2e)

27

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Tunisia

(7.16.1) Scope 1 emissions (metric tons CO2e)

410

(7.16.2) Scope 2, location-based (metric tons CO2e)

446

(7.16.3) Scope 2, market-based (metric tons CO2e)

446

Turkey

(7.16.1) Scope 1 emissions (metric tons CO2e)

2395

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Ukraine

(7.16.1) Scope 1 emissions (metric tons CO2e)

173

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

United Kingdom of Great Britain and Northern Ireland

(7.16.1) Scope 1 emissions (metric tons CO2e)

892

(7.16.2) Scope 2, location-based (metric tons CO2e)

4441

(7.16.3) Scope 2, market-based (metric tons CO2e)

1118

United States of America

(7.16.1) Scope 1 emissions (metric tons CO2e)

399,241

(7.16.2) Scope 2, location-based (metric tons CO2e)

326,943

(7.16.3) Scope 2, market-based (metric tons CO2e)

342,804

Viet Nam

(7.16.1) Scope 1 emissions (metric tons CO2e)

2

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0
[Fixed row]

(7.17) Indicate which gross global Scope 1 emissions breakdowns you are able to provide.

Select all that apply
☒ By business division

(7.17.1) Break down your total gross global Scope 1 emissions by business division.

	Business division	Scope 1 emissions (metric ton CO2e)
Row 1	Pfizer Global Supply (Manufacturing)	400,040
Row 2	Research and Development	129,751

	Business division	Scope 1 emissions (metric ton CO2e)
Row 4	<i>Fleet</i>	69,114
Row 5	<i>Logistics</i>	5051
Row 6	<i>Other Sites</i>	440
Row 7	<i>Commercial Offices</i>	15,726

[Add row]

(7.20) Indicate which gross global Scope 2 emissions breakdowns you are able to provide.

Select all that apply

☒ By business division

(7.20.1) Break down your total gross global Scope 2 emissions by business division.

	Business division	Scope 2, location-based (metric tons CO2e)	Scope 2, market-based (metric tons CO2e)
Row 1	<i>Pfizer Global Supply (Manufacturing)</i>	406,412	382,809
Row 2	<i>Commercial Offices</i>	19,966	20,401
Row 4	<i>Logistics</i>	9501	9702
Row 6	<i>Other Sites</i>	872	872
Row 7	<i>Research and Development</i>	63,326	72,600

[Add row]

(7.22) Break down your gross Scope 1 and Scope 2 emissions between your consolidated accounting group and other entities included in your response.

Consolidated accounting group

(7.22.1) Scope 1 emissions (metric tons CO2e)

620,125

(7.22.2) Scope 2, location-based emissions (metric tons CO2e)

500,077

(7.22.3) Scope 2, market-based emissions (metric tons CO2e)

486,384

(7.22.4) Please explain

Pfizer does not break down Scope 1 and 2 emissions by separate entities; all are reported under Pfizer Inc.

All other entities

(7.22.1) Scope 1 emissions (metric tons CO2e)

0

(7.22.2) Scope 2, location-based emissions (metric tons CO2e)

0

(7.22.3) Scope 2, market-based emissions (metric tons CO2e)

0

(7.22.4) Please explain

Not Applicable
[Fixed row]

(7.23) Is your organization able to break down your emissions data for any of the subsidiaries included in your CDP response?

Select from:

☒ Not relevant as we do not have any subsidiaries

(7.26) Allocate your emissions to your customers listed below according to the goods or services you have sold them in this reporting period.

Row 1

(7.26.1) Requesting member

Select from:

(7.26.2) Scope of emissions

Select from:

☒ Scope 1

(7.26.4) Allocation level

Select from:

☒ Company wide

(7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

(7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

(7.26.8) Market value or quantity of goods/services supplied to the requesting member

3,180,000,000

(7.26.9) Emissions in metric tonnes of CO₂e

33,712

(7.26.10) Uncertainty (±%)

5

(7.26.11) Major sources of emissions

Fuel used to support manufacturing, R&D and Commercial operations.

(7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated based on fuel consumption data reported by sites within Pfizer's operational control.

(7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report (https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

Row 2

(7.26.1) Requesting member

Select from:

(7.26.2) Scope of emissions

Select from:

☒ Scope 2: market-based

(7.26.4) Allocation level

Select from:

☒ Company wide

(7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

(7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

(7.26.8) Market value or quantity of goods/services supplied to the requesting member

3,180,000,000

(7.26.9) Emissions in metric tonnes of CO2e

26,441

(7.26.10) Uncertainty (±%)

5

(7.26.11) Major sources of emissions

Purchased electricity, steam and heat for manufacturing, R&D and Commercial operations.

(7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated using market-based emission factors and energy consumption data reported by sites within Pfizer's operational control.

(7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report (https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

Row 3

(7.26.1) Requesting member

Select from:

(7.26.2) Scope of emissions

Select from:

☒ Scope 1

(7.26.4) Allocation level

Select from:

☒ Facility

(7.26.5) Allocation level detail

Allocation based on manufacturing operations at Pfizer's Kalamazoo, Michigan facility and McPherson, Kansas facility.

(7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

(7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

(7.26.8) Market value or quantity of goods/services supplied to the requesting member

4728403

(7.26.9) Emissions in metric tonnes of CO₂e

163

(7.26.10) Uncertainty (±%)

5

(7.26.11) Major sources of emissions

Fuel used in manufacturing operations.

(7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated based on fuel consumption data reported by the Kalamazoo, Michigan and McPherson, Kansas facility. Allocation based % of total site revenue attributed to customer.

(7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report (https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

Row 4

(7.26.1) Requesting member

Select from:

(7.26.2) Scope of emissions

Select from:

☒ Scope 2: market-based

(7.26.4) Allocation level

Select from:

☒ Facility

(7.26.5) Allocation level detail

Allocation based on manufacturing operations at Pfizer's Kalamazoo, Michigan facility and McPherson, Kansas facility.

(7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

(7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

(7.26.8) Market value or quantity of goods/services supplied to the requesting member

4,728,403

(7.26.9) Emissions in metric tonnes of CO₂e

279

(7.26.10) Uncertainty (±%)

5

(7.26.11) Major sources of emissions

Purchased electricity for manufacturing operations.

(7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated using market-based emission factors and energy consumption data reported by Kalamazoo, Michigan and McPherson, Kansas facility.
Allocation based % of total site revenue attributed to customer.

(7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report
(https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf) and KPI Table
(<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

Row 5

(7.26.1) Requesting member

Select from:

(7.26.2) Scope of emissions

Select from:

☒ Scope 1

(7.26.4) Allocation level

Select from:

☒ Facility

(7.26.5) Allocation level detail

Allocation based on manufacturing operations at Pfizer's Newbridge, Ireland facility.

(7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

(7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

(7.26.8) Market value or quantity of goods/services supplied to the requesting member

4,625,280

(7.26.9) Emissions in metric tonnes of CO2e

166

(7.26.10) Uncertainty (±%)

5

(7.26.11) Major sources of emissions

Fuel used in manufacturing operations.

(7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated based on fuel consumption data reported by the Newbridge, Ireland facility. Allocation based % of total site revenue attributed to customer.

(7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report (https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

Row 6

(7.26.1) Requesting member

Select from:

(7.26.2) Scope of emissions

Select from:

☒ Scope 2: market-based

(7.26.4) Allocation level

Select from:

☒ Facility

(7.26.5) Allocation level detail

Allocation based on manufacturing operations at Pfizer's Newbridge, Ireland facility.

(7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

(7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

(7.26.8) Market value or quantity of goods/services supplied to the requesting member

4,625,280

(7.26.9) Emissions in metric tonnes of CO₂e

0

(7.26.10) Uncertainty (±%)

5

(7.26.11) Major sources of emissions

Purchased electricity for manufacturing operations.

(7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated using market-based emission factors and energy consumption data reported by Newbridge, Ireland facility. Allocation based % of total site revenue attributed to customer.

(7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report (https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

Row 7

(7.26.1) Requesting member

Select from:

(7.26.2) Scope of emissions

Select from:

☒ Scope 1

(7.26.4) Allocation level

Select from:

☒ Facility

(7.26.5) Allocation level detail

Allocation based on manufacturing operations at Pfizer's Newbridge, Ireland and Freiburg, Germany facility.

(7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

(7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

(7.26.8) Market value or quantity of goods/services supplied to the requesting member

75565523

(7.26.9) Emissions in metric tonnes of CO₂e

2027

(7.26.10) Uncertainty (±%)

5

(7.26.11) Major sources of emissions

Fuel used in manufacturing operations.

(7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated based on fuel consumption data reported by the Freiburg, Germany and Newbridge, Ireland facility. Allocation based % of total site revenue attributed to customer.

(7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report (https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

Row 8

(7.26.1) Requesting member

Select from:

(7.26.2) Scope of emissions

Select from:

☒ Scope 2: market-based

(7.26.4) Allocation level

Select from:

☒ Facility

(7.26.5) Allocation level detail

Allocation based on manufacturing operations at Pfizer's Newbridge, Ireland and Freiburg, Germany facility.

(7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

(7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

(7.26.8) Market value or quantity of goods/services supplied to the requesting member

75,565,523

(7.26.9) Emissions in metric tonnes of CO₂e

20

(7.26.10) Uncertainty (±%)

5

(7.26.11) Major sources of emissions

Purchased electricity for manufacturing operations.

(7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated using market-based emission factors and energy consumption data reported by Freiburg, Germany and Newbridge, Ireland facility.
Allocation based % of total site revenue attributed to customer.

(7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report
(https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf) and KPI Table
(<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

Row 9

(7.26.1) Requesting member

Select from:

(7.26.2) Scope of emissions

Select from:

☒ Scope 1

(7.26.4) Allocation level

Select from:

☒ Facility

(7.26.5) Allocation level detail

Allocation based on manufacturing operations at Pfizer's Kalamazoo, Michigan facility.

(7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

(7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

(7.26.8) Market value or quantity of goods/services supplied to the requesting member

15,158,000

(7.26.9) Emissions in metric tonnes of CO₂e

753

(7.26.10) Uncertainty (±%)

5

(7.26.11) Major sources of emissions

Fuel used in manufacturing operations.

(7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated based on fuel consumption data reported by the Kalamazoo, Michigan facility. Allocation based % of total site revenue attributed to customer.

(7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report (https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

Row 10

(7.26.1) Requesting member

Select from:

(7.26.2) Scope of emissions

Select from:

☒ Scope 2: market-based

(7.26.4) Allocation level

Select from:

☒ Facility

(7.26.5) Allocation level detail

Allocation based on manufacturing operations at Pfizer's Kalamazoo, Michigan facility.

(7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

(7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

(7.26.8) Market value or quantity of goods/services supplied to the requesting member

15,158,000

(7.26.9) Emissions in metric tonnes of CO2e

(7.26.10) Uncertainty (±%)

5

(7.26.11) Major sources of emissions*Purchased electricity for manufacturing operations.***(7.26.12) Allocation verified by a third party?***Select from:*☒ Yes**(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made***GHG emissions calculated using market-based emission factors and energy consumption data reported by Kalamazoo, Michigan facility. Allocation based % of total site revenue attributed to customer.***(7.26.14) Where published information has been used, please provide a reference***Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report (https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).***Row 11****(7.26.1) Requesting member***Select from:***(7.26.2) Scope of emissions***Select from:*

☒ Scope 1

(7.26.4) Allocation level

Select from:

☒ Facility

(7.26.5) Allocation level detail

Allocation based on manufacturing operations at Pfizer's Jakarta, Indonesia and Kalamazoo, Michigan facility.

(7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

(7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

(7.26.8) Market value or quantity of goods/services supplied to the requesting member

5,578,606

(7.26.9) Emissions in metric tonnes of CO₂e

337

(7.26.10) Uncertainty (±%)

5

(7.26.11) Major sources of emissions

Fuel used in manufacturing operations.

(7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated based on fuel consumption data reported by the Jakarta, Indonesia and Kalamazoo, Michigan facility. Allocation based % of total site revenue attributed to customer.

(7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report (https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

Row 12

(7.26.1) Requesting member

Select from:

(7.26.2) Scope of emissions

Select from:

☒ Scope 2: market-based

(7.26.4) Allocation level

Select from:

☒ Facility

(7.26.5) Allocation level detail

Allocation based on manufacturing operations at Pfizer's Jakarta, Indonesia and Kalamazoo, Michigan facility.

(7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

(7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

(7.26.8) Market value or quantity of goods/services supplied to the requesting member

5,578,606

(7.26.9) Emissions in metric tonnes of CO₂e

1967

(7.26.10) Uncertainty (±%)

5

(7.26.11) Major sources of emissions

Purchased electricity for manufacturing operations.

(7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated using market-based emission factors and energy consumption data reported by Jakarta, Indonesia and Kalamazoo, Michigan facility.
Allocation based % of total site revenue attributed to customer.

(7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report
(https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf) and KPI Table
(<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

Row 13

(7.26.1) Requesting member

Select from:

(7.26.2) Scope of emissions

Select from:

☒ Scope 1

(7.26.4) Allocation level

Select from:

☒ Company wide

(7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

(7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

(7.26.8) Market value or quantity of goods/services supplied to the requesting member

206,944

(7.26.9) Emissions in metric tonnes of CO2e

10

(7.26.10) Uncertainty (±%)

5

(7.26.11) Major sources of emissions

Fuel used to support manufacturing, R&D and Commercial operations.

(7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions based on fuel consumption data reported by sites within Pfizer's operational control.

(7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report (https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

Row 14

(7.26.1) Requesting member

Select from:

(7.26.2) Scope of emissions

Select from:

☒ Scope 2: market-based

(7.26.4) Allocation level

Select from:

☒ Company wide

(7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

(7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

(7.26.8) Market value or quantity of goods/services supplied to the requesting member

206,944

(7.26.9) Emissions in metric tonnes of CO₂e

15

(7.26.10) Uncertainty (±%)

5

(7.26.11) Major sources of emissions

Purchased electricity, steam and heat for manufacturing, R&D and Commercial operations.

(7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated using market-based emission factors and energy consumption data reported by sites within Pfizer's operational control.

(7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report (https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

Row 15

(7.26.1) Requesting member

Select from:

(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

We do not have sufficient information (e.g., sales revenue and manufacturing location(s)) to enable allocation of emissions to the Dow Chemical Company.

(7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report (https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

Row 16

(7.26.1) Requesting member

Select from:

(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

We do not have sufficient information (e.g., sales revenue and manufacturing location(s)) to enable allocation of emissions to the United Health Group Inc.

(7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report (https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

Row 17

(7.26.1) Requesting member

Select from:

(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

We do not have sufficient information (e.g., sales revenue and manufacturing location(s)) to enable allocation of emissions to the Ahold Delhaize Co.

(7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report (https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

Row 19

(7.26.1) Requesting member

Select from:

(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

We do not have sufficient information (e.g., sales revenue and manufacturing location(s)) to enable allocation of emissions to the Daiichi Sankyo Co.

(7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report (https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/Pfizer_2023_Impact_Report_11MAR2024.pdf) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).
[Add row]

(7.27) What are the challenges in allocating emissions to different customers, and what would help you to overcome these challenges?

Row 1

(7.27.1) Allocation challenges

Select from:

☒ Other, please specify: Lack of customer-specific information

(7.27.2) Please explain what would help you overcome these challenges

Many of our customers, especially in the United States, purchase Pfizer products through wholesalers. We therefore do not have access to data to enable us to allocate emissions.

(7.28) Do you plan to develop your capabilities to allocate emissions to your customers in the future?

	Do you plan to develop your capabilities to allocate emissions to your customers in the future?	Describe how you plan to develop your capabilities
	<i>Select from:</i> <input checked="" type="checkbox"/> Yes	<i>We are working to develop product-specific environmental footprint data that will enable us to more accurately allocate emissions for some customers.</i>

[Fixed row]

(7.29) What percentage of your total operational spend in the reporting year was on energy?

Select from:

☒ More than 0% but less than or equal to 5%

(7.30) Select which energy-related activities your organization has undertaken.

	Indicate whether your organization undertook this energy-related activity in the reporting year
Consumption of fuel (excluding feedstocks)	<i>Select from:</i> <input checked="" type="checkbox"/> Yes
Consumption of purchased or acquired electricity	<i>Select from:</i> <input checked="" type="checkbox"/> Yes
Consumption of purchased or acquired heat	<i>Select from:</i> <input checked="" type="checkbox"/> Yes
Consumption of purchased or acquired steam	<i>Select from:</i> <input checked="" type="checkbox"/> Yes
Consumption of purchased or acquired cooling	<i>Select from:</i>

	Indicate whether your organization undertook this energy-related activity in the reporting year
	<input checked="" type="checkbox"/> Yes
Generation of electricity, heat, steam, or cooling	Select from: <input checked="" type="checkbox"/> Yes

[Fixed row]

(7.30.1) Report your organization's energy consumption totals (excluding feedstocks) in MWh.

Consumption of fuel (excluding feedstock)

(7.30.1.1) Heating value

Select from:

☒ LHV (lower heating value)

(7.30.1.2) MWh from renewable sources

39,489

(7.30.1.3) MWh from non-renewable sources

2,987,477

(7.30.1.4) Total (renewable and non-renewable) MWh

3,026,965

Consumption of purchased or acquired electricity

(7.30.1.1) Heating value

Select from:

☒ LHV (lower heating value)

(7.30.1.2) MWh from renewable sources

94,054

(7.30.1.3) MWh from non-renewable sources

1,094,368

(7.30.1.4) Total (renewable and non-renewable) MWh

1,188,422

Consumption of purchased or acquired heat

(7.30.1.1) Heating value

Select from:

☒ LHV (lower heating value)

(7.30.1.2) MWh from renewable sources

0

(7.30.1.3) MWh from non-renewable sources

8008

(7.30.1.4) Total (renewable and non-renewable) MWh

8008

Consumption of purchased or acquired steam

(7.30.1.1) Heating value

Select from:

☒ LHV (lower heating value)

(7.30.1.2) MWh from renewable sources

0

(7.30.1.3) MWh from non-renewable sources

126,519

(7.30.1.4) Total (renewable and non-renewable) MWh

126,519

Consumption of purchased or acquired cooling

(7.30.1.1) Heating value

Select from:

☒ LHV (lower heating value)

(7.30.1.2) MWh from renewable sources

0

(7.30.1.3) MWh from non-renewable sources

72,714

(7.30.1.4) Total (renewable and non-renewable) MWh

72,714

Consumption of self-generated non-fuel renewable energy

(7.30.1.1) Heating value

Select from:

☒ LHV (lower heating value)

(7.30.1.2) MWh from renewable sources

15,387

(7.30.1.4) Total (renewable and non-renewable) MWh

15,387

Total energy consumption

(7.30.1.1) Heating value

Select from:

☒ LHV (lower heating value)

(7.30.1.2) MWh from renewable sources

148,930

(7.30.1.3) MWh from non-renewable sources

4,289,086

(7.30.1.4) Total (renewable and non-renewable) MWh

4,438,015

(7.30.6) Select the applications of your organization's consumption of fuel.

	Indicate whether your organization undertakes this fuel application
Consumption of fuel for the generation of electricity	Select from: <input checked="" type="checkbox"/> Yes
Consumption of fuel for the generation of heat	Select from: <input checked="" type="checkbox"/> No
Consumption of fuel for the generation of steam	Select from: <input checked="" type="checkbox"/> Yes
Consumption of fuel for the generation of cooling	Select from: <input checked="" type="checkbox"/> No
Consumption of fuel for co-generation or tri-generation	Select from: <input checked="" type="checkbox"/> Yes

[Fixed row]

(7.30.7) State how much fuel in MWh your organization has consumed (excluding feedstocks) by fuel type.

Sustainable biomass

(7.30.7.1) Heating value

Select from:

☒ LHV

(7.30.7.2) Total fuel MWh consumed by the organization

0

(7.30.7.3) MWh fuel consumed for self-generation of electricity

0

(7.30.7.4) MWh fuel consumed for self-generation of heat

0

(7.30.7.5) MWh fuel consumed for self-generation of steam

0

(7.30.7.6) MWh fuel consumed for self-generation of cooling

0

(7.30.7.7) MWh fuel consumed for self- cogeneration or self-trigeneration

0

(7.30.7.8) Comment

No Certificates for Biomass

Other biomass

(7.30.7.1) Heating value

Select from:

☒ LHV

(7.30.7.2) Total fuel MWh consumed by the organization

38,785

(7.30.7.3) MWh fuel consumed for self-generation of electricity

0

(7.30.7.4) MWh fuel consumed for self-generation of heat

0

(7.30.7.5) MWh fuel consumed for self-generation of steam

38,785

(7.30.7.6) MWh fuel consumed for self-generation of cooling

0

(7.30.7.7) MWh fuel consumed for self- cogeneration or self-trigeneration

0

(7.30.7.8) Comment

N/A

Other renewable fuels (e.g. renewable hydrogen)

(7.30.7.1) Heating value

Select from:

☒ LHV

(7.30.7.2) Total fuel MWh consumed by the organization

704

(7.30.7.3) MWh fuel consumed for self-generation of electricity

0

(7.30.7.4) MWh fuel consumed for self-generation of heat

0

(7.30.7.5) MWh fuel consumed for self-generation of steam

0

(7.30.7.6) MWh fuel consumed for self-generation of cooling

0

(7.30.7.7) MWh fuel consumed for self- cogeneration or self-trigeneration

0

(7.30.7.8) Comment

N/A

Coal

(7.30.7.1) Heating value

Select from:

☒ LHV

(7.30.7.2) Total fuel MWh consumed by the organization

0

(7.30.7.3) MWh fuel consumed for self-generation of electricity

0

(7.30.7.4) MWh fuel consumed for self-generation of heat

0

(7.30.7.5) MWh fuel consumed for self-generation of steam

0

(7.30.7.6) MWh fuel consumed for self-generation of cooling

0

(7.30.7.7) MWh fuel consumed for self- cogeneration or self-trigeneration

0

(7.30.7.8) Comment

N/A

Oil

(7.30.7.1) Heating value

Select from:

☒ LHV

(7.30.7.2) Total fuel MWh consumed by the organization

151441

(7.30.7.3) MWh fuel consumed for self-generation of electricity

11494

(7.30.7.4) MWh fuel consumed for self-generation of heat

0

(7.30.7.5) MWh fuel consumed for self-generation of steam

74864

(7.30.7.6) MWh fuel consumed for self-generation of cooling

0

(7.30.7.7) MWh fuel consumed for self- cogeneration or self-trigeneration

0

(7.30.7.8) Comment

N/A

Gas

(7.30.7.1) Heating value

Select from:

☒ LHV

(7.30.7.2) Total fuel MWh consumed by the organization

2634904

(7.30.7.3) MWh fuel consumed for self-generation of electricity

0

(7.30.7.4) MWh fuel consumed for self-generation of heat

0

(7.30.7.5) MWh fuel consumed for self-generation of steam

1739468

(7.30.7.6) MWh fuel consumed for self-generation of cooling

0

(7.30.7.7) MWh fuel consumed for self- cogeneration or self-trigeneration

895436

(7.30.7.8) Comment

N/A

Other non-renewable fuels (e.g. non-renewable hydrogen)

(7.30.7.1) Heating value

Select from:

☒ LHV

(7.30.7.2) Total fuel MWh consumed by the organization

201132

(7.30.7.3) MWh fuel consumed for self-generation of electricity

0

(7.30.7.4) MWh fuel consumed for self-generation of heat

0

(7.30.7.5) MWh fuel consumed for self-generation of steam

0

(7.30.7.6) MWh fuel consumed for self-generation of cooling

0

(7.30.7.7) MWh fuel consumed for self- cogeneration or self-trigeneration

0

(7.30.7.8) Comment

N/A

Total fuel

(7.30.7.1) Heating value

Select from:

☒ LHV

(7.30.7.2) Total fuel MWh consumed by the organization

3026965

(7.30.7.3) MWh fuel consumed for self-generation of electricity

11494

(7.30.7.4) MWh fuel consumed for self-generation of heat

0

(7.30.7.5) MWh fuel consumed for self-generation of steam

1853117

(7.30.7.6) MWh fuel consumed for self-generation of cooling

(7.30.7.7) MWh fuel consumed for self- cogeneration or self-trigeneration

895436

(7.30.7.8) Comment

N/A

[Fixed row]

(7.30.9) Provide details on the electricity, heat, steam, and cooling your organization has generated and consumed in the reporting year.

Electricity**(7.30.9.1) Total Gross generation (MWh)**

322871

(7.30.9.2) Generation that is consumed by the organization (MWh)

301135

(7.30.9.3) Gross generation from renewable sources (MWh)

25065

(7.30.9.4) Generation from renewable sources that is consumed by the organization (MWh)

15386

Heat**(7.30.9.1) Total Gross generation (MWh)**

0

(7.30.9.2) Generation that is consumed by the organization (MWh)

0

(7.30.9.3) Gross generation from renewable sources (MWh)

0

(7.30.9.4) Generation from renewable sources that is consumed by the organization (MWh)

0

Steam

(7.30.9.1) Total Gross generation (MWh)

0

(7.30.9.2) Generation that is consumed by the organization (MWh)

0

(7.30.9.3) Gross generation from renewable sources (MWh)

0

(7.30.9.4) Generation from renewable sources that is consumed by the organization (MWh)

0

Cooling

(7.30.9.1) Total Gross generation (MWh)

0

(7.30.9.2) Generation that is consumed by the organization (MWh)

0

(7.30.9.3) Gross generation from renewable sources (MWh)

0

(7.30.9.4) Generation from renewable sources that is consumed by the organization (MWh)

0

[Fixed row]

(7.30.16) Provide a breakdown by country/area of your electricity/heat/steam/cooling consumption in the reporting year.

Algeria

(7.30.16.1) Consumption of purchased electricity (MWh)

2982

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

2982.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Argentina

(7.30.16.1) Consumption of purchased electricity (MWh)

8604

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

8604.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Australia

(7.30.16.1) Consumption of purchased electricity (MWh)

12028

(7.30.16.2) Consumption of self-generated electricity (MWh)

328

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

12356.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Austria

(7.30.16.1) Consumption of purchased electricity (MWh)

7338

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

7583

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

14921.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Belarus

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Belgium

(7.30.16.1) Consumption of purchased electricity (MWh)

71003

(7.30.16.2) Consumption of self-generated electricity (MWh)

26408

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

97411.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Brazil

(7.30.16.1) Consumption of purchased electricity (MWh)

16568

(7.30.16.2) Consumption of self-generated electricity (MWh)

161

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

16729.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Bulgaria

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Canada

(7.30.16.1) Consumption of purchased electricity (MWh)

14129

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

14129.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Chile

(7.30.16.1) Consumption of purchased electricity (MWh)

169

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

169.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

China

(7.30.16.1) Consumption of purchased electricity (MWh)

7375

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

5837

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

13212.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Colombia

(7.30.16.1) Consumption of purchased electricity (MWh)

194

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

194.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Costa Rica

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Croatia

(7.30.16.1) Consumption of purchased electricity (MWh)

7098

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

7098.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Czechia

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Denmark

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Ecuador

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Egypt

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Estonia

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Finland

(7.30.16.1) Consumption of purchased electricity (MWh)

1023

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

1200

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

2223.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

France

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Germany

(7.30.16.1) Consumption of purchased electricity (MWh)

30155

(7.30.16.2) Consumption of self-generated electricity (MWh)

301

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

292

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

30748.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Greece

(7.30.16.1) Consumption of purchased electricity (MWh)

488

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

488.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Hungary

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

India

(7.30.16.1) Consumption of purchased electricity (MWh)

46,536

(7.30.16.2) Consumption of self-generated electricity (MWh)

2693

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

3915

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

53,144.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Indonesia

(7.30.16.1) Consumption of purchased electricity (MWh)

4876

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

4876.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Ireland

(7.30.16.1) Consumption of purchased electricity (MWh)

79,955

(7.30.16.2) Consumption of self-generated electricity (MWh)

76,548

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

156,503.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Israel

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Italy

(7.30.16.1) Consumption of purchased electricity (MWh)

27,090

(7.30.16.2) Consumption of self-generated electricity (MWh)

28,932

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

56,022.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Japan

(7.30.16.1) Consumption of purchased electricity (MWh)

30,406

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

17,058

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

47,464.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Kazakhstan

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Kenya

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Latvia

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Lithuania

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Luxembourg

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Malaysia

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Mexico

(7.30.16.1) Consumption of purchased electricity (MWh)

7731

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

7731.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Morocco

(7.30.16.1) Consumption of purchased electricity (MWh)

1969

(7.30.16.2) Consumption of self-generated electricity (MWh)

143

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

2112.00

(7.30.16.7) Provide details of the electricity consumption excluded

0

Netherlands

(7.30.16.1) Consumption of purchased electricity (MWh)

355

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

355.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

New Zealand

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Nigeria

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

0

Norway

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

0

Pakistan

(7.30.16.1) Consumption of purchased electricity (MWh)

18063

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

18063.00

(7.30.16.7) Provide details of the electricity consumption excluded

0

Peru

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

0

Philippines

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

0

Poland

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

0

Portugal

(7.30.16.1) Consumption of purchased electricity (MWh)

1065

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

1065.00

(7.30.16.7) Provide details of the electricity consumption excluded

0

Republic of Korea

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

0

Romania

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

0

Russian Federation

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

0

Saudi Arabi

(7.30.16.1) Consumption of purchased electricity (MWh)

6433

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

6433.00

(7.30.16.7) Provide details of the electricity consumption excluded

0

Serbia

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

0

Singapore

(7.30.16.1) Consumption of purchased electricity (MWh)

37732

(7.30.16.2) Consumption of self-generated electricity (MWh)

21104

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

58,836.00

(7.30.16.7) Provide details of the electricity consumption excluded

0

Slovakia

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Slovenia

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

South Africa

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Spain

(7.30.16.1) Consumption of purchased electricity (MWh)

12226

(7.30.16.2) Consumption of self-generated electricity (MWh)

540

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

12,766.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Sweden

(7.30.16.1) Consumption of purchased electricity (MWh)

10,372

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

18,961

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

29,333.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Switzerland

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Taiwan, China

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Thailand

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Tunisia

(7.30.16.1) Consumption of purchased electricity (MWh)

1057

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

1057.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Turkey

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Ukraine

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

United Kingdom of Great Britain and Northern Ireland

(7.30.16.1) Consumption of purchased electricity (MWh)

18,508

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

13,418

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

31,926.00

(7.30.16.7) Provide details of the electricity consumption excluded

N/A

United States of America

(7.30.16.1) Consumption of purchased electricity (MWh)

704,894

(7.30.16.2) Consumption of self-generated electricity (MWh)

143,977

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

138,977

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

987,848.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

Viet Nam

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

Not applicable

[Fixed row]

(7.30.17) Provide details of your organization's renewable electricity purchases in the reporting year by country/area.

Row 1

(7.30.17.1) Country/area of consumption of purchased renewable electricity

Select from:

☒ Austria

(7.30.17.2) Sourcing method

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

(7.30.17.3) Renewable electricity technology type

Select from:

☒ Hydropower (capacity unknown)

(7.30.17.4) Renewable electricity consumed via selected sourcing method in the reporting year (MWh)

7338

(7.30.17.5) Tracking instrument used

Select from:

☒ Contract

(7.30.17.6) Country/area of origin (generation) of purchased renewable electricity

Select from:

☒ Austria

(7.30.17.7) Are you able to report the commissioning or re-powering year of the energy generation facility?

Select from:

☒ No

(7.30.17.10) Supply arrangement start year

2022

(7.30.17.11) Ecolabel associated with purchased renewable electricity

Select from:

☒ Other, please specify :No brand, label or certification

(7.30.17.12) Comment

Year of commissioning and vintage unknown. Renewable energy supplied through contract with local utility provider. Origin assumed to be Austria.

Row 2

(7.30.17.1) Country/area of consumption of purchased renewable electricity

Select from:

☒ Croatia

(7.30.17.2) Sourcing method

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

(7.30.17.3) Renewable electricity technology type

Select from:

☒ Renewable electricity mix, please specify :Not detailed in contract

(7.30.17.4) Renewable electricity consumed via selected sourcing method in the reporting year (MWh)

7098

(7.30.17.5) Tracking instrument used

Select from:

☒ Contract

(7.30.17.6) Country/area of origin (generation) of purchased renewable electricity

Select from:

☒ Croatia

(7.30.17.7) Are you able to report the commissioning or re-powering year of the energy generation facility?

Select from:

☒ No

(7.30.17.10) Supply arrangement start year

2022

(7.30.17.11) Ecolabel associated with purchased renewable electricity

Select from:

☒ Other, please specify :No brand, label, or certification

(7.30.17.12) Comment

Year of commissioning and vintage unknown. Renewable energy supplied through contract with local utility provider. Origin assumed to be Croatia

Row 3

(7.30.17.1) Country/area of consumption of purchased renewable electricity

Select from:

☒ Ireland

(7.30.17.2) Sourcing method

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

(7.30.17.3) Renewable electricity technology type

Select from:

☒ Renewable electricity mix, please specify :Not detailed in contract

(7.30.17.4) Renewable electricity consumed via selected sourcing method in the reporting year (MWh)

79,739

(7.30.17.5) Tracking instrument used

Select from:

☒ Contract

(7.30.17.6) Country/area of origin (generation) of purchased renewable electricity

Select from:

☒ Ireland

(7.30.17.7) Are you able to report the commissioning or re-powering year of the energy generation facility?

Select from:

☒ No

(7.30.17.10) Supply arrangement start year

2021

(7.30.17.11) Ecolabel associated with purchased renewable electricity

Select from:

☒ Other, please specify :No brand, label or certification

(7.30.17.12) Comment

Year of commissioning and vintage unknown. Renewable energy supplied through contract with local utility provider. Origin assumed to be Ireland

Row 4

(7.30.17.1) Country/area of consumption of purchased renewable electricity

Select from:

☒ Spain

(7.30.17.2) Sourcing method

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

(7.30.17.3) Renewable electricity technology type

Select from:

☒ Solar

(7.30.17.4) Renewable electricity consumed via selected sourcing method in the reporting year (MWh)

11,113

(7.30.17.5) Tracking instrument used

Select from:

☒ Contract

(7.30.17.6) Country/area of origin (generation) of purchased renewable electricity

Select from:

☒ Spain

(7.30.17.7) Are you able to report the commissioning or re-powering year of the energy generation facility?

Select from:

☒ No

(7.30.17.10) Supply arrangement start year

2021

(7.30.17.11) Ecolabel associated with purchased renewable electricity

Select from:

☒ Other, please specify :No brand, label or certification

(7.30.17.12) Comment

Year of commissioning and vintage unknown. Renewable energy supplied through contract with local utility provider. Origin is assumed to be Spain.

Row 5

(7.30.17.1) Country/area of consumption of purchased renewable electricity

Select from:

☒ Sweden

(7.30.17.2) Sourcing method

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

(7.30.17.3) Renewable electricity technology type

Select from:

☒ Renewable electricity mix, please specify :Not detailed in contract

(7.30.17.4) Renewable electricity consumed via selected sourcing method in the reporting year (MWh)

10,372

(7.30.17.5) Tracking instrument used

Select from:

☒ Contract

(7.30.17.6) Country/area of origin (generation) of purchased renewable electricity

Select from:

☒ Sweden

(7.30.17.7) Are you able to report the commissioning or re-powering year of the energy generation facility?

Select from:

☒ No

(7.30.17.10) Supply arrangement start year

2021

(7.30.17.11) Ecolabel associated with purchased renewable electricity

Select from:

☒ Other, please specify :No brand, label, or certification

(7.30.17.12) Comment

Year of commissioning and vintage unknown. Renewable energy supplied through contract with local utility provider. Origin assumed to be Sweden.

Row 6

(7.30.17.1) Country/area of consumption of purchased renewable electricity

Select from:

☒ Brazil

(7.30.17.2) Sourcing method

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

(7.30.17.3) Renewable electricity technology type

Select from:

☒ Hydropower (capacity unknown)

(7.30.17.4) Renewable electricity consumed via selected sourcing method in the reporting year (MWh)

15,845

(7.30.17.5) Tracking instrument used

Select from:

☒ Contract

(7.30.17.6) Country/area of origin (generation) of purchased renewable electricity

Select from:

☒ Brazil

(7.30.17.7) Are you able to report the commissioning or re-powering year of the energy generation facility?

Select from:

☒ No

(7.30.17.9) Vintage of the renewable energy/attribute (i.e. year of generation)

Select from:

☒ 2023

(7.30.17.10) Supply arrangement start year

2023

(7.30.17.11) Ecolabel associated with purchased renewable electricity

Select from:

☒ Other, please specify :IREC

(7.30.17.12) Comment

Year of commissioning unknown. Renewable energy supplied through contract with local utility provider. Origin assumed to be Brazil.

Row 7

(7.30.17.1) Country/area of consumption of purchased renewable electricity

Select from:

☒ United Kingdom of Great Britain and Northern Ireland

(7.30.17.2) Sourcing method

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

(7.30.17.3) Renewable electricity technology type

Select from:

☒ Renewable electricity mix, please specify :Not detailed in contract

(7.30.17.4) Renewable electricity consumed via selected sourcing method in the reporting year (MWh)

2634

(7.30.17.5) Tracking instrument used

Select from:

☒ Contract

(7.30.17.6) Country/area of origin (generation) of purchased renewable electricity

Select from:

☒ United Kingdom of Great Britain and Northern Ireland

(7.30.17.7) Are you able to report the commissioning or re-powering year of the energy generation facility?

Select from:

☒ No

(7.30.17.10) Supply arrangement start year

2021

(7.30.17.11) Ecolabel associated with purchased renewable electricity

Select from:

☒ Other, please specify :No brand, label or certification

(7.30.17.12) Comment

Year of commissioning and vintage unknown. Renewable energy supplied through contract with local utility provider. Origin assumed to be the UK.

[Add row]

(7.30.18) Provide details of your organization's low-carbon heat, steam, and cooling purchases in the reporting year by country/area.

Row 1

(7.30.18.1) Sourcing method

Select from:

☒ Heat/steam/cooling supply agreement

(7.30.18.2) Country/area of consumption of low-carbon heat, steam or cooling

Select from:

☒ Sweden

(7.30.18.3) Energy carrier

Select from:

☒ Heat

(7.30.18.4) Low-carbon technology type

Select from:

☒ Other biomass

(7.30.18.5) Low-carbon heat, steam, or cooling consumed (MWh)

6516

(7.30.18.6) Comment

Supplier of district heat and steam has provided documentation that biomass is certified to a Swedish law that aligns with the Renewable Energy Directive and FQD

Row 2

(7.30.18.1) Sourcing method

Select from:

☒ Heat/steam/cooling supply agreement

(7.30.18.2) Country/area of consumption of low-carbon heat, steam or cooling

Select from:

☒ Sweden

(7.30.18.3) Energy carrier

Select from:

☒ Steam

(7.30.18.4) Low-carbon technology type

Select from:

☒ Other biomass

(7.30.18.5) Low-carbon heat, steam, or cooling consumed (MWh)

12445

(7.30.18.6) Comment

Supplier of district heat and steam has provided documentation that biomass is certified to a Swedish law that aligns with the Renewable Energy Directive and FQD
[Add row]

(7.30.19) Provide details of your organization's renewable electricity generation by country/area in the reporting year.

Row 1

(7.30.19.1) Country/area of generation

Select from:

☒ Morocco

(7.30.19.2) Renewable electricity technology type

Select from:

☒ Solar

(7.30.19.3) Facility capacity (MW)

0.21

(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

143

(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

143

(7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

(7.30.19.8) Comment

No Certificates

Row 2

(7.30.19.1) Country/area of generation

Select from:

☒ Australia

(7.30.19.2) Renewable electricity technology type

Select from:

☒ Solar

(7.30.19.3) Facility capacity (MW)

0.48

(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

328

(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

328

(7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

(7.30.19.8) Comment

No Certificates

Row 3

(7.30.19.1) Country/area of generation

Select from:

☒ India

(7.30.19.2) Renewable electricity technology type

Select from:

☒ Solar

(7.30.19.3) Facility capacity (MW)

0.24

(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

1437

(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

1187

(7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

(7.30.19.8) Comment

No Certificates

Row 4

(7.30.19.1) Country/area of generation

Select from:

☒ Singapore

(7.30.19.2) Renewable electricity technology type

Select from:

☒ Solar

(7.30.19.3) Facility capacity (MW)

1

(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

924

(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

924

(7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

(7.30.19.8) Comment

No Certificates

Row 5

(7.30.19.1) Country/area of generation

Select from:

☒ Belgium

(7.30.19.2) Renewable electricity technology type

Select from:

☒ Solar

(7.30.19.3) Facility capacity (MW)

0.47

(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

426

(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

426

(7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

(7.30.19.8) Comment

No Certificates

Row 6

(7.30.19.1) Country/area of generation

Select from:

☒ Belgium

(7.30.19.2) Renewable electricity technology type

Select from:

☒ Wind

(7.30.19.3) Facility capacity (MW)

4.6

(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

9036

(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

9036

(7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

(7.30.19.8) Comment

No Certificates

Row 7

(7.30.19.1) Country/area of generation

Select from:

☒ Germany

(7.30.19.2) Renewable electricity technology type

Select from:

☒ Solar

(7.30.19.3) Facility capacity (MW)

0.1

(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

157

(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

(7.30.19.6) Energy attribute certificates issued for this generation*Select from:*☒ No**(7.30.19.8) Comment***No Certificates***Row 8****(7.30.19.1) Country/area of generation***Select from:*☒ Germany**(7.30.19.2) Renewable electricity technology type***Select from:*☒ Geothermal**(7.30.19.3) Facility capacity (MW)***0.11***(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)***164***(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)***164*

(7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

(7.30.19.8) Comment

No Certificates

Row 9

(7.30.19.1) Country/area of generation

Select from:

☒ Ireland

(7.30.19.2) Renewable electricity technology type

Select from:

☒ Solar

(7.30.19.3) Facility capacity (MW)

0.19

(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

130

(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

130

(7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

(7.30.19.8) Comment

No Certificates

Row 10

(7.30.19.1) Country/area of generation

Select from:

☒ Italy

(7.30.19.2) Renewable electricity technology type

Select from:

☒ Solar

(7.30.19.3) Facility capacity (MW)

1.6

(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

1898

(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

1898

(7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

(7.30.19.8) Comment

No Certificates

Row 11

(7.30.19.1) Country/area of generation

Select from:

☒ Spain

(7.30.19.2) Renewable electricity technology type

Select from:

☒ Solar

(7.30.19.3) Facility capacity (MW)

1.4

(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

540

(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

540

(7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

(7.30.19.8) Comment

No Certificates

Row 12

(7.30.19.1) Country/area of generation

Select from:

☒ Brazil

(7.30.19.2) Renewable electricity technology type

Select from:

☒ Solar

(7.30.19.3) Facility capacity (MW)

1.21

(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

161

(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

161

(7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

(7.30.19.8) Comment

No Certificates

Row 13

(7.30.19.1) Country/area of generation

Select from:
☒ United States of America

(7.30.19.2) Renewable electricity technology type

Select from:
☒ Solar

(7.30.19.3) Facility capacity (MW)

0.24

(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

9721

(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

312

(7.30.19.6) Energy attribute certificates issued for this generation

Select from:
☒ No

(7.30.19.8) Comment

No Certificates
[Add row]

(7.30.20) Describe how your organization's renewable electricity sourcing strategy directly or indirectly contributes to bringing new capacity into the grid in the countries/areas in which you operate.

Pfizer invests in no- / low-carbon technologies at our sites and through power purchase agreements (PPAs) that enable sourcing of renewable energy. In 2023, we signed virtual PPAs (VPPAs) for four new solar projects in Spain that will collectively cover all of Pfizer's purchased electricity in the European Union. These EU VPPAs, along with the North America VPPA we signed in 2021, are key steps in our plan to achieve our RE100 goal of 100% renewable energy by 2030 and the voluntary Net Zero Standard by 2040. When the North America and EU VPPA solar projects come online, they are expected to cover approximately 68% of Pfizer's global electricity needs as measured against 2023 electricity consumption.

(7.30.21) In the reporting year, has your organization faced barriers or challenges to sourcing renewable electricity?

	Challenges to sourcing renewable electricity	Challenges faced by your organization which were not country/area-specific
	Select from: <input checked="" type="checkbox"/> Yes, both in specific countries/areas and in general	There is a limited supply of renewable electricity across all markets.

[Fixed row]

(7.30.22) Provide details of the country/area-specific challenges to sourcing renewable electricity faced by your organization in the reporting year.

Row 1

(7.30.22.1) Country/area

Select from:

☒ India

(7.30.22.2) Reason why it was challenging to source renewable electricity within selected country/area

Select all that apply

☒ Limited supply of renewable electricity in the market

(7.30.22.3) Provide additional details of the barriers faced within this country/area

The availability of national-level VPPAs is limited and unlikely to meet demand.

[Add row]

(7.45) Describe your gross global combined Scope 1 and 2 emissions for the reporting year in metric tons CO2e per unit currency total revenue and provide any additional intensity metrics that are appropriate to your business operations.

Row 1

(7.45.1) Intensity figure

0.000019

(7.45.2) Metric numerator (Gross global combined Scope 1 and 2 emissions, metric tons CO2e)

1,106,508

(7.45.3) Metric denominator

Select from:

☒ unit total revenue

(7.45.4) Metric denominator: Unit total

58,496,000,000

(7.45.5) Scope 2 figure used

Select from:

☒ Market-based

(7.45.6) % change from previous year

68

(7.45.7) Direction of change

Select from:

☒ Increased

(7.45.8) Reasons for change

Select all that apply

☒ Change in output

(7.45.9) Please explain

Company Revenue decreased in 2023 as compared to 2022

[Add row]

(7.53) Did you have an emissions target that was active in the reporting year?

Select all that apply

☒ Absolute target

(7.53.1) Provide details of your absolute emissions targets and progress made against those targets.

Row 1

(7.53.1.1) Target reference number

Select from:

☒ Abs 3

(7.53.1.2) Is this a science-based target?

Select from:

- ☒ Yes, and this target has been approved by the Science Based Targets initiative

(7.53.1.3) Science Based Targets initiative official validation letter

PFIZ-USA-002-OFF_ApprovalLetter_V4.1.pdf

(7.53.1.4) Target ambition

Select from:

- ☒ 1.5°C aligned

(7.53.1.5) Date target was set

11/23/2020

(7.53.1.6) Target coverage

Select from:

- ☒ Organization-wide

(7.53.1.7) Greenhouse gases covered by target

Select all that apply

- | | |
|---|---|
| <input checked="" type="checkbox"/> Methane (CH ₄) | <input checked="" type="checkbox"/> Sulphur hexafluoride (SF ₆) |
| <input checked="" type="checkbox"/> Nitrous oxide (N ₂ O) | <input checked="" type="checkbox"/> Nitrogen trifluoride (NF ₃) |
| <input checked="" type="checkbox"/> Carbon dioxide (CO ₂) | |
| <input checked="" type="checkbox"/> Perfluorocarbons (PFCs) | |
| <input checked="" type="checkbox"/> Hydrofluorocarbons (HFCs) | |

(7.53.1.8) Scopes

Select all that apply

- ☒ Scope 1

☒ Scope 2

(7.53.1.9) Scope 2 accounting method

Select from:

☒ Market-based

(7.53.1.11) End date of base year

12/31/2019

(7.53.1.12) Base year Scope 1 emissions covered by target (metric tons CO2e)

700,185

(7.53.1.13) Base year Scope 2 emissions covered by target (metric tons CO2e)

570,557

(7.53.1.31) Base year total Scope 3 emissions covered by target (metric tons CO2e)

0.000

(7.53.1.32) Total base year emissions covered by target in all selected Scopes (metric tons CO2e)

1,270,742.000

(7.53.1.33) Base year Scope 1 emissions covered by target as % of total base year emissions in Scope 1

100

(7.53.1.34) Base year Scope 2 emissions covered by target as % of total base year emissions in Scope 2

100

(7.53.1.53) Base year emissions covered by target in all selected Scopes as % of total base year emissions in all selected Scopes

100

(7.53.1.54) End date of target

12/31/2030

(7.53.1.55) Targeted reduction from base year (%)

46

(7.53.1.56) Total emissions at end date of target covered by target in all selected Scopes (metric tons CO2e)

686,200.680

(7.53.1.57) Scope 1 emissions in reporting year covered by target (metric tons CO2e)

620,125

(7.53.1.58) Scope 2 emissions in reporting year covered by target (metric tons CO2e)

486,384

(7.53.1.77) Total emissions in reporting year covered by target in all selected scopes (metric tons CO2e)

1,106,509.000

(7.53.1.78) Land-related emissions covered by target

Select from:

☒ No, it does not cover any land-related emissions (e.g. non-FLAG SBT)

(7.53.1.79) % of target achieved relative to base year

(7.53.1.80) Target status in reporting year

Select from:

☒ Underway**(7.53.1.82) Explain target coverage and identify any exclusions**

Pfizer's near-term Scope 1&2 GHG emissions reduction goal is company-wide, covering all owned sites and leased sites where Pfizer has operational control, and includes biogenic emissions and removals from bioenergy feedstocks. Pfizer's biogenic emissions are limited to the burning of wood pellets and chips at two of our manufacturing facilities and comprise approximately 1% of our Scope 1&2 footprint.

(7.53.1.83) Target objective

Pfizer recognizes global climate change as one of the defining issues of our time, requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. Mitigation of the risks posed by a changing climate is an ESG priority for Pfizer and is connected to our corporate purpose and strategy.

(7.53.1.84) Plan for achieving target, and progress made to the end of the reporting year

Pfizer is making progress toward our near-term goal although emission reductions will vary from year to year as we work to implement emission reduction projects and transition to renewable electricity sources. Our manufacturing and R&D sites have long-term environmental sustainability master plans to reduce impact, including actions ranging in scale and complexity. We seek opportunities to design new facility or renovation projects with reduced environmental impact (such as energy consumption, water usage and waste management) so we can deliver greener buildings, invest in no/low carbon technologies at our sites and in contractual agreements that enable sourcing of clean energy from renewable sources, and undertake process enhancements within our product manufacturing to reduce the number of steps and resources required. In 2023, we signed virtual PPAs (VPPAs) for four new solar projects in Spain that will collectively cover all of Pfizer's purchased electricity in the European Union. These EU VPPAs, along with the North America VPPA we signed in 2021, are key steps in our plan to achieve our RE100 goal of 100% renewable energy by 2030 and the voluntary Net Zero Standard by 2040. When the North America and EU VPPA solar projects come online, they are expected to cover approximately 68% of Pfizer's global electricity needs as measured against 2023 electricity consumption. As of the end of 2023, Pfizer has reduced scope 1 and 2 GHG emissions by 13% from our 2019 baseline.

(7.53.1.85) Target derived using a sectoral decarbonization approach

Select from:

☒ No

Row 2

(7.53.1.1) Target reference number

Select from:

☒ Abs 4

(7.53.1.2) Is this a science-based target?

Select from:

☒ Yes, and this target has been approved by the Science Based Targets initiative

(7.53.1.3) Science Based Targets initiative official validation letter

PFIZ-USA-002-OFF_ApprovalLetter_V4.1.pdf

(7.53.1.4) Target ambition

Select from:

☒ 1.5°C aligned

(7.53.1.5) Date target was set

11/23/2020

(7.53.1.6) Target coverage

Select from:

☒ Organization-wide

(7.53.1.7) Greenhouse gases covered by target

Select all that apply

☒ Methane (CH₄)

☒ Nitrous oxide (N₂O)

☒ Sulphur hexafluoride (SF₆)

☒ Nitrogen trifluoride (NF₃)

- ☒ Carbon dioxide (CO2)
- ☒ Perfluorocarbons (PFCs)
- ☒ Hydrofluorocarbons (HFCs)

(7.53.1.8) Scopes

Select all that apply

- ☒ Scope 3

(7.53.1.10) Scope 3 categories

Select all that apply

- ☒ Scope 3, Category 4 – Upstream transportation and distribution

(7.53.1.11) End date of base year

12/31/2019

(7.53.1.17) Base year Scope 3, Category 4: Upstream transportation and distribution emissions covered by target (metric tons CO2e)

248,613

(7.53.1.31) Base year total Scope 3 emissions covered by target (metric tons CO2e)

248,613.000

(7.53.1.32) Total base year emissions covered by target in all selected Scopes (metric tons CO2e)

248,613.000

(7.53.1.38) Base year Scope 3, Category 4: Upstream transportation and distribution covered by target as % of total base year emissions in Scope 3, Category 4: Upstream transportation and distribution (metric tons CO2e)

100

(7.53.1.52) Base year total Scope 3 emissions covered by target as % of total base year emissions in Scope 3 (in all Scope 3 categories)

6.8

(7.53.1.53) Base year emissions covered by target in all selected Scopes as % of total base year emissions in all selected Scopes

6.8

(7.53.1.54) End date of target

12/31/2025

(7.53.1.55) Targeted reduction from base year (%)

10

(7.53.1.56) Total emissions at end date of target covered by target in all selected Scopes (metric tons CO2e)

223,751.700

(7.53.1.62) Scope 3, Category 4: Upstream transportation and distribution emissions in reporting year covered by target (metric tons CO2e)

305,229

(7.53.1.76) Total Scope 3 emissions in reporting year covered by target (metric tons CO2e)

305,229.000

(7.53.1.77) Total emissions in reporting year covered by target in all selected scopes (metric tons CO2e)

305,229.000

(7.53.1.78) Land-related emissions covered by target

Select from:

☒ No, it does not cover any land-related emissions (e.g. non-FLAG SBT)

(7.53.1.79) % of target achieved relative to base year

-227.73

(7.53.1.80) Target status in reporting year

Select from:

☒ Underway

(7.53.1.82) Explain target coverage and identify any exclusions

Upstream transportation and distribution emissions represent approximately 7% of Pfizer's current Scope 3 footprint and are our second largest source of Scope 3 emissions. Target coverage includes Pfizer-paid transportation and distribution of Pfizer products.

(7.53.1.83) Target objective

Pfizer recognizes global climate change as one of the defining issues of our time, requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. Mitigation of the risks posed by a changing climate is an ESG priority for Pfizer and is connected to our corporate purpose and strategy.

(7.53.1.84) Plan for achieving target, and progress made to the end of the reporting year

Pfizer is continuing to make progress in reducing emissions associated with upstream transportation and distribution after experiencing increases in 2021 and 2022 associated with the global distribution of the COVID-19 vaccine and treatment (Paxlovid). We worked internally to educate over 1,500 logistics colleagues on environmental sustainability principles and to improve data and analytics across all markets where Pfizer operates. We continued to transition shipments from air to ocean where possible and engaged with our third-party logistics providers to identify and invest in opportunities to use low emission fuels and vehicles to deliver our medicines to markets around the world. We began working with one of our transporters to pilot the use of electric trucks to decarbonize shipments in a major urban area within the US and are working to decarbonize all full truckload shipments within Europe. As of the end of 2023, Pfizer's emissions in this category were 31% lower than in 2022 and 22% higher than the 2019 baseline.

(7.53.1.85) Target derived using a sectoral decarbonization approach

Select from:

☒ No

Row 3

(7.53.1.1) Target reference number

Select from:

☒ Abs 5

(7.53.1.2) Is this a science-based target?

Select from:

☒ Yes, and this target has been approved by the Science Based Targets initiative

(7.53.1.3) Science Based Targets initiative official validation letter

PFIZ-USA-002-OFF_ApprovalLetter_V4.1.pdf

(7.53.1.4) Target ambition

Select from:

☒ Well-below 2°C aligned

(7.53.1.5) Date target was set

11/23/2020

(7.53.1.6) Target coverage

Select from:

☒ Organization-wide

(7.53.1.7) Greenhouse gases covered by target

Select all that apply

- | | |
|---|---|
| <input checked="" type="checkbox"/> Methane (CH ₄) | <input checked="" type="checkbox"/> Sulphur hexafluoride (SF ₆) |
| <input checked="" type="checkbox"/> Nitrous oxide (N ₂ O) | <input checked="" type="checkbox"/> Nitrogen trifluoride (NF ₃) |
| <input checked="" type="checkbox"/> Carbon dioxide (CO ₂) | |
| <input checked="" type="checkbox"/> Perfluorocarbons (PFCs) | |
| <input checked="" type="checkbox"/> Hydrofluorocarbons (HFCs) | |

(7.53.1.8) Scopes

Select all that apply

- ☒ Scope 3

(7.53.1.10) Scope 3 categories

Select all that apply

- ☒ Scope 3, Category 6 – Business travel

(7.53.1.11) End date of base year

12/31/2019

(7.53.1.19) Base year Scope 3, Category 6: Business travel emissions covered by target (metric tons CO₂e)

384,314

(7.53.1.31) Base year total Scope 3 emissions covered by target (metric tons CO₂e)

384,314.000

(7.53.1.32) Total base year emissions covered by target in all selected Scopes (metric tons CO₂e)

384,314.000

(7.53.1.40) Base year Scope 3, Category 6: Business travel emissions covered by target as % of total base year emissions in Scope 3, Category 6: Business travel (metric tons CO2e)

100.0

(7.53.1.52) Base year total Scope 3 emissions covered by target as % of total base year emissions in Scope 3 (in all Scope 3 categories)

10.5

(7.53.1.53) Base year emissions covered by target in all selected Scopes as % of total base year emissions in all selected Scopes

10.5

(7.53.1.54) End date of target

12/31/2025

(7.53.1.55) Targeted reduction from base year (%)

25

(7.53.1.56) Total emissions at end date of target covered by target in all selected Scopes (metric tons CO2e)

288,235.500

(7.53.1.64) Scope 3, Category 6: Business travel emissions in reporting year covered by target (metric tons CO2e)

172,510

(7.53.1.76) Total Scope 3 emissions in reporting year covered by target (metric tons CO2e)

172,510.000

(7.53.1.77) Total emissions in reporting year covered by target in all selected scopes (metric tons CO2e)

172,510.000

(7.53.1.78) Land-related emissions covered by target

Select from:

☒ No, it does not cover any land-related emissions (e.g. non-FLAG SBT)

(7.53.1.79) % of target achieved relative to base year

220.45

(7.53.1.80) Target status in reporting year

Select from:

☒ Underway

(7.53.1.82) Explain target coverage and identify any exclusions

Business travel has historically represented approximately 6% of Pfizer's Scope 3 footprint. The target covers emissions from air travel, hotel stays, automobile use (rental as well as business use of personal vehicles), and rail transportation associated with Pfizer business.

(7.53.1.83) Target objective

Pfizer recognizes global climate change as one of the defining issues of our time, requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. Mitigation of the risks posed by a changing climate is an ESG priority for Pfizer and is connected to our corporate purpose and strategy.

(7.53.1.84) Plan for achieving target, and progress made to the end of the reporting year

Business travel increased in 2023 with the removal of pandemic restrictions, but travel-related emissions in 2023 remained 55% lower than the 2019 baseline. We expect travel-related emissions to continue to increase through the remainder of the target period. Pfizer has implemented digital tools to reduce the need for travel and, if travel is necessary, help Pfizer colleagues choose lower-emission options.

(7.53.1.85) Target derived using a sectoral decarbonization approach

Select from:

☒ No

[Add row]

(7.54) Did you have any other climate-related targets that were active in the reporting year?

Select all that apply

☒ Targets to increase or maintain low-carbon energy consumption or production

☒ Net-zero targets

☒ Other climate-related targets

(7.54.1) Provide details of your targets to increase or maintain low-carbon energy consumption or production.

Row 1

(7.54.1.1) Target reference number

Select from:

☒ Low 1

(7.54.1.2) Date target was set

11/23/2020

(7.54.1.3) Target coverage

Select from:

☒ Organization-wide

(7.54.1.4) Target type: energy carrier

Select from:

☒ Electricity

(7.54.1.5) Target type: activity

Select from:

☒ Consumption

(7.54.1.6) Target type: energy source

Select from:

☒ Renewable energy source(s) only

(7.54.1.7) End date of base year

12/31/2019

(7.54.1.8) Consumption or production of selected energy carrier in base year (MWh)

1,445,719

(7.54.1.9) % share of low-carbon or renewable energy in base year

9.6

(7.54.1.10) End date of target

12/31/2030

(7.54.1.11) % share of low-carbon or renewable energy at end date of target

100

(7.54.1.12) % share of low-carbon or renewable energy in reporting year

10

(7.54.1.13) % of target achieved relative to base year

0.44

(7.54.1.14) Target status in reporting year

Select from:

☒ Underway

(7.54.1.16) Is this target part of an emissions target?

Yes, Pfizer's commitment to 100% renewable electricity is a component of our Scope 1&2 emissions reduction target (Abs 3).

(7.54.1.17) Is this target part of an overarching initiative?

Select all that apply

☒ RE100

☒ Science Based Targets initiative

(7.54.1.18) Science Based Targets initiative official validation letter

PFIZ-USA-002-OFF_ApprovalLetter_V4.1.pdf

(7.54.1.19) Explain target coverage and identify any exclusions

This target is company-wide with no exclusions.

(7.54.1.20) Target objective

The sourcing of renewable electricity is a key component of Pfizer's decarbonization strategy.

(7.54.1.21) Plan for achieving target, and progress made to the end of the reporting year

Pfizer signed virtual PPAs (VPPAs) in 2023 for four new solar projects in Spain that will collectively cover all of Pfizer's purchased electricity in the European Union. These EU VPPAs, along with the North America VPPA we signed in 2021, are key steps in our plan to achieve our RE100 goal of 100% renewable energy by 2030

and the voluntary Net Zero Standard by 2040. When the North America and EU VPPA solar projects come online, they are expected to cover approximately 68% of Pfizer's global electricity needs as measured against 2023 electricity consumption. Pfizer sourced 10% renewable electricity in 2023.
[Add row]

(7.54.2) Provide details of any other climate-related targets, including methane reduction targets.

Row 1

(7.54.2.1) Target reference number

Select from:

☒ Oth 1

(7.54.2.2) Date target was set

11/23/2020

(7.54.2.3) Target coverage

Select from:

☒ Organization-wide

(7.54.2.4) Target type: absolute or intensity

Select from:

☒ Intensity

(7.54.2.5) Target type: category & Metric (target numerator if reporting an intensity target)

Engagement with suppliers

☒ Percentage of suppliers (by procurement spend) with a science-based target

(7.54.2.6) Target denominator (intensity targets only)

Select from:

☒ Other, please specify: Total procurement spend

(7.54.2.7) End date of base year

12/31/2019

(7.54.2.8) Figure or percentage in base year

0

(7.54.2.9) End date of target

12/31/2025

(7.54.2.10) Figure or percentage at end of date of target

64

(7.54.2.11) Figure or percentage in reporting year

51

(7.54.2.12) % of target achieved relative to base year

79.6875000000

(7.54.2.13) Target status in reporting year

Select from:

☒ Underway

(7.54.2.15) Is this target part of an emissions target?

No

(7.54.2.16) Is this target part of an overarching initiative?

Select all that apply

☒ Science Based Targets initiative – approved supplier engagement target

(7.54.2.17) Science Based Targets initiative official validation letter

PFIZ-USA-002-OFF_ApprovalLetter_V4.1.pdf

(7.54.2.18) Please explain target coverage and identify any exclusions

Pfizer currently estimates GHG emissions associated with purchased goods and services based on spend and aligned with the GHG Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard. Estimated emissions for this category currently represent 78% of Pfizer's Scope 3 footprint. Pfizer is committed to accelerating change across our supply chain and aims to drive 64% of our suppliers of goods and services by spend to set their own science-based emission reduction goals by 2025. Base year Scope 3 emissions were calculated using spend-based emission factors.

(7.54.2.19) Target objective

Procurement of goods and services, which are essential to producing medicines and vaccines, is the most significant contributor to our scope 3 emissions. We therefore expect all our suppliers to commit to ambitious, science based GHG reduction targets and have integrated environmental criteria in our supplier sourcing, contracting, and performance management processes.

(7.54.2.20) Plan for achieving target, and progress made to the end of the reporting year

In 2023 we conducted a virtual supplier summit to communicate our expectations and provide resources to assist suppliers in progressing climate action. The event was attended by over 1,200 participants from more than 650 companies and was well-received, with high levels of engagement and positive feedback. To support suppliers in their decarbonization journey, we encouraged renewable power purchase agreement education through the Energize program and offered sponsorships for the Activate program, a global pharmaceutical collective action initiative that targets sustainability / GHG emission improvements at active pharmaceutical ingredient (API) suppliers including Contract Manufacturing Organizations. As of the end of 2023, over 230 suppliers have registered for Energize as a result of Pfizer's invitations and we have sponsored more than 70 participants in Activate. As of the end of 2023, 51% of our suppliers by spend have committed to science-based emission reduction targets.

[Add row]

(7.54.3) Provide details of your net-zero target(s).

Row 1

(7.54.3.1) Target reference number

Select from:

☒ NZ1

(7.54.3.2) Date target was set

06/30/2022

(7.54.3.3) Target Coverage

Select from:

☒ Organization-wide

(7.54.3.4) Targets linked to this net zero target

Select all that apply

☒ Abs3

☒ Abs4

☒ Abs5

☒ Low1

(7.54.3.5) End date of target for achieving net zero

12/31/2040

(7.54.3.6) Is this a science-based target?

Select from:

☒ Yes, we consider this a science-based target, and we have committed to seek validation of this target by the Science Based Targets initiative in the next two years

(7.54.3.8) Scopes

Select all that apply

- ☒ Scope 1
- ☒ Scope 2
- ☒ Scope 3

(7.54.3.9) Greenhouse gases covered by target

Select all that apply

- | | |
|---|--|
| <input checked="" type="checkbox"/> Methane (CH4) | <input checked="" type="checkbox"/> Sulphur hexafluoride (SF6) |
| <input checked="" type="checkbox"/> Nitrous oxide (N2O) | <input checked="" type="checkbox"/> Nitrogen trifluoride (NF3) |
| <input checked="" type="checkbox"/> Carbon dioxide (CO2) | |
| <input checked="" type="checkbox"/> Perfluorocarbons (PFCs) | |
| <input checked="" type="checkbox"/> Hydrofluorocarbons (HFCs) | |

(7.54.3.10) Explain target coverage and identify any exclusions

Pfizer's Net Zero target covers at least 95% of total scope 1 and 2 emissions and at least 90% of total scope 3 emissions.

(7.54.3.11) Target objective

Pfizer recognizes global climate change as one of the defining issues of our time, requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. Mitigation of the risks posed by a changing climate is an ESG priority for Pfizer and is connected to our corporate purpose and strategy.

(7.54.3.12) Do you intend to neutralize any residual emissions with permanent carbon removals at the end of the target?

Select from:

- ☒ Yes

(7.54.3.13) Do you plan to mitigate emissions beyond your value chain?

Select from:

- ☒ No, and we do not plan to within the next two years

(7.54.3.14) Do you intend to purchase and cancel carbon credits for neutralization and/or beyond value chain mitigation?

Select all that apply

☒ No, we do not plan to purchase and cancel carbon credits for neutralization and/or beyond value chain mitigation

(7.54.3.15) Planned milestones and/or near-term investments for neutralization at the end of the target

While Pfizer's focus is driving absolute GHG reductions, we anticipate that a carbon removal strategy may be necessary to address hard-to-abate emissions as we progress towards the target end dates.

(7.54.3.17) Target status in reporting year

Select from:

☒ Underway

(7.54.3.19) Process for reviewing target

Environmental sustainability has been integrated into the overarching Pfizer strategy and GHG emissions reduction is monitored as a key performance indicator (KPI). Performance against targets is monitored throughout the year by the PGS Executive Leadership Team.

[Add row]

(7.55) Did you have emissions reduction initiatives that were active within the reporting year? Note that this can include those in the planning and/or implementation phases.

Select from:

☒ Yes

(7.55.1) Identify the total number of initiatives at each stage of development, and for those in the implementation stages, the estimated CO2e savings.

	Number of initiatives	Total estimated annual CO2e savings in metric tonnes CO2e (only for rows marked *)
Under investigation	0	`Numeric input
To be implemented	0	0
Implementation commenced	5	58
Implemented	239	30,483
Not to be implemented	69	`Numeric input

[Fixed row]

(7.55.2) Provide details on the initiatives implemented in the reporting year in the table below.

Row 1

(7.55.2.1) Initiative category & Initiative type

Energy efficiency in buildings

☒ Other, please specify: Energy Efficiency in buildings

(7.55.2.2) Estimated annual CO2e savings (metric tonnes CO2e)

30,483

(7.55.2.3) Scope(s) or Scope 3 category(ies) where emissions savings occur

Select all that apply

- ☒ Scope 1
- ☒ Scope 2 (location-based)
- ☒ Scope 2 (market-based)

(7.55.2.4) Voluntary/Mandatory

Select from:

☒ Voluntary

(7.55.2.5) Annual monetary savings (unit currency – as specified in C0.4)

10,240,837

(7.55.2.6) Investment required (unit currency – as specified in C0.4)

28,311,358

(7.55.2.7) Payback period

Select from:

☒ 1-3 years

(7.55.2.8) Estimated lifetime of the initiative

Select from:

☒ 6-10 years

(7.55.2.9) Comment

Multiple Initiatives across Pfizer

[Add row]

(7.55.3) What methods do you use to drive investment in emissions reduction activities?

Row 1

(7.55.3.1) Method

Select from:

☒ Internal incentives/recognition programs

(7.55.3.2) Comment

Pfizer's internal "Safety and Sustainability STAR Awards" program recognizes projects advanced by colleagues across Pfizer related to driving sustainability improvements including demand and GHG reductions, green biotech and chemistry. These awards encourage sites to implement sustainability initiatives. In 2023, two emissions reduction projects were recognized with STAR awards.

Row 2

(7.55.3.1) Method

Select from:

☒ Lower return on investment (ROI) specification

(7.55.3.2) Comment

Projects with environmental benefits may be approved for funding despite not meeting internally established financial hurdle rates.

Row 3

(7.55.3.1) Method

Select from:

☒ Compliance with regulatory requirements/standards

(7.55.3.2) Comment

Pfizer prioritizes funding for projects that reduce energy demand and GHG emissions associated with regulatory compliance requirements.
[Add row]

(7.73) Are you providing product level data for your organization's goods or services?

Select from:

☒ No, I am not providing data

(7.74) Do you classify any of your existing goods and/or services as low-carbon products?

Select from:

☒ Yes

(7.74.1) Provide details of your products and/or services that you classify as low-carbon products.

Row 1

(7.74.1.1) Level of aggregation

Select from:

☒ Product or service

(7.74.1.2) Taxonomy used to classify product(s) or service(s) as low-carbon

Select from:

☒ Other, please specify: Life Cycle Assessment (LCA) using in-house collaborative tools

(7.74.1.3) Type of product(s) or service(s)

Chemicals and plastics

☒ Other, please specify: Elimination of materials used in manufacturing of product

(7.74.1.4) Description of product(s) or service(s)

The product, Enviero progesterone, is now synthesized using a plant sterols pathway which uses fewer natural resources (than the original synthesis pathway) during its manufacture, reducing waste, GHG emissions, and use of hazardous solvents. The product can be used as a final active pharmaceutical ingredient or as an intermediate for more advanced steroidal products based on the customers intentions.

(7.74.1.5) Have you estimated the avoided emissions of this low-carbon product(s) or service(s)

Select from:

☒ Yes

(7.74.1.6) Methodology used to calculate avoided emissions

Select from:

☒ Other, please specify: Performed in-house using a collaborative LCA tool created by the American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable (ACS GCIPR). The tool is underpinned with Life Cycle Inventory (LCI) from the Ecoinvent database.

(7.74.1.7) Life cycle stage(s) covered for the low-carbon product(s) or services(s)

Select from:

☒ Cradle-to-gate

(7.74.1.8) Functional unit used

kg of progesterone product sold in its primary form (i.e., not with excipients or in solution, etc.)

(7.74.1.9) Reference product/service or baseline scenario used

The original and historical longer chemical synthesis route used to manufacture progesterone

(7.74.1.10) Life cycle stage(s) covered for the reference product/service or baseline scenario

Select from:

☒ Cradle-to-gate

(7.74.1.11) Estimated avoided emissions (metric tons CO₂e per functional unit) compared to reference product/service or baseline scenario

0.18

(7.74.1.12) Explain your calculation of avoided emissions, including any assumptions

The emissions (in kg CO₂e) are determined from the manufacturing process via a cradle to gate LCA using Ecoinvent Life Cycle Inventory (LCI) databases. Based on LCA calculations, the historical chemical synthesis manufacturing process generated approximately 256 kg CO₂e per kg of progesterone produced. The new process, based on plant sterols, generated approximately 72 kg CO₂e per kg of progesterone produced, a reduction of approximately 184 kg CO₂e per kg of progesterone. This equates to a 72% reduction. Key assumptions: 1) Where compound-specific LCIs were not available, analogous proxies have been used (or built) within the same tools. 2) The lifecycle tool used (ACS GCIPR PMI-LCA tool) does not include energy for processing. This will lead to a conservative estimate of benefit as the new process is largely at room temperature conditions whereas the original route used several heating and cooling steps. Likewise, the new route is half the number of internal processing steps as the original route. Previous studies show that the GHG emissions associated with energy consumption in chemical synthesis commonly represent 15 to 25% of the carbon footprint when compared to bill of materials.

(7.74.1.13) Revenue generated from low-carbon product(s) or service(s) as % of total revenue in the reporting year

0.01

[Add row]

(7.79) Has your organization canceled any project-based carbon credits within the reporting year?

Select from:

☒ No

C9. Environmental performance - Water security

(9.1) Are there any exclusions from your disclosure of water-related data?

Select from:

☒ Yes

(9.1.1) Provide details on these exclusions.

Row 1

(9.1.1.1) Exclusion

Select from:

☒ Facilities

(9.1.1.2) Description of exclusion

Withdrawals and discharges of water from logistics centers and office buildings not associated with manufacturing or research activities.

(9.1.1.3) Reason for exclusion

Select from:

☒ Water used for internal WASH services

(9.1.1.7) Percentage of water volume the exclusion represents

Select from:

☒ Less than 1%

(9.1.1.8) Please explain

Logistics centers and commercial office buildings comprise

Row 2

(9.1.1.1) Exclusion

Select from:

☒ Other, please specify: Remediation Operations

(9.1.1.2) Description of exclusion

Withdrawal of groundwater as part of remediation operations.

(9.1.1.3) Reason for exclusion

Select from:

☒ Other, please specify: Groundwater is pumped and treated as part of remediation activities. Most of this water is returned to the environment; losses are negligible.

(9.1.1.7) Percentage of water volume the exclusion represents

Select from:

☒ Less than 1%

(9.1.1.8) Please explain

Groundwater is pumped and treated as part of remediation activities. Most of this water is returned to the environment; losses are negligible.

[Add row]

(9.2) Across all your operations, what proportion of the following water aspects are regularly measured and monitored?

Water withdrawals – total volumes

(9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

(9.2.2) Frequency of measurement

Select from:

☒ Monthly

(9.2.3) Method of measurement

Water withdrawal volumes are measured and monitored at the site level through a combination of municipal and internal flow meters and are reported centrally via our global environmental reporting system.

(9.2.4) Please explain

Pfizer collects and reports water withdrawal for all manufacturing and research and development (R&D) locations where we maintain operational control. Manufacturing and R&D sites report monthly withdrawal data (with a few exceptions where water data is only available quarterly). Total water withdrawal is reported annually in our Impact Report.

Water withdrawals – volumes by source

(9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

(9.2.2) Frequency of measurement

Select from:

☒ Monthly

(9.2.3) Method of measurement

Water withdrawal volumes are measured and monitored at the site level and are reported centrally by source. Volume data is obtained in a variety of ways depending on site specific factors: purchased water through utility providers' invoices; ground water and fresh water through municipal and internal flow meters; and rainwater through actual measurement with local mechanical flow meters.

(9.2.4) Please explain

Pfizer collects and reports water withdrawal by source for all manufacturing and R&D locations where we maintain operational control. Manufacturing and R&D sites report monthly withdrawal data by source (with a few exceptions where water data is only available quarterly).

Water withdrawals quality

(9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

(9.2.2) Frequency of measurement

Select from:

☒ Monthly

(9.2.3) Method of measurement

Water withdrawal quality is monitored through sampling and is tested onsite and by external labs analysis and includes pH, biological oxygen demand (BOD), and chemical oxygen demand (COD) among other parameters.

(9.2.4) Please explain

Water quality is monitored at the site level as required by regulation (local potable water standards) and as necessary to help ensure conformance with quality standards for manufacturing by all manufacturing and R&D locations where Pfizer maintains operational control. Water is purified as necessary to support manufacturing and R&D operations.

Water discharges – total volumes

(9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

(9.2.2) Frequency of measurement

Select from:

☒ Monthly

(9.2.3) Method of measurement

Total volume data is obtained through utility invoices and/or internal flow meters. In some cases, discharges may be estimated using operations and engineering data. Estimation methodologies are documented and reviewed periodically. See Pfizer's website for our calculation methodology.

https://cdn.pfizer.com/pfizercom/Waste_and_Water_Methodology_MAR2024.pdf

(9.2.4) Please explain

Water discharge volumes are monitored by all manufacturing and R&D locations where we maintain operational control and are reported centrally by discharge destination via our global environmental reporting system. Manufacturing and R&D locations report monthly discharge volumes. Total water discharge is reported annually in our Impact report.

Water discharges – volumes by destination

(9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

(9.2.2) Frequency of measurement

Select from:

☒ Monthly

(9.2.3) Method of measurement

Volume data for water discharged to municipal treatment plants is obtained through utility invoices and/or internal flow meters. Discharges to fresh and salt water are monitored through internal flow meters. In some cases, discharges may be estimated using operations and engineering data. Estimation methodologies are documented and reviewed periodically. See Pfizer's website for our calculation methodology.

https://cdn.pfizer.com/pfizercom/Waste_and_Water_Methodology_MAR2024.pdf

(9.2.4) Please explain

Water discharge volumes are monitored by all manufacturing and research and development (R&D) sites under Pfizer's operational control and are reported centrally by discharge destination via our global environmental reporting system. Manufacturing and R&D locations report monthly discharge volumes.

Water discharges – volumes by treatment method

(9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

(9.2.2) Frequency of measurement

Select from:

☒ Monthly

(9.2.3) Method of measurement

All manufacturing and R&D sites where we maintain operational control monitor their treatment processes and track discharge volumes through invoices and/or internal flow meters. In some cases, discharges may be estimated using operations and engineering data. Estimation methodologies are documented and reviewed periodically. Discharges are managed in accordance with the jurisdictional requirements applicable to the location. Pfizer's calculation methodology is available on our website.

(9.2.4) Please explain

Pfizer collects information on wastewater treatment technologies and quantities of wastewater discharged at our manufacturing and research and development (R&D) sites via our global environmental reporting system.

Water discharge quality – by standard effluent parameters

(9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

(9.2.2) Frequency of measurement

Select from:

☒ Monthly

(9.2.3) Method of measurement

Water is monitored through sampling and is tested onsite and by external labs as required by site permits and applicable regulations. Monitoring data is maintained by the site and is not collected at the corporate level, but conformance with applicable requirements is reviewed periodically through our EHS audit program.

(9.2.4) Please explain

Pfizer requires all manufacturing and R&D sites where we maintain operational control to monitor wastewater discharge quality and meet all applicable permit and regulatory requirements. Sites are required to notify corporate as well as the relevant regulatory authority (as appropriate) of any monitoring results that exceed applicable permit and/or regulatory limits. Water discharge quality is monitored as frequently as required by local regulations.

Water discharge quality – emissions to water (nitrates, phosphates, pesticides, and/or other priority substances)

(9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

(9.2.2) Frequency of measurement

Select from:

☒ Other, please specify: as required by local regulations.

(9.2.3) Method of measurement

Water discharge quality is monitored through sampling and is tested onsite and by external certified labs as required by site permits and applicable regulations. Monitoring data is maintained by the site and is not collected at the corporate level, but conformance with applicable requirements is reviewed periodically through Pfizer's EHS audit program.

(9.2.4) Please explain

Pfizer requires all manufacturing and R&D sites where we maintain operational control to monitor wastewater discharge quality and meet all applicable permit and regulatory requirements. Sites are required to notify corporate as well as the relevant regulatory authority (as appropriate) of any monitoring results that exceed applicable permit and/or regulatory limits.

Water discharge quality – temperature

(9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

(9.2.2) Frequency of measurement

Select from:

☒ Other, please specify: as required by local regulations.

(9.2.3) Method of measurement

Water discharge quality, including temperature, is monitored through sampling as required by site permits and applicable regulations. This data is maintained by the site and is not collected at the corporate level, but conformance with applicable requirements is reviewed periodically through Pfizer's EHS audit program.

(9.2.4) Please explain

Pfizer requires all manufacturing and R&D sites where we maintain operational control to monitor wastewater discharge quality, including temperature, and meet all applicable permit and regulatory requirements. Sites are required to notify corporate as well as the relevant regulatory authority (as appropriate) of any monitoring results that exceed applicable permit and/or regulatory limits. Water temperature is monitored as frequently as required by local regulations.

Water consumption – total volume

(9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

(9.2.2) Frequency of measurement

Select from:

☒ Yearly

(9.2.3) Method of measurement

Aggregated monthly or quarterly data is used to calculate water consumption annually.

(9.2.4) Please explain

Water withdrawal and discharge volumes are monitored by all manufacturing and R&D sites under Pfizer's operational control and are reported monthly.

Water recycled/reused

(9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

(9.2.2) Frequency of measurement

Select from:

☒ Monthly

(9.2.3) Method of measurement

Volume data is obtained through flowmeters and/or estimated based on operations and engineering knowledge and data. Manufacturing and R&D sites report monthly recycled water volumes via our global environmental reporting system.

(9.2.4) Please explain

All manufacturing and R&D sites under Pfizer's operational control where recycled water is used monitor volumes and report centrally.

The provision of fully-functioning, safely managed WASH services to all workers

(9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

(9.2.2) Frequency of measurement

Select from:

☒ Continuously

(9.2.3) Method of measurement

Pfizer's Global Environment, Health and Safety (EHS) Standards require all facilities to provide safe, fully functioning WASH services for all employees. Compliance to our standard is monitored through our internal audit program. In addition, compliance with WASH standards is also reviewed through the sites' periodic EHS self-assessment program. Finally, colleagues can report any issues through the Compliance Helpline.

(9.2.4) Please explain

Pfizer's Global Environment, Health and Safety Standards require all facilities to provide safe, fully functioning WASH services for all employees.
[Fixed row]

(9.2.2) What are the total volumes of water withdrawn, discharged, and consumed across all your operations, how do they compare to the previous reporting year, and how are they forecasted to change?

Total withdrawals

(9.2.2.1) Volume (megaliters/year)

31729

(9.2.2.2) Comparison with previous reporting year

Select from:

☒ Much higher

(9.2.2.3) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

(9.2.2.4) Five-year forecast

Select from:

☒ Higher

(9.2.2.5) Primary reason for forecast

Select from:

☒ Increase/decrease in business activity

(9.2.2.6) Please explain

In 2023 Pfizer's total water withdrawal increased 11% compared to 2022. Pfizer defines "much higher" as an increase of more than 10% when compared to the previous year. The increase in 2023 was primarily due to an increase in non-contact cooling water use at our Kalamazoo, Michigan manufacturing plant related to changes in product mix and production increases. Pfizer collects and reports water withdrawal for all manufacturing and research and development (R&D) locations where we maintain operational control. Water withdrawal volumes are measured and monitored at the site level through a combination of municipal and internal flow meters and are reported centrally via our global environmental reporting system. Total annual water withdrawal is calculated by summing monthly/quarterly data for the year for all sites within Pfizer's operational control. Water withdrawal is expected to increase over the next five years due to planned expansions and increased production at our biologics manufacturing sites.

Total discharges

(9.2.2.1) Volume (megaliters/year)

28,849

(9.2.2.2) Comparison with previous reporting year

Select from:

☒ Much higher

(9.2.2.3) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

(9.2.2.4) Five-year forecast

Select from:

☒ Higher

(9.2.2.5) Primary reason for forecast

Select from:

☒ Increase/decrease in business activity

(9.2.2.6) Please explain

Pfizer's wastewater discharge increased by 13% compared to 2022 primarily due to an increase in non-contact cooling water use at our Kalamazoo, Michigan manufacturing plant related to changes in product mix and production increases. Pfizer defines "much higher" as an increase of more than 10% when compared to the previous year. Water discharge volumes are monitored by all manufacturing and R&D locations where we maintain operational control and are reported centrally by discharge destination via our global environmental reporting system. Total volume data is obtained through utility invoices and/or internal flow meters. In some cases, discharges may be estimated using operations and engineering data. Estimation methodologies are documented and reviewed on an ongoing basis. Total annual water discharge is calculated by summing monthly/quarterly data for the year for all sites within Pfizer's operational control. Water discharge is expected to increase over the next five years due to planned expansions and increased production at our biologics manufacturing sites.

Total consumption

(9.2.2.1) Volume (megaliters/year)

2880

(9.2.2.2) Comparison with previous reporting year

Select from:

☒ About the same

(9.2.2.3) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

(9.2.2.4) Five-year forecast

Select from:

☒ Higher

(9.2.2.5) Primary reason for forecast

Select from:

☒ Increase/decrease in business activity

(9.2.2.6) Please explain

Pfizer's total water consumption in 2023 was about the same as in 2022. Pfizer defines "about the same" as an increase or decrease of 0% to 2% compared to the previous year. Water consumption is calculated at the corporate level by subtracting total water discharged from total water withdrawn. The consumption corresponds to water incorporated in products, as well as water lost through evaporation in cooling towers. Total consumption is expected to increase over the next five years due to planned expansions and increased production at our biologics manufacturing sites.

[Fixed row]

(9.2.4) Indicate whether water is withdrawn from areas with water stress, provide the volume, how it compares with the previous reporting year, and how it is forecasted to change.

(9.2.4.1) Withdrawals are from areas with water stress

Select from:

☒ Yes

(9.2.4.2) Volume withdrawn from areas with water stress (megaliters)

1185

(9.2.4.3) Comparison with previous reporting year

Select from:

☒ Higher

(9.2.4.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in efficiency

(9.2.4.5) Five-year forecast

Select from:

☒ Lower

(9.2.4.6) Primary reason for forecast

Select from:

☒ Increase/decrease in efficiency

(9.2.4.7) % of total withdrawals that are withdrawn from areas with water stress

3.73

(9.2.4.8) Identification tool

Select all that apply

☒ WRI Aqueduct

(9.2.4.9) Please explain

Pfizer's methodology used to identify sites located in water-stressed areas is described in the Pfizer Water Stewardship position statement published in Jan 2022 and is based on the UN CEO Water Mandate definition of water stress which considers other physical aspects related to water resources in addition to water scarcity, including water quality, environmental flows, and the accessibility of water. Our methodology uses the WRI Aqueduct tool, considering all indicators outlined in the tool in our assessment, including those related to water quality, environmental flows, and water accessibility. Based on Pfizer's assessment methodology, 14% of our

manufacturing and research and development sites are located in “High” or “Extremely High” water-stressed areas. These sites are required to develop water stewardship plans. The percentage of water withdrawn from water-stressed areas in 2023 was 3%. Pfizer defines “higher” as an increase of 2% to 10% when compared to the previous year. Water withdrawal from areas with water stress is expected to decrease in the next five years due to increases in efficiency and implementation of water stewardship projects.

[Fixed row]

(9.2.7) Provide total water withdrawal data by source.

Fresh surface water, including rainwater, water from wetlands, rivers, and lakes

(9.2.7.1) Relevance

Select from:

☒ Relevant

(9.2.7.2) Volume (megaliters/year)

774

(9.2.7.3) Comparison with previous reporting year

Select from:

☒ Much lower

(9.2.7.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

(9.2.7.5) Please explain

Pfizer’s use of fresh surface water is primarily for non-contact cooling and includes water sourced from lakes and a small amount from rain. Pfizer’s use of fresh surface water decreased 15% compared to 2022 due to weather variations and decrease in production at our Strangnas, Sweden site (our primary user of surface water) in 2023. Going forward we anticipate fresh surface water withdrawal to continue to decrease due to changes in business activity. Pfizer defines “much lower” as a decrease greater than 10% when compared to the previous year.

Brackish surface water/Seawater

(9.2.7.1) Relevance

Select from:

☒ Not relevant

(9.2.7.5) Please explain

Pfizer has not used brackish surface water in our operations since 2016. We do not anticipate using brackish surface water or seawater in our operations in the coming years.

Groundwater – renewable

(9.2.7.1) Relevance

Select from:

☒ Relevant

(9.2.7.2) Volume (megaliters/year)

23386

(9.2.7.3) Comparison with previous reporting year

Select from:

☒ Much higher

(9.2.7.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

(9.2.7.5) Please explain

Pfizer's Kalamazoo, Michigan site is the company's largest user of groundwater. Groundwater is used for manufacturing operations, non-contact cooling, and potable and sanitary purposes. Pfizer's groundwater withdrawal increased 18% compared to 2022, primarily due to the increase in non-contact cooling water use at the Kalamazoo plant related to changes in product mix and production increases. Going forward, we anticipate water consumption to increase, largely due to increased production, but we will continue to work to offset these increases through improvements in water management and the implementation of conservation projects. Pfizer defines "much higher" as an increase more than 10% when compared to the previous year.

Groundwater – non-renewable

(9.2.7.1) Relevance

Select from:

☒ Not relevant

(9.2.7.5) Please explain

Pfizer's groundwater use is limited to renewable water from shallow wells. Pfizer's operating sites do not withdraw water from non-renewable groundwater sources, and we do not anticipate doing so in the future.

Produced/Entrained water

(9.2.7.1) Relevance

Select from:

☒ Not relevant

(9.2.7.5) Please explain

Pfizer does not use produced water in operations. Given our need for high quality and very pure water, it is expensive and energy intensive to source produced water. Going forward, we do not anticipate using produced water in our operations.

Third party sources

(9.2.7.1) Relevance

Select from:

☒ Relevant

(9.2.7.2) Volume (megaliters/year)

7569

(9.2.7.3) Comparison with previous reporting year

Select from:

☒ About the same

(9.2.7.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

(9.2.7.5) Please explain

Pfizer's use of municipal water did not change compared to 2022. Going forward, we anticipate water consumption to increase, largely due to expansions and increased production at our biologics manufacturing sites, but we will continue to work to offset these increases through improvements in water management and the implementation of conservation projects. Pfizer defines "about the same" as an increase or decrease between 0% and 2% when compared to the previous year.

[Fixed row]

(9.2.8) Provide total water discharge data by destination.

Fresh surface water

(9.2.8.1) Relevance

Select from:

☒ Relevant

(9.2.8.2) Volume (megaliters/year)

20401

(9.2.8.3) Comparison with previous reporting year

Select from:

☒ Much higher

(9.2.8.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

(9.2.8.5) Please explain

Pfizer's discharge to surface water increased 17% compared to 2022 due to an increase in non-contact cooling water use at our Kalamazoo, Michigan manufacturing plant related to changes in product mix and production increases. Going forward, we anticipate some near-term increases in water discharge due to increased production, but we will continue to work to offset these increases through improvements in water management and the implementation of conservation projects. Pfizer defines "much higher" as an increase of more than 10% compared to the previous year.

Brackish surface water/seawater

(9.2.8.1) Relevance

Select from:

☒ Relevant

(9.2.8.2) Volume (megaliters/year)

958

(9.2.8.3) Comparison with previous reporting year

Select from:

☒ Higher

(9.2.8.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

(9.2.8.5) Please explain

Pfizer's discharge to saltwater increased 3% compared to 2022. The increase was primarily attributed to higher rainfall and a construction project that necessitated groundwater pumping from the excavation area at our Ringaskiddy, Ireland plant. Going forward, we anticipate some near-term increases in water discharge due to increased production, but we will continue to work to offset these increases through improvements in water management and the implementation of conservation projects. Pfizer defines "higher" as an increase of 2 to 10% when compared to the previous year.

Groundwater

(9.2.8.1) Relevance

Select from:

☒ Not relevant

(9.2.8.5) Please explain

Pfizer does not discharge to groundwater.

Third-party destinations

(9.2.8.1) Relevance

Select from:

☒ Relevant

(9.2.8.2) Volume (megaliters/year)

7489

(9.2.8.3) Comparison with previous reporting year

Select from:

☒ Higher

(9.2.8.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

(9.2.8.5) Please explain

Pfizer's discharge to third party (municipal) wastewater treatment facilities increased by 3% compared to 2022. The increase was primarily attributed to changes in product mix and increased production at our Kalamazoo, Michigan manufacturing plant. We do not discharge any wastewater to other organizations for further use. Going forward, we anticipate some near-term increases in water discharge due to increased production, but we will continue to work to offset these increases through improvements in water management and the implementation of conservation projects. Pfizer defines "higher" as an increase of 2% to 10% compared to the previous year.

[Fixed row]

(9.2.9) Within your direct operations, indicate the highest level(s) to which you treat your discharge.

Tertiary treatment

(9.2.9.1) Relevance of treatment level to discharge

Select from:

☒ Relevant

(9.2.9.2) Volume (megaliters/year)

1140

(9.2.9.3) Comparison of treated volume with previous reporting year

Select from:

☒ Higher

(9.2.9.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

(9.2.9.5) % of your sites/facilities/operations this volume applies to

Select from:

☒ 11-20

(9.2.9.6) Please explain

Seven Pfizer sites provide onsite tertiary treatment of wastewater prior to discharge. The volume of wastewater to which tertiary treatment was applied in 2023 was 2% higher than in 2022 mainly due variation in production in Tuas, Singapore. This volume represents approximately 4% of our total wastewater discharge. Pfizer defines "higher" as an increase of 2% to 10% compared to the previous year. Percentage of operations based on discharge volume.

Secondary treatment

(9.2.9.1) Relevance of treatment level to discharge

Select from:

☒ Relevant

(9.2.9.2) Volume (megaliters/year)

764

(9.2.9.3) Comparison of treated volume with previous reporting year

Select from:

☒ Lower

(9.2.9.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

(9.2.9.5) % of your sites/facilities/operations this volume applies to

Select from:

☒ 11-20

(9.2.9.6) Please explain

Eight Pfizer sites provide onsite secondary treatment of wastewater prior to discharge. The volume of wastewater processed through secondary treatment at Pfizer facilities in 2023 decreased by 5% compared to 2022 due to changes in production in our site in Sanford, North Carolina. This volume represents 3% of our total wastewater discharge. Pfizer defines "lower" as a decrease of 2% to 10% when compared to the previous year. Percentage of operations based on discharge volume.

Primary treatment only

(9.2.9.1) Relevance of treatment level to discharge

Select from:

☒ Relevant

(9.2.9.2) Volume (megaliters/year)

63

(9.2.9.3) Comparison of treated volume with previous reporting year

Select from:

☒ About the same

(9.2.9.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

(9.2.9.5) % of your sites/facilities/operations this volume applies to

Select from:

☒ 1-10

(9.2.9.6) Please explain

Two Pfizer sites, less than 1% in terms of water discharge volume, provide onsite primary treatment of wastewater prior to discharge to municipal/third party wastewater treatment plants. The volume of wastewater processed through primary treatment prior to offsite discharge remained unchanged in 2023 compared to 2022.

Discharge to the natural environment without treatment

(9.2.9.1) Relevance of treatment level to discharge

Select from:

☒ Relevant

(9.2.9.2) Volume (megaliters/year)

20145

(9.2.9.3) Comparison of treated volume with previous reporting year

Select from:

☒ Much higher

(9.2.9.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

(9.2.9.5) % of your sites/facilities/operations this volume applies to

Select from:

☒ 61-70

(9.2.9.6) Please explain

Pfizer's discharges to the natural environment include non-contact cooling water and utility wastewater (e.g., cooling tower blowdown and boiler blowdown). This water is monitored to help ensure compliance with the sites' discharge permits (e.g., temperature, turbidity, etc.). The volume of water discharged from Pfizer sites to the natural environment increased by 18% compared to 2022, primarily due to increase in non-contact cooling water at the Kalamazoo, Michigan site related to changes in product mix and production increases. Pfizer defines "much higher" as an increase of more than 10% when compared to the previous year. Percentage of operations based on discharge volume.

Discharge to a third party without treatment

(9.2.9.1) Relevance of treatment level to discharge

Select from:

☒ Relevant

(9.2.9.2) Volume (megaliters/year)

6738

(9.2.9.3) Comparison of treated volume with previous reporting year

Select from:

☒ Higher

(9.2.9.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

(9.2.9.5) % of your sites/facilities/operations this volume applies to

Select from:

☒ 21-30

(9.2.9.6) Please explain

Pfizer's discharges to third parties such as municipal wastewater treatment plants without pre-treatment increased by 4% primarily due to changes in product mix at our Kalamazoo, Michigan manufacturing plant. Pfizer does not discharge any wastewater to other organizations for further use. Pfizer defines "higher" as an increase of 2% to 10% compared to the previous year. Percentage of operations based on discharge volume.

Other

(9.2.9.1) Relevance of treatment level to discharge

Select from:

☒ Not relevant

(9.2.9.6) Please explain

Pfizer does not treat wastewater using any other techniques.

[Fixed row]

(9.2.10) Provide details of your organization's emissions of nitrates, phosphates, pesticides, and other priority substances to water in the reporting year.

(9.2.10.1) Emissions to water in the reporting year (metric tons)

0

(9.2.10.2) Categories of substances included

Select all that apply

☒ Nitrates

☒ Phosphates

☒ Priority substances listed under the EU Water Framework Directive

(9.2.10.3) List the specific substances included

Nitrates, phosphates and other priority substances are monitored across our network of sites where required by local regulatory requirements and site discharge permits. This data is not aggregated at the corporate level.

(9.2.10.4) Please explain

Nitrates, phosphates and other priority substances are monitored across our network of sites where required by local regulatory requirements and site discharge permits. This data is not aggregated at the corporate level.

[Fixed row]

(9.3) In your direct operations and upstream value chain, what is the number of facilities where you have identified substantive water-related dependencies, impacts, risks, and opportunities?

Direct operations

(9.3.1) Identification of facilities in the value chain stage

Select from:

☒ Yes, we have assessed this value chain stage and identified facilities with water-related dependencies, impacts, risks, and opportunities

(9.3.2) Total number of facilities identified

8

(9.3.3) % of facilities in direct operations that this represents

Select from:

☒ 1-25

(9.3.4) Please explain

We have identified our facilities in La Jolla, California, US; Andover, Massachusetts, US; Toluca, Mexico; Ascoli, Italy; Karachi, Pakistan; Vizag, India; Chennai, India; and King Abdullah Economic City (KAEC), Saudi Arabia as facilities exposed to water risks. Although these sites do not present a substantive risk to Pfizer's overall

operation, they are important priorities from a water risk perspective and illustrative of the work we are doing to advance water stewardship across our operations. (Note that the Karachi facility was divested in August 2024.)

Upstream value chain

(9.3.1) Identification of facilities in the value chain stage

Select from:

☒ No, we have assessed this value chain stage but did not identify any facilities with water-related dependencies, impacts, risks, and opportunities

(9.3.4) Please explain

Pfizer uses natural hazard analysis and mapping tools to monitor short-, medium- and long-term physical threats for more than 5,000 contract manufacturers and material suppliers. We did not identify any contract manufacturers or material suppliers with substantive water-related dependencies, impacts, risks, and opportunities.
[Fixed row]

(9.3.1) For each facility referenced in 9.3, provide coordinates, water accounting data, and a comparison with the previous reporting year.

Row 1

(9.3.1.1) Facility reference number

Select from:

☒ Facility 1

(9.3.1.2) Facility name (optional)

KAEC, Saudi Arabia

(9.3.1.3) Value chain stage

Select from:

☒ Direct operations

(9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

(9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

(9.3.1.7) Country/Area & River basin

Saudi Arabia

☒ Other, please specify: Saudi Arabia; Red Sea, East Coast

(9.3.1.8) Latitude

22.5102

(9.3.1.9) Longitude

39.1004

(9.3.1.10) Located in area with water stress

Select from:

☒ Yes

(9.3.1.13) Total water withdrawals at this facility (megaliters)

17

(9.3.1.14) Comparison of total withdrawals with previous reporting year

Select from:

☒ Much lower

(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes

0

(9.3.1.16) Withdrawals from brackish surface water/seawater

0

(9.3.1.17) Withdrawals from groundwater - renewable

0

(9.3.1.18) Withdrawals from groundwater - non-renewable

0

(9.3.1.19) Withdrawals from produced/entrained water

0

(9.3.1.20) Withdrawals from third party sources

17

(9.3.1.21) Total water discharges at this facility (megaliters)

9

(9.3.1.22) Comparison of total discharges with previous reporting year

Select from:

☒ Lower

(9.3.1.23) Discharges to fresh surface water

0

(9.3.1.24) Discharges to brackish surface water/seawater

0

(9.3.1.25) Discharges to groundwater

0

(9.3.1.26) Discharges to third party destinations

9

(9.3.1.27) Total water consumption at this facility (megaliters)

8

(9.3.1.28) Comparison of total consumption with previous reporting year

Select from:

☒ Much lower

(9.3.1.29) Please explain

The total water withdrawal at the KAEC, Saudi Arabia facility decreased by 13%, while the total water consumption decreased by 19%. Water discharges decreased by 7%. The decrease in withdrawal and consumption was due to changes in product mix and production. Pfizer defines "much lower" as a decrease of more than 10% compared to the previous year. Pfizer defines "lower" as a decrease of 2% to 10% compared to the previous year.

Row 2

(9.3.1.1) Facility reference number

Select from:

☒ Facility 2

(9.3.1.2) Facility name (optional)

Karachi, Pakistan

(9.3.1.3) Value chain stage

Select from:

☒ Direct operations

(9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

(9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

(9.3.1.7) Country/Area & River basin

Pakistan

☒ Other, please specify: Arabian Sea Coast, Hob/Porali

(9.3.1.8) Latitude

24.9103

(9.3.1.9) Longitude

67.0113

(9.3.1.10) Located in area with water stress

Select from:

☒ Yes

(9.3.1.13) Total water withdrawals at this facility (megaliters)

41

(9.3.1.14) Comparison of total withdrawals with previous reporting year

Select from:

☒ Lower

(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes

0

(9.3.1.16) Withdrawals from brackish surface water/seawater

0

(9.3.1.17) Withdrawals from groundwater - renewable

0

(9.3.1.18) Withdrawals from groundwater - non-renewable

0

(9.3.1.19) Withdrawals from produced/entrained water

0

(9.3.1.20) Withdrawals from third party sources

41

(9.3.1.21) Total water discharges at this facility (megaliters)

33

(9.3.1.22) Comparison of total discharges with previous reporting year

Select from:

☒ Lower

(9.3.1.23) Discharges to fresh surface water

0

(9.3.1.24) Discharges to brackish surface water/seawater

0

(9.3.1.25) Discharges to groundwater

0

(9.3.1.26) Discharges to third party destinations

33

(9.3.1.27) Total water consumption at this facility (megaliters)

8

(9.3.1.28) Comparison of total consumption with previous reporting year

Select from:

☒ Lower

(9.3.1.29) Please explain

The total water withdrawal and discharges at the Karachi, Pakistan facility decreased by 2%, while the total water consumption decreased by 5%. Decreases in withdrawal, discharges and consumption were lower in 2023 due to changes in production. Pfizer defines "lower" as a decrease of 2% to 10% compared to the previous year.

Row 3

(9.3.1.1) Facility reference number

Select from:

☒ Facility 3

(9.3.1.2) Facility name (optional)

La Jolla, California, US

(9.3.1.3) Value chain stage

Select from:

☒ Direct operations

(9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

(9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

(9.3.1.7) Country/Area & River basin

United States of America

☒ Other, please specify: San Diego, California

(9.3.1.8) Latitude

32.898

(9.3.1.9) Longitude

-117.2287

(9.3.1.10) Located in area with water stress

Select from:

☒ Yes

(9.3.1.13) Total water withdrawals at this facility (megaliters)

98

(9.3.1.14) Comparison of total withdrawals with previous reporting year

Select from:

☒ Much higher

(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes

0

(9.3.1.16) Withdrawals from brackish surface water/seawater

0

(9.3.1.17) Withdrawals from groundwater - renewable

0

(9.3.1.18) Withdrawals from groundwater - non-renewable

0

(9.3.1.19) Withdrawals from produced/entrained water

0

(9.3.1.20) Withdrawals from third party sources

98

(9.3.1.21) Total water discharges at this facility (megaliters)

77

(9.3.1.22) Comparison of total discharges with previous reporting year

Select from:

☒ Higher

(9.3.1.23) Discharges to fresh surface water

0

(9.3.1.24) Discharges to brackish surface water/seawater

0

(9.3.1.25) Discharges to groundwater

0

(9.3.1.26) Discharges to third party destinations

(9.3.1.27) Total water consumption at this facility (megaliters)

21

(9.3.1.28) Comparison of total consumption with previous reporting year*Select from:*☒ Much higher**(9.3.1.29) Please explain**

The total water withdrawal at the La Jolla, California facility increased by 11%, while the total water consumption increased by 19%. Pfizer defines 'much higher' as an increase of more than 10% compared to the previous year. Water discharges increased by 9%. Pfizer defines 'higher' as an increase of 2% to 10% compared to the previous year. The increases in water withdrawal, discharges, and consumption were due to the impacts of research projects and activities.

Row 4**(9.3.1.1) Facility reference number***Select from:*☒ Facility 4**(9.3.1.2) Facility name (optional)***Chennai, India***(9.3.1.3) Value chain stage***Select from:*☒ Direct operations**(9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility***Select all that apply*

☒ Risks

(9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

(9.3.1.7) Country/Area & River basin

India

☒ Other, please specify: India East Coast

(9.3.1.8) Latitude

12.9922

(9.3.1.9) Longitude

80.2437

(9.3.1.10) Located in area with water stress

Select from:

☒ Yes

(9.3.1.13) Total water withdrawals at this facility (megaliters)

1

(9.3.1.14) Comparison of total withdrawals with previous reporting year

Select from:

☒ Much higher

(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes

0

(9.3.1.16) Withdrawals from brackish surface water/seawater

0

(9.3.1.17) Withdrawals from groundwater - renewable

0

(9.3.1.18) Withdrawals from groundwater - non-renewable

0

(9.3.1.19) Withdrawals from produced/entrained water

0

(9.3.1.20) Withdrawals from third party sources

1

(9.3.1.21) Total water discharges at this facility (megaliters)

1

(9.3.1.22) Comparison of total discharges with previous reporting year

Select from:

☒ Much higher

(9.3.1.23) Discharges to fresh surface water

0

(9.3.1.24) Discharges to brackish surface water/seawater

0

(9.3.1.25) Discharges to groundwater

0

(9.3.1.26) Discharges to third party destinations

1

(9.3.1.27) Total water consumption at this facility (megaliters)

0.3

(9.3.1.28) Comparison of total consumption with previous reporting year

Select from:

☒ Much higher

(9.3.1.29) Please explain

Water withdrawal and discharges in 2023 at the Chennai, India site were 36% higher while consumption increased 37%. The increases were due to increases in site activity and colleague relocation to the site. Pfizer defines "much higher" as an increase of more than 10% when compared to the previous year.

Row 5

(9.3.1.1) Facility reference number

Select from:

☒ Facility 5

(9.3.1.2) Facility name (optional)

Vizag, India

(9.3.1.3) Value chain stage

Select from:

☒ Direct operations

(9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

(9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

(9.3.1.7) Country/Area & River basin

India

☒ Other, please specify: India East Coast

(9.3.1.8) Latitude

13.0494

(9.3.1.9) Longitude

80.239

(9.3.1.10) Located in area with water stress

Select from:

☒ Yes

(9.3.1.13) Total water withdrawals at this facility (megaliters)

(9.3.1.14) Comparison of total withdrawals with previous reporting year*Select from:*☒ Higher**(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes**

0

(9.3.1.16) Withdrawals from brackish surface water/seawater

0

(9.3.1.17) Withdrawals from groundwater - renewable

0

(9.3.1.18) Withdrawals from groundwater - non-renewable

0

(9.3.1.19) Withdrawals from produced/entrained water

0

(9.3.1.20) Withdrawals from third party sources

364

(9.3.1.21) Total water discharges at this facility (megaliters)

183

(9.3.1.22) Comparison of total discharges with previous reporting year

Select from:

☒ Much lower

(9.3.1.23) Discharges to fresh surface water

0

(9.3.1.24) Discharges to brackish surface water/seawater

0

(9.3.1.25) Discharges to groundwater

0

(9.3.1.26) Discharges to third party destinations

183

(9.3.1.27) Total water consumption at this facility (megaliters)

181

(9.3.1.28) Comparison of total consumption with previous reporting year

Select from:

☒ Much higher

(9.3.1.29) Please explain

Water withdrawal at the Vizag, India plant in 2023 increased 2%, water discharge was 13% lower due to the reuse of cooled condensate in the site's cooling towers. The site water consumption increased 23%. Pfizer defines "higher" as an increase or decrease of 2% to 10% compared to the previous year. Pfizer defines "much higher" as an increase of more than 10% compared to the previous year. Pfizer defines "much lower" as a decrease of more than 10% compared to the previous year.

Row 6

(9.3.1.1) Facility reference number

Select from:

☒ Facility 6

(9.3.1.2) Facility name (optional)

Ascoli, Italy

(9.3.1.3) Value chain stage

Select from:

☒ Direct operations

(9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

(9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

(9.3.1.7) Country/Area & River basin

Italy

☒ Other, please specify: Italy East Coast

(9.3.1.8) Latitude

42.8446

(9.3.1.9) Longitude

13.6541

(9.3.1.10) Located in area with water stress

Select from:

☒ Yes

(9.3.1.13) Total water withdrawals at this facility (megaliters)

132

(9.3.1.14) Comparison of total withdrawals with previous reporting year

Select from:

☒ Lower

(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes

0

(9.3.1.16) Withdrawals from brackish surface water/seawater

0

(9.3.1.17) Withdrawals from groundwater - renewable

92

(9.3.1.18) Withdrawals from groundwater - non-renewable

0

(9.3.1.19) Withdrawals from produced/entrained water

0

(9.3.1.20) Withdrawals from third party sources

40

(9.3.1.21) Total water discharges at this facility (megaliters)

132

(9.3.1.22) Comparison of total discharges with previous reporting year

Select from:

☒ Lower

(9.3.1.23) Discharges to fresh surface water

81

(9.3.1.24) Discharges to brackish surface water/seawater

0

(9.3.1.25) Discharges to groundwater

0

(9.3.1.26) Discharges to third party destinations

51

(9.3.1.27) Total water consumption at this facility (megaliters)

0

(9.3.1.28) Comparison of total consumption with previous reporting year

Select from:

☒ About the same

(9.3.1.29) Please explain

Water withdrawal and discharges in 2023 at the Ascoli, Italy plant were 5% lower due to changes in the production schedule. Water consumption in 2023 remained approximately the same compared to the previous reporting period. Pfizer defines "lower" as a decrease of 2% to 10% compared to the previous year. Pfizer defines "about the same" as an increase or decrease of 0% to 2% compared to the previous year.

Row 7

(9.3.1.1) Facility reference number

Select from:

☒ Facility 7

(9.3.1.2) Facility name (optional)

Toluca, Mexico

(9.3.1.3) Value chain stage

Select from:

☒ Direct operations

(9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

(9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

(9.3.1.7) Country/Area & River basin

Mexico

☒ Other, please specify :Río Lerma

(9.3.1.8) Latitude

19.2897

(9.3.1.9) Longitude

-99.6251

(9.3.1.10) Located in area with water stress

Select from:

☒ Yes

(9.3.1.13) Total water withdrawals at this facility (megaliters)

36

(9.3.1.14) Comparison of total withdrawals with previous reporting year

Select from:

☒ Lower

(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes

0

(9.3.1.16) Withdrawals from brackish surface water/seawater

0

(9.3.1.17) Withdrawals from groundwater - renewable

(9.3.1.18) Withdrawals from groundwater - non-renewable

0

(9.3.1.19) Withdrawals from produced/entrained water

0

(9.3.1.20) Withdrawals from third party sources

0

(9.3.1.21) Total water discharges at this facility (megaliters)

29

(9.3.1.22) Comparison of total discharges with previous reporting year*Select from:*☒ Much lower**(9.3.1.23) Discharges to fresh surface water**

0

(9.3.1.24) Discharges to brackish surface water/seawater

0

(9.3.1.25) Discharges to groundwater

0

(9.3.1.26) Discharges to third party destinations

(9.3.1.27) Total water consumption at this facility (megaliters)

7

(9.3.1.28) Comparison of total consumption with previous reporting year*Select from:*☒ Much higher**(9.3.1.29) Please explain**

Water withdrawal at the Toluca, Mexico plant was 5% lower and water discharges were 20% lower. The decreases in water withdrawal and discharges were due to the implementation of water-saving initiatives at the plant. Pfizer defines "much lower" as a decrease of more than 10% compared to the previous year. Pfizer defines "lower" as a decrease of 2% to 10% compared to the previous year. Pfizer defines "much higher" as an increase of more than 10% when compared to the previous year.

Row 8**(9.3.1.1) Facility reference number***Select from:*☒ Facility 8**(9.3.1.2) Facility name (optional)***Andover, Massachusetts, US***(9.3.1.3) Value chain stage***Select from:*☒ Direct operations**(9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility**

Select all that apply

☒ Risks

(9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

(9.3.1.7) Country/Area & River basin

United States of America

☒ Other, please specify :Atlantic Ocean Seaboard

(9.3.1.8) Latitude

42.6135

(9.3.1.9) Longitude

-71.1716

(9.3.1.10) Located in area with water stress

Select from:

☒ Yes

(9.3.1.13) Total water withdrawals at this facility (megaliters)

495

(9.3.1.14) Comparison of total withdrawals with previous reporting year

Select from:

☒ Higher

(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes

0

(9.3.1.16) Withdrawals from brackish surface water/seawater

0

(9.3.1.17) Withdrawals from groundwater - renewable

0

(9.3.1.18) Withdrawals from groundwater - non-renewable

0

(9.3.1.19) Withdrawals from produced/entrained water

0

(9.3.1.20) Withdrawals from third party sources

495

(9.3.1.21) Total water discharges at this facility (megaliters)

398

(9.3.1.22) Comparison of total discharges with previous reporting year

Select from:

☒ Much higher

(9.3.1.23) Discharges to fresh surface water

0

(9.3.1.24) Discharges to brackish surface water/seawater

0

(9.3.1.25) Discharges to groundwater

0

(9.3.1.26) Discharges to third party destinations

398

(9.3.1.27) Total water consumption at this facility (megaliters)

97

(9.3.1.28) Comparison of total consumption with previous reporting year

Select from:

☒ Much lower

(9.3.1.29) Please explain

Water withdrawal at the Andover, Massachusetts plant was 6% higher and discharges were 17% higher due to site growth and production changes. Water consumption was 23% lower due to an issue with cooling tower metering, which has been resolved. Pfizer defines "higher" as an increase of 2% to 10% when compared to the previous year. Pfizer defines "much higher" as an increase of more than 10% when compared to the previous year. Pfizer defines "much lower" as a decrease of more than 10% compared to the previous year.

[Add row]

(9.3.2) For the facilities in your direct operations referenced in 9.3.1, what proportion of water accounting data has been third party verified?

Water withdrawals – total volumes

(9.3.2.1) % verified

Select from:

☒ 76-100

(9.3.2.2) Verification standard used

ISAE 3000. 2023 water data is independently verified to the limited assurance level.

Water withdrawals – volume by source

(9.3.2.1) % verified

Select from:

☒ Not verified

(9.3.2.3) Please explain

Assurance verification of 2023 water data was limited to water withdrawal, water discharges and water consumption totals.

Water withdrawals – quality by standard water quality parameters

(9.3.2.1) % verified

Select from:

☒ Not verified

(9.3.2.3) Please explain

Assurance verification of 2023 water data was limited to water withdrawal, water discharges and water consumption totals.

Water discharges – total volumes

(9.3.2.1) % verified

Select from:

☒ 76-100

(9.3.2.2) Verification standard used

ISAE 3000. 2023 water data is independently verified to the limited assurance level.

Water discharges – volume by destination

(9.3.2.1) % verified

Select from:

☒ Not verified

(9.3.2.3) Please explain

Assurance verification of 2023 water data was limited to water withdrawal, water discharges and water consumption totals.

Water discharges – volume by final treatment level

(9.3.2.1) % verified

Select from:

☒ Not verified

(9.3.2.3) Please explain

Assurance verification of 2023 water data was limited to water withdrawal, water discharges and water consumption totals.

Water discharges – quality by standard water quality parameters

(9.3.2.1) % verified

Select from:

☒ Not verified

(9.3.2.3) Please explain

Assurance verification of 2023 water data was limited to water withdrawal, water discharges and water consumption totals.

Water consumption – total volume

(9.3.2.1) % verified

Select from:

☒ 76-100

(9.3.2.2) Verification standard used

ISAE 3000. 2023 water data is independently verified to the limited assurance level.

[Fixed row]

(9.4) Could any of your facilities reported in 9.3.1 have an impact on a requesting CDP supply chain member?

Select from:

☒ No, CDP supply chain members do not buy goods or services from facilities listed in 9.3.1

(9.5) Provide a figure for your organization's total water withdrawal efficiency.

	Revenue (currency)	Total water withdrawal efficiency	Anticipated forward trend
	58,496,000,000	1,843,613.10	We expect water withdrawal to increase near-term, largely due to planned expansions and increased production.

[Fixed row]

(9.13) Do any of your products contain substances classified as hazardous by a regulatory authority?

(9.13.1) Products contain hazardous substances

Select from:

☒ Unknown

(9.13.2) Comment

At Pfizer we produce medicines and vaccines regulated by health authorities around the world for quality, safety and efficacy. Additional guidance is needed to understand how this question applies to the bio-pharma sector.

[Fixed row]

(9.14) Do you classify any of your current products and/or services as low water impact?

(9.14.1) Products and/or services classified as low water impact

Select from:

☒ No, but we plan to address this within the next two years

(9.14.3) Primary reason for not classifying any of your current products and/or services as low water impact

Select from:

☒ Other, please specify: Currently working on developing product sustainability criteria.

(9.14.4) Please explain

To support environmental footprint reduction efforts, Pfizer is conducting representative life cycle assessments (LCAs) across our small molecule, large molecule, vaccines, and device portfolios. Guided by these assessments, we are working to define environmental sustainability criteria across the product lifecycle.

[Fixed row]

(9.15) Do you have any water-related targets?

Select from:

☒ Yes

(9.15.1) Indicate whether you have targets relating to water pollution, water withdrawals, WASH, or other water-related categories.

Water pollution

(9.15.1.1) Target set in this category

Select from:

☒ No, and we do not plan to within the next two years

(9.15.1.2) Please explain

Pfizer is committed to limiting discharges to wastewater from our manufacturing processes as described within our Water Stewardship Position Statement (https://cdn.pfizer.com/pfizercom/Pfizer_Water_Stewardship_Public_Position_Statement_2022.pdf).

Water withdrawals

(9.15.1.1) Target set in this category

Select from:

☒ Yes

Water, Sanitation, and Hygiene (WASH) services

(9.15.1.1) Target set in this category

Select from:

☒ No, and we do not plan to within the next two years

(9.15.1.2) Please explain

Pfizer's Global Environment, Health and Safety Standards require all facilities to provide safe, fully functioning WASH services for all employees and therefore a WASH target is not relevant for our organization.

Other

(9.15.1.1) Target set in this category

Select from:

☒ No, and we do not plan to within the next two years

(9.15.1.2) Please explain

Pfizer is committed to limiting discharges to wastewater from our manufacturing processes as described within our Water Stewardship Position Statement (https://cdn.pfizer.com/pfizercom/Pfizer_Water_Stewardship_Public_Position_Statement_2022.pdf).

[Fixed row]

(9.15.2) Provide details of your water-related targets and the progress made.

Row 1

(9.15.2.1) Target reference number

Select from:

☒ Target 1

(9.15.2.2) Target coverage

Select from:

☒ Business division

(9.15.2.3) Category of target & Quantitative metric

Water withdrawals

☒ Reduction in total water withdrawals

(9.15.2.4) Date target was set

01/01/2020

(9.15.2.5) End date of base year

12/31/2019

(9.15.2.6) Base year figure

11,690,183

(9.15.2.7) End date of target year

12/31/2030

(9.15.2.8) Target year figure

11,105,674

(9.15.2.9) Reporting year figure

10,990,429

(9.15.2.10) Target status in reporting year

Select from:

☒ Underway

(9.15.2.11) % of target achieved relative to base year

120

(9.15.2.12) Global environmental treaties/initiatives/ frameworks aligned with or supported by this target

Select all that apply

☒ Sustainable Development Goal 6

(9.15.2.13) Explain target coverage and identify any exclusions

Pfizer has established an internal target to reduce water withdrawal, excluding non-contact cooling water, 5% by 2030 compared to a 2019 baseline. This target covers Pfizer's manufacturing sites, which account for approximately 95% of Pfizer's water withdrawal. Water withdrawal data for this target is presented in cubic meters.

(9.15.2.14) Plan for achieving target, and progress made to the end of the reporting year

Manufacturing sites are required to set annual water withdrawal targets and to maintain site masterplans which include water conservation projects. Pfizer's water withdrawal excluding non-contact cooling water increased by 1% in 2023 compared to 2022 but remained 6.5% lower than the 2019 baseline.

(9.15.2.16) Further details of target

Pfizer anticipates water withdrawal to increase in the next 2-4 years largely due to expansions and increased production at our biologics manufacturing sites, but we will continue to work to offset these increases through improvements in water management and the implementation of conservation projects.

[Add row]

C10. Environmental performance - Plastics

(10.1) Do you have plastics-related targets, and if so what type?

(10.1.1) Targets in place

Select from:

☒ Yes

(10.1.2) Target type and metric

End-of-life management

- ☒ Increase the proportion of recyclable plastic waste that we collect, sort, and recycle
- ☒ Reduce the proportion of plastic waste which is sent to landfill and/or incinerated

Extended Producer Responsibility (EPR)

- ☒ Ensure compliance with EPR policies and schemes

(10.1.3) Please explain

Pfizer uses an internal performance metric to track site waste management practices as they relate to the hierarchy of control principles: avoid, reduce, reuse, recycle, dispose. This metric covers both hazardous and non-hazardous wastes, including plastic wastes, and is used to drive waste minimization and waste handling decisions to improve circularity. Our manufacturing sites set annual internal improvement targets and review performance quarterly. We are also able to use this metric to benchmark performance against others in the industry and identify opportunities for improvement.

[Fixed row]

(10.2) Indicate whether your organization engages in the following activities.

Production/commercialization of plastic polymers (including plastic converters)

(10.2.1) Activity applies

Select from:

☒ No

(10.2.2) Comment

Pfizer manufactures pharmaceuticals. Pfizer does not engage in the production of plastic polymers.

Production/commercialization of durable plastic goods and/or components (including mixed materials)

(10.2.1) Activity applies

Select from:

☒ No

(10.2.2) Comment

Pfizer manufactures pharmaceuticals. Pfizer does not engage in the production of plastic components.

Usage of durable plastics goods and/or components (including mixed materials)

(10.2.1) Activity applies

Select from:

☒ Yes

(10.2.2) Comment

Pfizer manufactures pharmaceuticals. Plastic packaging is a necessary and non-discretionary component of our final products required by law but are not directly incorporated into our medicines and vaccines.

Production/commercialization of plastic packaging

(10.2.1) Activity applies

Select from:

☒ No

(10.2.2) Comment

Pfizer manufactures pharmaceuticals. Pfizer does not engage in the production/commercialization of plastic packaging.

Production/commercialization of goods/products packaged in plastics

(10.2.1) Activity applies

Select from:

☒ Yes

(10.2.2) Comment

Pfizer manufactures pharmaceuticals. Plastic packaging is a necessary and non-discretionary component of our final products required by law but are not directly incorporated into our medicines and vaccines.

Provision/commercialization of services that use plastic packaging (e.g., food services)

(10.2.1) Activity applies

Select from:

☒ Yes

(10.2.2) Comment

Pfizer manufactures pharmaceuticals. Plastic packaging is a necessary and non-discretionary component of our final products required by law but are not directly incorporated into our medicines and vaccines.

Provision of waste management and/or water management services

(10.2.1) Activity applies

Select from:

☒ No

(10.2.2) Comment

Pfizer manufactures pharmaceuticals. Pfizer does not engage in the provision of waste and/or water management services.

Provision of financial products and/or services for plastics-related activities

(10.2.1) Activity applies

Select from:

☒ No

(10.2.2) Comment

Pfizer manufactures pharmaceuticals. Pfizer does not provide financial products or services.

Other activities not specified

(10.2.1) Activity applies

Select from:

☒ No

(10.2.2) Comment

Pfizer manufactures pharmaceuticals. Pfizer uses plastic packaging is a necessary and non-discretionary component of our pharmaceutical products but does not engage in plastics production, commercialization, or other plastics-related activities.

[Fixed row]

(10.4) Provide the total weight of plastic durable goods and durable components produced, sold and/or used, and indicate the raw material content.

Durable goods and durable components used

(10.4.2) Raw material content percentages available to report

Select all that apply

☒ None

(10.4.7) Please explain

Pfizer tracks quantities of plastic packaging use and its circularity potential where required by regulation, however this information is not collected at the corporate level.

[Fixed row]

(10.5) Provide the total weight of plastic packaging sold and/or used and indicate the raw material content.

Plastic packaging used

(10.5.2) Raw material content percentages available to report

Select all that apply

☒ None

(10.5.7) Please explain

Pfizer tracks quantities of plastic packaging use and its circularity potential where required by regulation, however this information is not collected at the corporate level.

[Fixed row]

(10.5.1) Indicate the circularity potential of the plastic packaging you sold and/or used.

Plastic packaging used

(10.5.1.1) Percentages available to report for circularity potential

Select all that apply

☒ None

(10.5.1.5) Please explain

Pfizer tracks quantities of plastic packaging use and its circularity potential where required by regulation, however this information is not collected at the corporate level.
[Fixed row]

C11. Environmental performance - Biodiversity

(11.4.1) Provide details of your organization’s activities in the reporting year located in or near to areas important for biodiversity.

C13. Further information & sign off

(13.1) Indicate if any environmental information included in your CDP response (not already reported in 7.9.1/2/3, 8.9.1/2/3/4, and 9.3.2) is verified and/or assured by a third party?

	Other environmental information included in your CDP response is verified and/or assured by a third party
	Select from: <input checked="" type="checkbox"/> Yes

[Fixed row]

(13.1.1) Which data points within your CDP response are verified and/or assured by a third party, and which standards were used?

Row 1

(13.1.1.1) Environmental issue for which data has been verified and/or assured

Select all that apply

☒ Climate change

(13.1.1.2) Disclosure module and data verified and/or assured

Environmental performance – Climate change

☒ Renewable Electricity/Steam/Heat/Cooling consumption

☒ Waste data

☒ Other data point in module 7, please specify: Emissions intensity

(13.1.1.3) Verification/assurance standard

General standards

☒ ISAE 3000

(13.1.1.4) Further details of the third-party verification/assurance process

Renewable electricity consumption, hazardous waste, and emissions intensity data for facilities within Pfizer's operational control were verified to the limited assurance level. Verification is performed annually.

(13.1.1.5) Attach verification/assurance evidence/report (optional)

ERM CVS Limited Assurance Report for Pfizer - 2024 CDP Questionnaire (FINAL).pdf

Row 2

(13.1.1.1) Environmental issue for which data has been verified and/or assured

Select all that apply

☒ Climate change

(13.1.1.2) Disclosure module and data verified and/or assured

Environmental performance – Climate change

☒ Other data point in module 7, please specify: Total Scope 3 GHG emissions from all reported categories (Categories 1, 2, 3, 4, 5, 6, 7, 8 and 15)

(13.1.1.3) Verification/assurance standard

General standards

☒ ISAE 3000

(13.1.1.4) Further details of the third-party verification/assurance process

Total 2023 scope 3 emissions for all reported categories (categories 1-8 and 15) were 4,334,041 mt CO2e.

(13.1.1.5) Attach verification/assurance evidence/report (optional)

ERM CVS Limited Assurance Report for Pfizer - 2024 CDP Questionnaire (FINAL).pdf

Row 3

(13.1.1.1) Environmental issue for which data has been verified and/or assured

Select all that apply

☒ Water

(13.1.1.2) Disclosure module and data verified and/or assured

Environmental performance – Water security

☒ Water consumption– total volume

☒ Water discharges– total volumes

☒ Water withdrawals– total volumes

(13.1.1.3) Verification/assurance standard

General standards

☒ ISAE 3000

(13.1.1.4) Further details of the third-party verification/assurance process

Assurance verification of 2023 water data was limited to water withdrawal, water discharges and water consumption totals.

(13.1.1.5) Attach verification/assurance evidence/report (optional)

ERM CVS Limited Assurance Report for Pfizer - 2024 CDP Questionnaire (FINAL).pdf

[Add row]

(13.3) Provide the following information for the person that has signed off (approved) your CDP response.

(13.3.1) Job title

Executive Vice President, Chief Global Supply Officer

(13.3.2) Corresponding job category

Select from:

☒ President

[Fixed row]